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Chapter 1
Introduction
1. Hyaluronic acid
1.1 Structure and physicochemical properties
In 1934, hyaluronic acid (HA), a linear polymer of a disaccharide composed of
N-acetylglucosamine and glucuronic acid linked together through alternating
β-1,4 and β-1,3 glycosidic bonds, was isolated for the first time from the vitre-
ous humor of bovine eyes by Karl Meyer (Meyer et al. 1934).
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Fig. 1: Structure of hyaluronic acid
Hyaluronic acid (hyaluronan) is a member of the glycosaminoglycanes, a family
of mostly linear polymers of high molecular weight composed of aminosugars
(N-acetylglucosamine or N-acetylgalactosamine) and uronic acids (glucuronic
or iduronic acid). The most important members of the glycosaminoglycanes
are, apart from HA, chondroitin-, keratan- and dermatane sulphate, heparin and
heparan sulphate. One important difference between HA and all other glyco-
saminoglycanes is the lack of sulphation - hyaluronan is strictly composed of
non-sulphated sugar units shown in Fig. 1. The number of repeating disaccha-
ride units can reach 10000 or more resulting in a molecular weight higher than
4•106 Da. The average length of a disaccharide unit is ~1 nm, thus a hyaluro-
nan molecule of 10000 units could extend to 10 µm if stretched.
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For decades, it was considered that hyaluronan chains in solution were random
coils. The first indications that hyaluronan has preferred shapes were given by
J. E. Scott (Scott 1989). Nuclear magnetic resonance confirmed the presence
of an ordered structure in solution in which each disaccharide unit is twisted by
180 degrees compared with those ahead and behind it in the chain (cf. Fig. 2).
The original orientation of the hyaluronan chain is achieved by a second twist,
so that its structure is a two-fold helix. In solution, the HA-backbone is stabilised
by internal hydrogen bonds and interaction with the solvent (Scott et al. 1991).
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Fig. 2: Stabilisation of hyaluronic acid by internal hydrogen bonds: a tetrasac-
charide unit of HA-chain a) in non-aqueous solution (DMSO); b) in aqueous
solution; G = glucuronic acid, N = N-acetylglucoseamine. In aqueous solution,
the two disaccharide units are distorted about 180° creating a twisting ribbon
structure [according to Scott (Scott 1989)].
Due to the two-fold helix, the striking feature of this secondary structure is an
extensive hydrophobic patch of about 8 CH-groups of 3 carbohydrate units.
Thus, hyaluronan is amphiphilic, i.e. it has the properties of a highly hydrophilic
material simultaneously with hydrophobic characteristics. By binding water, the
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volume of HA increases by about 1000-fold compared to the non-hydrated
state (Laurent et al. 1996). During the hydrated state the diffusion of e.g. pro-
teins and electrolytes is substantially facilitated. In principle, all molecules can
pass through a hyaluronan network, but with different velocity depending on
their hydrodynamic volume.
1.2 Occurrence and physiological importance
Hyaluronan is a major constituent of the extracellular matrix, for example in the
vitreous humor of the human eye (0.1-0.4 mg/g wet weight), in the synovial joint
fluid (3-4 mg/ml), in the matrix produced by the cumulus cells around the oocyte
prior to ovulation (~0.5 mg/ml), or in the pathological matrix that occludes the
artery in coronary restenosis (http://www.glycoforum.gr.jp/).Hyaluronan is pres-
ent in all vertebrates and also in the capsule of some Streptococci strains.
As hyaluronan serves as an essential structural element in the matrix, it plays
an important role for tissue architecture. Furthermore, hyaluronan is important
for cell proliferation, cell migration and cell growth as well as the metastasis of
tumour cells. Morphogenesis, embryonic development, wound healing and in-
flammation are associated with an increase of hyaluronan production (Laurent
et al. 1992; Laurent et al. 1996).
Hyaluronic acid interacts with a variety of receptors and binding proteins on the
surface of cells (Laurent et al. 1992). The most common hyaluronan receptor
and the most studied to date is CD44 (lymphocyte homing receptor). Further-
more, several hyaluronan binding proteins have been identified including the
RHAMM (receptor for hyaluronan which mediates motility), ICAM-1 (intercellular
adhesion molecule-1) and the LEC receptor (Liver Endothelial Cell clearance
receptor) (http://www.glycoforum.gr.jp/; Laurent et al. 1996).
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2. Hyaluronidases
2.1 History and occurrence
Hyaluronidase was first identified in an extract of mammalian testes and other
tissues as a “spreading factor” that facilitated diffusion of antiviral vaccines,
dyes, toxins injected subcutaneously (Duran-Reynals 1928). After the first iso-
lation of hyaluronan by Meyer et al. (Meyer et al. 1934) and the identification of
a HA degrading enzyme in bacteria (Meyer et al. 1937) it could soon be shown
that the aforementioned spreading factor was an enzyme degrading hyaluronan
(Chain et al. 1939). Similar hyaluronidase-like enzymes were detected and/or
isolated from a large number of tissues and organisms e.g. liver, kidney,
spleen, testes, uterus, placenta etc., from the venom of snakes, lizards, fish,
bees, wasps, scorpions, spiders as well as from some bacteria, fungi and in-
vertebrate animals. The isolated hyaluronidases differ in their molecular weight,
substrate specificity and pH optima (Kreil 1995; Frost et al. 1996; Csoka et al.
1997). Although ubiquitously found, hyaluronidases are not well characterised
and are a group of neglected enzymes due to difficult purification and lack of
scientific interest over a larg period of time.
2.2 Classification of hyaluronidases
In 1971, K. Meyer (Meyer 1971) classified the hyaluronan degrading enzymes
into three main families according to their catalytic mechanism (cf. Fig. 3).
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Fig. 3: Classification of hyaluronidases according to Meyer (Meyer 1971)
The first group of hyaluronidases are the hyaluronate 4-glycanohydrolases (EC
3.2.1.35) that degrade hyaluronan by cleavage of the 1,4-β-glycosidic bond to
the tetrasaccharide as the main product. Furthermore, these enzymes degrade
chondroitin, chondroitin 4- and 6-sulphate as well as in some cases dermatane
sulphate. As a special characteristic, these enzyme also catalyse transglycosi-
lation reactions (Cramer et al. 1994; Takagaki et al. 1994). The best known en-
zymes are the testicular, the bee venom and the lysosomal hyaluronidase.
The second type is represented by hyaluronidases from leeches and from
hookworms. These enzymes are hyaluronate 3-glycanohydrolases (EC
3.2.1.36) that degrade HA by cleavage of the 1,3-β-glycosidic bond. The main
product of this reaction is a tetrasaccharide, too.
The third group, the bacterial hyaluronidases (EC 4.2.2.1) are called hyaluro-
nate lyases. These enzymes degrade hyaluronan by a β-elimination reaction to
yield the unsaturated disaccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-ene-
pyranosyluronic acid)-D-glucose as main product (Kreil 1995; Pritchard et al.
2000). The best known and characterised hyaluronate lyases are S. pneumo-
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niae and S. agalactiae hyaluronate lyases (Jedrzejas 2000; Pritchard et al.
2000; Jedrzejas 2002).
As an alternative to the classification according to Meyer (Meyer 1971), hyalu-
ronidases are divided in two main families – the procaryotic and eucaryotic
hyaluronidases – according to amino acid sequence homology (Csoka et al.
1997; Csoka et al. 2001). In the last years, many mammalian hyaluronidase
genes were decoded. The human genome contains six hyaluronidase-like
genes, clustered on chromosome 3p21.3 (HYAL1, HYAL2 and HYAL3) and
chromosome 7q31.3 (HYAL4, PH-20/SPAM1 and HYALP1) (Csoka et al.
2001). The testicular hyaluronidase, PH-20/SPAM1, was first identified by
monoclonal antibodies present on the acrosomal membrane of sperm. Its ho-
mology to bee venom hyaluronidase led to its identification as a hyaluronidase
that is essential for the penetration through the hyaluronan-rich cumulus mass
that surrounds the ovum and consequently necessary for fertilisation
(http://www.glycoforum.gr.jp/; Primakoff et al. 1985; Cherr et al. 1996).
In this study the bovine testicular hyaluronidase (BTH), the bee venom hyalu-
ronidase (BVH) and the S. agalactiae hyaluronate lyase strain 4755 (hylB4755)
were used for pharmacological investigations. Therefore, these enzymes are
briefly characterised in the following.
2.3 Bovine testicular hyaluronidase (BTH)
The bovine testicular hyaluronidase (EC 3.2.1.35) is an endo-glycanohydrolase
that cleaves the 1,4-β glycosidic bond of hyaluronan. In addition to hyaluronic
acid, BTH degrades chondroitin and chondroitin 4- and 6-sulphate, which are
structurally related to HA. Depending on the BTH preparation, the used sub-
strate, the hyaluronidase assay and the incubation conditions different pH op-
tima were detected: pH value of 3.7 (Muckenschnabel et al. 1998), pH value of
5.2 (Gorham et al. 1975) and pH value of 7.5 (Meyer 1971).
In addition to the hydrolase activity, the bovine testicular hyaluronidase exhibits
transglycosylase activity. Cramer et al. (Cramer et al. 1994) reported that satu-
rated oligosaccharides with N-acetylglucosamine at the reducing end are pro-
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duct of hyaluronan degradation. Hydrolase and transglycosylase activity takes
place if oligosaccharides with 6 to 12 monomer units are available.
C-6 + C-6 C-12
C-12 C-8 + C-4
C-8 C-4 + C-4
C-8 + C-6 C-10 + C-4
C-10 C-6 + C4
T
T
H
H
H
Fig. 4: Hydrolase (H) and transglycosylase (T) activity catalysed by BTH: C-4 to
C-12 are HA oligosaccharides with N-acetylglucosamine at the reducing end
(Cramer et al. 1994).
By contrast, Takagaki et al. (Takagaki et al. 1994) reported that saturated di-
saccharides are the smallest product of the degradation but tetrasaccharides
are the main product.
Transglycosylation reactions are dependent on the pH value and the salt con-
tent of the incubation buffer. The optimal pH value for hydrolase activity is
about 4-5, whereas pH 7 is optimal for transglycosylation reaction. In the pres-
ence of NaCl transglycosylase activity is partially inhibited and nearly com-
pletely inhibited at concentration higher than 0.5 M (Saitoh et al. 1995).
2.4 Bee venom hyaluronidase (BVH)
BVH is a member of the hyaluronate 4-glycanohydrolase (EC 3.2.1.35) like the
bovine testicular hyaluronidase with similar properties and degradation mecha-
nism. The crystal structure of the bee venom hyaluronidase was recently eluci-
dated by Markovic-Housley et al. (Markovic-Housley et al. 2000; Markovic-
Housley et al. 2002). In general, the glycosidases act via a double or a single
nucleophilic displacement mechanism which results in either retention or inver-
sion of the configuration of the anomeric carbon atom, respectively (Withers et
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al. 1995; Markovic-Housley et al. 2002). The crystal structure of BVH suggests
a catalytic mechanism, in which the amino acid residue Glu113 acts as the
proton donor and the N-acetyl group of the substrate as the nucleophile
(Markovic-Housley et al. 2002).
The bee venom hyaluronidase is a major allergen of bee venom and knowledge
of the structural determinants responsible for the allergenic potency is expected
to have importance for clinical implications.
2.5 S. agalactiae hyaluronate lyase (hylB4755)
Streptococcus pneumoniae and S. agalactiae hyaluronate lyase degrade hyalu-
ronic acid at the β-1,4-glycosidic linkage between D-glucuronic acid and
N-acetyl-D-glucosamine. The product of this elimination reaction is the unsatu-
rated disaccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic
acid)-D-glucose (Kreil 1995; Pritchard et al. 2000). Furthermore, hylB4755 also
cleaves chondroitin and chondroitin sulphate but only with specific sulphation
pattern (Pritchard et al. 2000). The three-dimensional structures of S. pneumo-
niae and S. agalactiae were recently elucidated by X-ray analyses (Jedrzejas et
al. 2000; Li et al. 2000; Li et al. 2001; Jedrzejas et al. 2002). Based on the
crystal structure and mechanistical studies, the mechanism of the elimination
reaction was revealed (Jedrzejas et al. 2000; Kelly et al. 2001; Li et al. 2001;
Jedrzejas 2002). The active centre of hylB3502 is composed of two main parts, a
catalytic group responsible for the substrate degradation and an aromatic patch
responsible for the selection of cleavage sites on the substrate chains (Li et al.
2000). The proposed mechanism of catalysis is described in detail in chapter 5.
Investigations in our work group detected the highest hydrolytic activity of
S. agalactiae hyaluronate lyase at a pH value of 5.0, independent of the used
assay (Oettl et al. 2003),  whereas Ozegowski et al. (Ozegowski et al. 1994)
reported maximal activity at pH 6.3.
S. agalactiae hyaluronate lyase is a virulence factor which facilitates the
spreading of the microorganisms and their toxins by degradation of hyaluronan.
Human infection by this pathogen is one of the major causes of meningitis and
septicaemia and many other serious diseases leading the death in neonates
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(Dillon et al. 1987; Hynes et al. 2000). To study the role of hyaluronan and
hyaluronidases in bacterial infection, the design and development of hyaluro-
nate lyase inhibitors become more and more important.
3. Medical applications
In the late 1950s, the probably first medical application of hyaluronan to hu-
mans was a vitreous humor supplement/replacement during eye surgery.
Due to hyaluronan’s high water-binding capacity and high viscoelasticity, HA is
suitable for various medical and pharmaceutical applications. For example,
given that HA retains moisture it is used in some cosmetics to keep skin young
and fresh-looking.
A rapid increase of hyaluronan levels can occur in many clinical situation, for
example during urticaria, the edema associated with wound healing and in-
flammation and the organ enlargement that occurs after transplantation. Fur-
thermore, circulating levels of hyaluronan rapidly increase in situations such as
shock, septicaemia and in burn patients (Frost et al. 1996; Natowicz et al. 1996;
Csoka et al. 1997).
One of the most successful medical applications of HA is the use of sodium
hyaluronate and a covalently cross-linked form of hyaluronan for the treatment
of osteoarthritis (Balazs et al. 1989). It has been reported that sodium hyaluro-
nate suppresses cartilage degeneration, protects the surface of articular carti-
lage (Fukuda et al. 1996), normalises the properties of synovial fluids (Asari et
al. 1998) and reduces the perception of pain (Gotoh et al. 1993; Iwata 1993).
By cleaving hyaluronan in tissues, hyaluronidases increase the membrane
permeability, reduce the viscosity and render the tissues more readily perme-
able to injected fluids (spreading effect). Thus, these enzymes could be used
therapeutically to increase the speed of absorption, to promote resorption of
excess fluids, to increase the effectiveness of local anaesthesia and to diminish
tissue destruction by subcutaneous and intramuscular injection of fluids (Frost
et al. 1996; Farr et al. 1997). Hyaluronidases are widely used in many fields like
orthopaedia, surgery, ophthalmology, internal medicine, oncology, dermatology
and gynaecology etc. (http://www.glycoforum.gr.jp/; Few 1987; Bertelli et al.
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1994; Farr et al. 1997). Sperm hyaluronidase plays an important role for suc-
cessful fertilisation in most mammals, including human (Primakoff et al. 1985;
Lin et al. 1994).
Hyaluronidase has been investigated as an additive to chemotherapeutic drugs
for augmentation of the anticancer effect (Spruss et al. 1995; Muckenschnabel
et al. 1996; Baumgartner 1998; Muckenschnabel et al. 1998). There is evi-
dence that hyaluronidase may have intrinsic anticancer effects and can sup-
press tumour development. Furthermore, it was reported, that treatment with
hyaluronidase blocks lymph node invasion by tumour cells in an animal model
of T cell lymphoma (Zahalka et al. 1995).
To prove and to affirm the role and the importance of hyaluronan and hyalu-
ronidase in all aforementioned processes, selective and potent inhibitors are
required.
4. Inhibitors of hyaluronidases
The first studies of hyaluronidase inhibitors were published half a century ago
(Haas 1946; Dorfman et al. 1948; Meyer et al. 1951). In 1951, Meyer et al.
(Meyer et al. 1951) reported on hyaluronidase inhibition by iron, cooper and
zinc salts, heparin, polyphenols and flavonoids. It has also been reported that
heparin and heparan sulphate are inhibitor of hyaluronidase, but the inhibition
was achieved only at concentrations by far higher than physiological levels
(Houck 1957; Wolf et al. 1984; Farr et al. 1997; Mio et al. 2002). The inhibitory
activity of heparin and heparan sulphate was explained by the structural simi-
larity of these oligosaccharides to hyaluronic acid. Asada et al. examined the
effect of various types of alginic acid consisting of L-glucuronic acids and
D-mannuronic acids on the bovine testicular hyaluronidase (Asada et al. 1997).
The inhibition of the hyaluronidase by sodium alginate was dependent on the
molecular weight – the higher the molecular weight, the stronger the inhibition.
Based on these results, Toida et al. investigated O-sulphated glucosaminogly-
canes whereby the fully sulphated compounds showed the highest inhibitory
effect on the activity of hyaluronidases.
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It was published that some flavones and flavone analogues were potent hyalu-
ronidase inhibitors (Kakegawa et al. 1988; Kuppusamy et al. 1990; Kuppusamy
et al. 1991; Kakegawa et al. 1992). The representative and widely accepted
hyaluronidase inhibitors of this class of compounds are apigenin and kaempfe-
rol. Taken together the published results show that, in principle, flavones and
related compounds are suitable to inhibit hyaluronidases but are unselective
and only weakly active, i.e. at in millimolar concentration (cf. chapter 6).
Further compounds with inhibitory activity at millimolar concentration were de-
tected, e.g. vitamin C, aescin; disodium cromoglycate, tranilast, traxanox, hede-
ragenin, guanidine hydrochloride, L-arginine, norlignane, urolithin B etc.
(Kakegawa et al. 1992; Tung et al. 1994; Facino et al. 1995; Jeong et al. 1999;
Jeong et al. 2000; Akhtar et al. 2003). Indeed, the published data (% inhibition
and IC50 values) of all aforementioned compounds are not comparable with
each other because of differences in the applied test systems (e.g. incubation
condition, enzymes and substrate concentrations).
It is apparent that the development of hyaluronidase inhibitors has barely be-
gun. Due to the importance of hyaluronan and hyaluronidase in many clinical
applications selective and potent inhibitors are worthwhile.
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Chapter 2
Scope of this thesis
To study the physiological and pathophysiological role of hyaluronan and hyalu-
ronidase potent and selective hyaluronidase inhibitors are required as pharma-
cological tools. Additionally, such compounds are of potential therapeutic value
for the treatment of a variety of diseases, e.g. cancer, arthroses or bacterial
infections. As potent and selective hyaluronidase inhibitors are not known so far
(cf. chapter 1), the goal of this thesis was to synthesise and identify lead-like
compounds, to investigate their inhibitory effects on the S. agalactiae hyaluro-
nate lyase, the bovine testicular hyaluronidase and the bee venom hyaluroni-
dase and to study the structure-activity relationships.
For the design and development of enzyme inhibitors several approaches are
known. The classical way of drug discovery and evaluation involves sequential
testing of chemicals or extracts from biological materials in isolated organs fol-
lowed by test in whole animals. Many new drugs were discovered by this clas-
sical approach during the 20th century. Following such approaches, it was pub-
lished that isolated flavons and flavone related compounds as well as some
natural products have inhibitory activities on hyaluronidase. As a first goal of
this thesis new and diverse flavone derivatives should be synthesised and
pharmacologically investigated as well as several isolated flavonoids and re-
lated compounds.
Due to the structural similarity to hyaluronic acid heparin and heparan sulphate
were also considered as hyaluronidase inhibitors. Therefore, a set of sulphated
and non-sulphated oligosaccharides were investigated for their inhibitory activi-
ties.
The X-ray structure of S. pneumoniae and S. agalactiae hyaluronate lyase were
recently elucidated and the mechanism of the elimination reaction was re-
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vealed. Based on mechanistical study of the hyaluronan degradation by bacte-
rial hyaluronidase, the design and synthesis of a substrate analogue as a po-
tential inhibitor was envisaged.
With the elucidation of the three-dimensional structure of receptors and en-
zymes, virtual screening and computer-based molecular design become of in-
creasing importance. As a part of a project to design hyaluronidase inhibitors, a
structure-based strategy to discover inhibitors of bacterial hyaluronan lyases (S.
agalactiae, hylB4755) has been carried out using the de novo design software
LUDI. The main focus of this thesis was the synthesis and pharmacological
evaluation of the compounds proposed by LUDI calculations1. Based on the
results of this approach and to get more information about structural require-
ments for hyaluronate lyase inhibitory activity, differently substituted diphen-
ylacrylic acids and diphenylpropionic acids as well as a set of indole derivatives
were investigated as lead-like compounds.
To further elaborate structure-activity relationships of indole-type hyaluronidase
inhibitors a series of 2-phenylindole derivatives was synthesised and pharma-
cologically investigated. For more detailed information about the interaction of
2-phenylindole derivatives with the amino acid residues inside the active site of
S. pneumoniae hyaluronate lyase, a crystal structure of the enzyme-inhibitor
complex should be elucidated2.
1 The construction of the hylB4755 model and the LUDI calculations have been carried out by
Alexander Botzki (Botzki  2004) as part of his PhD project.
2 The co-crystallisation experiments have been carried out by Mark J. Jedrzejas (Children's Hos-
pital Oakland Research Institute, Oakland, California 94609, USA) and Daniel J. Rigden (Na-
tional Centre of Genetic Resources and Biotechnology, Cenargen/Embrapa, Brasília, D.F.
70770-900, Brazil).
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Chapter 3
Methods and assays for the determination of
hyaluronidase activity
1. Classifications
A variety of methods has been developed over the years to measure the hyalu-
ronidase activity, but many of these assays appear to be rarely used today
(Stern et al. 1992; Muckenschnabel et al. 1998; Muckenschnabel et al. 1998;
Mio et al. 2002). As there are many different assays for hyaluronidase activity
the published methods are classified into groups based on the type of assay
performed according to the classification of Hynes et al. (Hynes et al. 1994).
1.1 Chemical assays
The quantification of reducing sugars, which are formed during the degrada-
tion of hyaluronic acid by hyaluronidases is one method to detect and to count
hyaluronidase activity (Meyer et al. 1941; Hynes et al. 1994). For example,
Linker et al. (Linker 1966) developed a colorimetric method to assay bacterial
hyaluronidase based on the reduction of ferricyanide to ferrocyanide by reduc-
ing sugar.
The detection of the N-acetylglucosamine residues at the reducing end of hya-
luronan degradation products as indicator of hyaluronidase activity is one of the
most commonly used method to assay hyaluronidase (Meyer et al. 1941; Hum-
phrey 1946; Humphrey 1946; Meyer 1947; Reissig et al. 1955; Ingham et al.
1979; Rouleau 1980; Hamai et al. 1989; Muckenschnabel et al. 1998; Muck-
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enschnabel et al. 1998). A number of approaches have been developed for this
method. One of the first assay was described by Reissig et al. (Reissig et al.
1955) in 1955. The optimised colorimetric method is based on the reaction of
p-dimethylaminobenzaldehyde with N-acetylglucosamine to a coloured product
which can be detected at 585 nm. Methods based on the assay of Reissig et al.
(Reissig et al. 1955) have been used to study hyaluronidase from different
sources for example from Propionibacterium acnes (Ingham et al. 1979),
S. dysgalactiae (Hamai et al. 1989) and bovine testis (Muckenschnabel et al.
1998; Muckenschnabel et al. 1998).
A modified assay described by Muckenschnabel et al. (Muckenschnabel et al.
1998; Muckenschnabel et al. 1998) is one of the methods we used for the in-
vestigation of the hyaluronidase inhibitors. The advantage and the disadvan-
tage of this method and the exact assay procedure are described later in this
chapter (cf. Section 2. Colorimetric assay – Morgan-Elson assay).
Hyaluronate lyases (EC 4.2.2.1) differ from hyaluronidase from other sources
by their mode of action. They cleave the hyaluronic acid by an elimination reac-
tion resulting in an unsaturated hexuronic acid at the nonreducing ends (Kreil
1995). The detection and quantification of this unsaturated hexuronic acid can
also be used to assay hyaluronidase activity (Greiling et al. 1965; Greiling et al.
1965; Linker 1966; Ohya et al. 1970). The formation of the elimination product
can be detected and quantified spectrophotometrically by measuring the ab-
sorbance at a wavelength of 230-235 nm. Method and the detailed experimen-
tal procedure are described later in this chapter (cf. Section 4. UV difference
spectroscopy).
1.2 Fluorogenic assays
Hyaluronic acid labeled with the fluorogenic reagent 2-aminopyridine has been
used as substrate in a rapid, simple and sensitive fluorescence assay de-
scribed by Nakamura et al. (Nakamura et al. 1990) for the detection of testicular
hyaluronidase. After incubation with hyaluronidase, dilution with ethanol and
centrifugation, the fluorescence of the supernatant was determined by fluoro-
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spectrophotometry. It was found that the increase of the pyridylamino products
is linearly correlated with the enzyme concentration under these conditions.
The fluorogenic substrate has also been used for the determination of crude
hyaluronidase e.g. hyaluronidase extract from liver (Nakamura et al. 1990; Hy-
nes et al. 1994).
1.3 Indirect enzymoimmunological assays
Hyaluronectin, a hyaluronan-binding proteoglycan can be used as a probe in an
indirect enzymoimmunological hyaluronidase assay (Delpech et al. 1987). Mi-
crotiter plates were coated with hyaluronic acid and incubated with hyaluro-
nidase. After rinsing the residual, hyaluronic acid was incubated with hyaluro-
nectin immune complexes conjugated with alkaline phosphatase, again rinsed
and incubated with diluted conjugated antibodies. Hyaluronidase activity is indi-
cated by a decrease in the absorbance measured at 405 nm. This method was
developed for the detection of small amounts of hyaluronidase  from the bovine
testis, hepatoma cell lines, bee venom, leech, human sera and streptomyces
species (Delpech et al. 1987; Hynes et al. 1994).
An ELISA-like assay for hyaluronidases and hyaluronidase inhibitors, similar to
the assay of Delpech et al. (Delpech et al. 1987) was reported by Stern et al.
(Stern et al. 1992). This assay is based on a high affinity biotinylated HA-
binding peptide and the avidine-biotin reaction and seems to be a sensitive,
rapid and simple assay.
1.4 Physicochemical assays
A turbidimetric assay, based on the observation that acidified hyaluronic acid
forms a stable colloidal suspension in the presence of diluted serum was pub-
lished by different authors (Hynes et al. 1994). After the degradation of the
substrate with hyaluronidase the incubation mixture is remaining clear. Hyalu-
ronidase activity is indicated by a decrease in the turbidity, measured with a
spectrophotometer at around 600 nm. A sensitive, simple, reproducible and
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economical semi quantitative microassay based on the turbidimetric assay was
reported by Ibrahim et al. (Ibrahim et al. 1973).
The turbidimetric assay based on the precipitation of nondegradated hyaluronic
acid with different reagents like cetyltrimethylammonium bromide is discussed
later in this chapter (cf. 3. Turbidimetric assay).
A number of approaches have been developed for detection of hyaluronidase
activity using the viscosity reduction of dissolved hyaluronic acid as indicator
of enzyme activity (Meyer et al. 1941; Meyer 1947).
Meyer et al. (Meyer et al. 1941; Meyer 1947) described a standardised proce-
dure in which many variations of this type of assay (substrate and buffer con-
centration, pH, temperature etc.) are combined. The viscosimetric assay is an
assay which is reliable for investigations of different hyaluronidases
(Tirunarayanan et al. 1968; Hynes et al. 1994).
The Mucin Clot Prevention (MCP) assay is based on the coprecipitation of
native hyaluronic acid with protein to form mucin clot. The quality and character
of the mucin clot is reduced when the substrate hyaluronic acid is degradated
by hyaluronidase. The most widely used MCP assay was originally described
by Robertson et al. (Robertson et al. 1940) and modified by McClean et al.
(McClean 1943). Other modified MCP tests are described by Unsworth
(Unsworth 1989), Halperin et al. (Halperin et al. 1987) and Murphy (Murphy
1972).
1.5 Plate (solid media) assays
Many assays have been developed for the detection of hyaluronidase using
solid media (Hynes et al. 1994). One of the simple plate assay is described by
Smith et al. (Smith et al. 1968). In this assay, petri dishes were coated with a
mixture of agar and hyaluronic acid and incubated with bacteria. Hyaluronidase
activity is detected as a zone of clearing around the bacteria in a cloudy back-
ground, resulting from acetic acid precipitation of a complex consisting of albu-
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min and nondegradated hyaluronic acid. The same assay can be used to test
isolated hyaluronidases instead of the whole bacteria (Hynes et al. 1989).
1.6 Radiochemical assays
A radiochemical method for detection of hyaluronidase activity was described
by Coulson and Girkin in 1975 (Coulson et al. 1975). The principle of this radio-
chemical assay is that cetylpyridinium chloride precipitates the radioactive la-
belled hyaluronic acid but not the smaller polysaccharides obtained by diges-
tion with hyaluronidase. In this procedure, hyaluronic acid is partially deacylated
and then reacylated in the presence of [3H]acetic anhydride. The radioactivity of
the undigested substrate, precipitated with cetylpyridinium chloride is compared
with the radioactivity of the blanks to get the hyaluronidase activity (Coulson et
al. 1975; Hynes et al. 1994).
Hotez et al. (Hotez et al. 1992) described an alternative radiochemical assay for
the detection of hookworm hyaluronidase activity. After incubation of the 3H-
labeled hyaluronic acid with hyaluronidase the degraded substrate is applied to
a polyacrylamide gel, fixed and prepared for autoradiography. Hyaluronidase
activity is observed as a decrease in the size of the labelled hyaluronic acid
(Hotez et al. 1992; Hynes et al. 1994).
1.7 Spectroscopic assays
Benchetrit et al. (Benchetrit et al. 1977) developed a sensitive method for the
detection of hyaluronidase based on a shift in maximal absorbance following
interaction of anionic mucoploysaccharides with a carbocynine dye. The hyalu-
ronidase activity is indicated by a decrease of the absorbance of the hyaluro-
nan-dye complex. This method is useful for the detection and quantification of
purified hyaluronidase, but it is not reliable for the detection of activity in crude
preparations where other substances may interfere (Hynes et al. 1994).
A modification of this procedure was described for the assay of chondroitin sul-
phate depolymerase and hyaluronidase activity in viridans Streptococci by
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Homer et al. (Homer et al. 1993; Homer et al. 1993). The principle of this assay
is the reaction of undegradated hyaluronan with 1-ethyl-2-[3-(1-ethylnaphtho-
[1,2-d]thiazolin-2-ylidene)-2-methylpropenyl]naphtho[1,2-d]thiazolium bromide
to give a complex with a characteristic absorbance maximum at 650 nm. The
increase in absorbance is directly proportional to the concentration of substrate
interacting with the dye. Similar spectroscopic assays are described by Coulson
(Coulson et al. 1975), Pryce-Jones (Pryce-Jones et al. 1979), Pritchard
(Pritchard et al. 1993) and Turner (Turner et al. 1985).
1.8 Zymographic analysis
Zymography is a method with allows the visualisation of enzyme activity follow-
ing electrophoretic fractions which has been used for the quantitative analysis
of a number of hyaluronidases (Abramson et al. 1967; Liefländer et al. 1968;
Herd et al. 1974; Fiszer-Szafarz et al. 1989; Hotez et al. 1992; Steiner et al.
1992; Hynes et al. 1994). Zymographic analysis can be carried out on a variety
of solid supports such as agar (Abramson et al. 1967), cellulose acetate mem-
branes (Herd et al. 1974) or acrylamide (Liefländer et al. 1968; Fiszer-Szafarz
et al. 1989; Steiner et al. 1992; Yamagata 1996; Mio et al. 2002).
The electrophoresis on a cellulose acetate membrane is described by Herd et
al. (Herd et al. 1974). After electrophoresis, the membrane is overlaid with a
second membrane saturated with hyaluronic acid and incubated at 37 °C. After
treating of the overlay membrane with alcian blue, the hyaluronidase activity is
seen as white bands in a blue background.
Abramson and Friedman (Abramson et al. 1967) used the electrophoresis on
agar to detect hyaluronidase activity in concentrated preparations from
Staphylococcus aureus, Streptococcus pyogenes and bovine testis.
Fiszer-Szafarz incorporated hyaluronic acid into polyacrylamide gels before
electrophoresis (Fiszer-Szafarz et al. 1989; Hynes et al. 1994). The hyaluro-
nidase activity is indicated by pink bands (polyacrylamide staining) in a blue
background (undegradated hyaluronan staining).
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2. Colorimetric assay – Morgan-Elson assay
For the investigation of the potential enzyme inhibitors described in this thesis,
the hyaluronidase activity was determined by a modified colorimetric assay,
which is based on the method of Gacesa et al. (Gacesa et al. 1981) and Reis-
sig et al. (Reissig et al. 1955) and reported in detail by Muckenschnabel et al.
(Muckenschnabel et al. 1998). The colorimetric assay (Reissig assay, Morgan-
Elson assay) is based on the reaction of the N-acetyl-D-glucosamine (GlucNAc)
at the reducing ends of hyaluronan and its fragments with p-dimethylamino-
benzaldehyde resulting in a red coloured product.
As shown in Fig. 1, the postulated main product of the degradation of hyaluro-
nic acid by the bovine testicular hyaluronidase is a tetrasaccharide with
N-acetyl-D-glucosamine at the reducing end. The chromogens I and II are
formed under alkaline conditions (100 °C, pH 9) of the Morgan-Elson reaction.
The chromogen III, which is formed by elimination of water under acidic condi-
tions (conc. HCl / glacial acetic acid) react in the final step with p-dimethyl-
aminobenzaldehyde (Ehrlich´s reagent) to give the instable red - coloured
product, which can be photometrically measured at 586 nm. The described
structure of the red product was postulated by Muckenschnabel et al. in 1998
(Muckenschnabel et al. 1998) on the basis of HPLC-MS investigations.
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Fig. 1: Mechanism of the Morgan-Elson reaction - reaction of the N-acetyl-
D-glucosamine with p-dimethylaminobenzaldehyde resulting in the red coloured
product postulated by Muckenschnabel et al. (Muckenschnabel et al. 1998).
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Effect of organic solvents on the enzyme activity
Our examined compounds were not soluble in the citrate-phosphate buffer, but
soluble in organic solvents such as dimethylformamide, dimethylsulphoxide,
methanol and ethanol. To find the appropriate solvent and the tolerated con-
centration bovine testicular hyaluronidase and hyaluronate lyase were investi-
gated in the presence of different concentrations of various organic solvents.
For this purpose the activities of the two enzymes were determined as a func-
tion of the solvent concentration in the incubation mixture. The effects of the
solvents on the bovine testicular hyaluronidase are shown in Fig. 2. Whereas
for all four solvents concentrations were accepted up to 4% higher concentra-
tions resulted in weak or strong inhibition of the enzyme depending on the type
of solvent.
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Fig. 2: Effect of DMF, DMSO, MeOH and EtOH on the activity of the bovine
testicular hyaluronidase at optimum pH (3.6)
The effects of the four organic solvents on the hyaluronate lyase are shown in
Fig. 3. Whereas the inhibitory effect of dimethylsulphoxide, methanol and
ethanol at concentrations up to 4 % were negligible, concentrations higher than
5 % affected the enzyme activity negatively. The inhibitory effect of DMF was
already significant at a concentration of 3 %.
Methods and assays for the  determination of hyaluronidase activity
26
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    0
20
40
60
80
100
2 3 4 5 10 15 22,2
[%] (v/v) organic solvent
Ac
tiv
ity
[%
]
DMF
DMSO
    
    MeOH
    EtOH
Fig. 3: Influence of the solvents DMF, DMSO, MeOH and EtOH on the activity
of the bacterial hyaluronidase at optimum pH (5.0)
Because of the good solubility of the test compounds in DMSO and the low in-
hibitory effect of DMSO (< 4%) on the two enzymes, dimethylsulphoxide was
used as solvent for pharmacological investigations.
Measurement of hyaluronidase activity
The procedure of the Morgan-Elson assay described in the literature was
scaled down to minimise the required amounts of test compounds and en-
zymes. The enzyme concentrations and the incubation periods were optimised
both for investigations at pH optimum and physiological pH. The incubation
mixture, the enzyme concentrations, the incubation periods etc. of the modified
assay are described in the following.
The test compounds (0.1 µM - 20 mM) dissolved in DMSO (7 µl), were incu-
bated at 37 °C in an incubation mixture containing 60 µl of citrate-phosphate
buffer (solution A: 0.1 M Na2HPO4 / 0.1 M NaCl, solution B: 0.1 M citric acid /
0.1 M NaCl; solution A and B were mixed in appropriate portions to adjust the
required pH), 40 µl BSA solution (0.2 mg BSA per ml of water), 20 µl substrate
solution (2 mg or 5 mg hyaluronic acid from rooster comb or Streptococcus
zooepidemicus per ml of water), 33 µl H2O and 20 µl enzyme solution (equiac-
tive concentration: 8 IU BTH (pH 3.6), 40 IU BTH (pH 7.4), 0.4 IU hyalB4755 (pH
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5.0 and 7.4)). The pH of the incubation mixture was adjusted to the pH opti-
mum of the enzymes (for BTH pH value of 3.6 and for hylB4755 pH value of 5.0)
and to physiological pH (7.4). The incubation time varied with the pH of the in-
cubation mixtures: an incubation period of 1.5 h at optimum pH and 3 h at
physiological pH for both enzymes.
The enzyme reaction was stopped by addition of 45 µl of alkaline borate solu-
tion and subsequent heating for 4.5 min in a boiling water bath. The alkaline
borate solution was prepared immediately before use from the borate solution
(17.3 g H3BO4 and 7.8 g KOH in 100 ml water) and the potassium carbonate
solution (8.0 g K2CO3 in 10 ml water). After cooling on ice for 1 min 600 µl of
N,N-dimethylaminobenzaldehyde (20.0 g N,N-dimethylaminobenzaldehyde dis-
solved in 25 ml concentrated hydrochloric acid and 75 ml glacial acetic acid; the
solution was diluted with 4 volumes of glacial acetic acid immediately before
use) was added and the mixture was incubated at 37 °C for 20 min. The re-
sulting solution was transferred to 96 well plates and the absorbance of the col-
oured product was photometrically measured at 590 nm.
Enzyme activity was calculated from the formation of the red coloured product
measured at 590 nm. The effect of the inhibitors on the enzyme activity was
calculated according to the equation:
A % = (B - C) / (D - E)
A: calculated enzyme activity
B: absorbance of the incubation mixture containing inhibitor
C: absorbance of the incubation mixture containing inhibitor in absence of the
enzyme (enzyme solution replaced with buffer)
D: absorbance of the incubation mixture in absence of the inhibitor (inhibitor
solution replaced with DMSO)
E: absorbance of the incubation mixture in absence of both enzyme and in-
hibitor (enzyme solution replaced with buffer, inhibitor solution replaced with
DMSO)
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The IC50 ± SEM values were calculated using the standard curves analysis of
SigmaPlotTM (version 8.0) and are the means of three independent experiments
performed in duplicate.
The Morgan-Elson assay is a useful method for the determination of hyaluroni-
dase activity in the presence of inhibitors. With respect to the required incuba-
tion times, the assay is practicable and reproducible for the quantitation of en-
zyme activities. However, not all compounds can be examined with this assay.
For instance, this assay is not suitable for the investigation of indole derivatives
since the indole ring reacts with the Ehrlich´s reagent (p-dimethylaminobenz-
aldehyde) to a coloured product which is also detectable at 590 nm and falsifies
the quantification of the red coloured product of the Morgan-Elson reaction (cf.
chapter 9)
3. Turbidimetric assay
The turbidimetric measurement of hyaluronidase activity was carried out ac-
cording to the method described by Di Ferrante (Di Ferrante 1956). The turbi-
dimetric assay is based on the formation of insoluble complexes of cetyltri-
methylammonium bromide (CTAB) and the remaining high molecular weight
substrate (mw > 8 kDa) after incubation with enzyme (cf. Fig.4).
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Fig. 4: Principle of the turbidimetric assay; precipitation of the polysaccharides
with cetyltrimethylammonium bromide (Di Ferrante 1956).
The test compounds (0.1 µM - 20 mM) dissolved in DMSO (10 µl), were incu-
bated at 37 °C in an incubation mixture containing 120 µl of citrate-phosphate
buffer (solution A: 0.1 M Na2HPO4 / 0.1 M NaCl, solution B: 0.1 M citric acid /
0.1 M NaCl; solution A and B were mixed in appropriate portions to adjust the
required pH), 30 µl BSA solution (0.2 mg BSA per ml of water), 30 µl substrate
solution (2 mg hyaluronic acid from Streptococcus zooepidemicus per ml of
water), 50 µl H2O and 30 µl enzyme solution (equiactive concentration: 2 IU
BTH (pH 3.6), 6 IU BTH (pH 7.4), 0.6 IU hyalB4755 (pH 5.0) and 1 IU hyalB4755
(pH 7.4)). The pH of the incubation mixture was adjusted to the pH optimum of
the enzymes (BTH pH value of 3.6, hylB4755 pH value of 5.0) and the physio-
logical pH (7.4). The incubation time varied with the pH of the incubation mix-
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tures: an incubation period of 1.5 h at optimum pH and 3 h at physiological pH
for both enzymes. After addition of 720 µl of a 2.5 % cetyltrimethylammonium
bromide solution (2.5 g CTAB dissolved in 100 ml 0.5 M sodium hydroxide so-
lution, pH 12.5) the mixture was incubated at 25 °C for 20 min. Afterwards, the
solution was transferred to UV cuvettes and the optical density was photometri-
cally measured at 600 nm.
Enzyme activity was calculated from the formation of the precipitation meas-
ured at 600 nm. The effect of the inhibitors on the enzyme activity was calcu-
lated according to the equation
A % = (B - C) / (B - D)
A: calculated enzyme activity
B: absorbance of the incubation mixture in absence of both enzyme and in-
hibitor (enzyme solution replaced with buffer, inhibitor solution replaced with
DMSO)
C: absorbance of the incubation mixture in presence of  inhibitor
D: absorbance of the incubation mixture in absence of the inhibitor (inhibitor
solution replaced with DMSO)
For all examined compounds it can be excluded that the compounds precipitate
with cetyltrimethylammonium bromide at the investigated concentrations. Fur-
thermore, the inhibitors do not absorb light at the wave-length of 600 nm used
in the turbidimetric assay.
The IC50 ± SEM values were calculated using the standard curves analysis of
SigmaPlotTM (version 8.0) and are the means of three independent experiments
performed in duplicate.
With respect to the required incubation times, the turbidimetric assay is a prac-
ticable and reproducible method for the quantification of enzyme activity. Fur-
thermore, it is possible to investigate compounds which cannot be examined
with the Morgan-Elson assay or with the UV differential spectroscopy assay (cf.
section 4 of this chapter). Nevertheless, a disadvantage of this assay is the
poor solubility of the examined compounds in the incubation mixture, a disad-
vantage which also applies for other methods.
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4. UV difference spectroscopy
The hyaluronate lyases (EC 4.2.2.1) differ from hyaluronidase from other
sources by their mode of action. They cleave the substrate hyaluronic acid by
an elimination reaction resulting in an unsaturated hexuronic acid at the nonre-
ducing ends (Kreil 1995; Pritchard et al. 2000) (cf. Fig. 5).
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Fig. 5: Cleavage of hyaluronic acid by bacterial hyaluronidases (EC 4.2.2.1);
2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-D-glucos-
amine as main product
The activity of the hyaluronate lyases from S. agalactiae can also be deter-
mined by quantifying the unsaturated degradation product 2-acetamido-2-
deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-D-glucosamine and the un-
saturated uronic acid residues of hyaluronan fragments photometrically at
232 nm according to Greiling (Greiling 1957).
To quantify the product formation, a set of matched tandem cuvettes, contain-
ing two compartments of equal pathlength (l = 4.375 mm) was used. The left
compartment of the sample cuvette was filled with the incubation mixture A,
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whereas the right compartment of the cell was filled with the solution B. The left
compartment of the reference cuvette was filled with the incubation mixture C,
the right compartment with the incubation mixture D (Table 1).
Table 1: Incubation mixtures used to quantify the formation of the unsaturated
hexuronic acid.
Incubation mixture A Incubation mixture B
50 µl inhibitor dissolved in DMSO 50 µl inhibitor dissolved in DMSO
300 µl citrate - phosphate buffer with
NaCl (pH = 5.0)
300 µl citrate - phosphate buffer with
NaCl (pH = 5.0)
200 µl BSA solution
(0.2 mg / ml of water)
200 µl BSA solution
(0.2 mg / ml of water)
250 µl HA solution
(2 mg / ml of water)
250 µl H2O
100 µl hyaluronate lyase dissolved in
BSA solution (0.2 mg / ml of water)
100 µl hyaluronate lyase dissolved in
BSA solution (0.2 mg / ml of water)
Incubation mixture C Incubation mixture D
50 µl inhibitor dissolved in DMSO 50 µl inhibitor dissolved in DMSO
300 µl citrate - phosphate buffer with
NaCl (pH = 5.0)
300 µl citrate - phosphate buffer with
NaCl (pH = 5.0)
200 µl BSA solution
(0.2 mg / ml of water)
200 µl BSA solution
(0.2 mg / ml of water)
250 µl H2O
250 µl HA solution
(2 mg / ml of water)
100 µl BSA solution
(0.2 mg / ml of water)
100 µl BSA solution
(0.2 mg / ml of water)
The cuvettes were placed in the sample and the reference beam of the spec-
trophotometer and the increase in absorbance was monitored at 232 nm as
function of time at 37 °C.
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From the increase of absorbance (∆A) at 232 nm per time (∆t) the enzymatic
activity (A%) was calculated according to the following equation
A% = (∆A /∆t) / (∆Amax /∆t)
where ∆Amax is equivalent to the absorbance of the incubation mixture contain-
ing DMSO instead of the inhibitor.
The IC50 ± SEM values were calculated using the standard curves analysis of
SigmaPlotTM (version 8.0) and are the means of three independent experiments
performed in duplicate.
The advantage of the UV difference spectroscopy assay is the short incubation
time (5 to 10 minutes), the sensitivity and the good reproducibility of the assay.
However, as an unsaturated hexuronic acid is determined, this assay can only
be used for the investigation of inhibitors of hyaluronate lyases. Compounds,
which show absorbance at 232 nm, the wave-length used for the detection of
the double-bond formation cannot be tested with this assay. A further dis-
advantage of this assay is the poor solubility of the examined compounds in the
incubation mixture, a disadvantage which also applies for other methods.
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Chapter 4
Investigations of sulphated oligosaccharides as
inhibitors of hyaluronidases from bovine testis,
bee venom and from S. agalactiae
1. Introduction
It was reported that apigenin (1) and kaempferol (2) are potent hyaluronidase
inhibitors (Kuppusamy et al. 1990; Kuppusamy et al. 1991) (cf. Fig. 1). These
two inhibitors are widely accepted as inhibitors of hyaluronidases and often
used as positive controls for inhibition.
To verify the published results, we examined the effect of apigenin and kaemp-
ferol on the activity of the bovine testicular hyaluronidase at optimum pH (3.6).
The inhibitory activities were determined in an optimised colorimetric assay
based on the method of Reissig et al. (Reissig et al. 1955; Muckenschnabel et
al. 1998).
As shown in Fig. 1 the inhibitory effects of apigenin (1) and kaempferol (2) on
the bovine testicular hyaluronidase were only 56% and 36% at the highest con-
centration of 1 mM and 10 mM, respectively. Furthermore, the inhibition by
compound 1 was not concentration dependent.
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Fig. 1: Inhibitory effect of the classical inhibitors apigenin (1, R = H) and
kaempferol (2, R = OH) on the activity of the bovine testicular hyaluronidase at
optimum pH (3.6).
Asada et al. (Asada et al. 1997) examined the effect of various types of alginic
acid consisting of L-glucuronic acids and D-mannuronic acids on the bovine
testicular hyaluronidase. These investigations were stimulated by the structural
resemblance of alginic acid to hyaluronic acid. The inhibition of the hyaluro-
nidase by sodium alginate was dependent on the molecular weight – the higher
the molecular weight, the stronger the inhibition.
It has also been reported that heparin, a sulphated glucosaminoglycane, is an
inhibitor of hyaluronidase (Houck 1957; Wolf et al. 1984; Farr et al. 1997; Mio et
al. 2002). The inhibition of hyaluronidase activity by heparin is achieved only at
concentrations by far higher than physiological levels. The inhibition by heparin
is non-competitive and the compound does not bind to the catalytic site of the
enzyme. Mio et al. (Mio et al. 2002) reported that heparan sulphate, a glucos-
aminoglycane too, inhibited the hyaluronidase activity. The inhibitory activity of
heparin and heparan sulphate was explained by the high structural similarity of
these oligosaccharides to hyaluronic acid. Based on these results, Toida et al.
(Toida et al. 1999) investigated O-sulphated glucosaminoglycanes whereby the
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fully sulphated compounds showed the highest inhibitory effect on the activity of
hyaluronidases.
In summary, oligosaccharides with sulphate and/or carboxylate as functional
groups seem to be promising compounds as hyaluronidase inhibitors.
2. Pharmacological investigations
As part of our project on hyaluronidase inhibitors we studied a set of structurally
different oligosaccharides against bovine testicular hyaluronidase (BTH),
Streptococcus agalactiae hyaluronate lyase (hylB4755) and bee venom hyalu-
ronidase (BVH). The inhibitory effect of some sulphated and non-sulphated oli-
gosaccharides (cf. Table 1) on the activity of hyaluronidases were examined.
2.1 The influence of sulphated and non-sulphated β-(1,4)-ga-
lacto-oligosaccharides on the activity of hyaluronidases
The first investigated compounds were a series of sulphated and non-sulphated
β-(1,4)-galacto-oligosaccharides (3-8, cf. Table 1) with 3, 4, 5 or 8 sugar mo-
nomers and with a degree of sulphation (DS) ranging from 0.35 to 0.67 (DS = 1
equivalent to a sulphation of all hydroxyl groups). The inhibitory effects on the
activity of the bovine testicular hyaluronidase (BTH), of the bee venom hyalu-
ronidase (BVH) and of the hyaluronate lyase from S. agalactiae (hylB4755) at
optimum pH are summarised in Table.1.
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Table 1: IC50 values of a series of sulphated and non-sulphated β-(1,4)-
galacto-oligosaccharides investigated on BTH, BVH and hylB4755.
O
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OR
n
β-(1,4)-galacto-
oligosaccharides
No             n / R                    DS
BTH
IC50 [µM]a
at pH = 3.6
BVH
IC50 [µM]a
at pH = 3.6
hylB4755
IC50 [µM]a
at pH = 5.0
3 n = 1R = H or SO3Na
0.67 40 25 630
4 n = 2R = H 0 >> 1000 n.d. >> 1000
5 n = 2R = H or SO3Na
0.56 35 40 320
6 n = 3H 0 >> 1000 n.d. >> 1000
7 n = 3R = H or SO3Na
0.59 20 20 200
8 n = 6R = H or SO3Na
0.35 600 n.d. 4
a the SEM values of the calculated IC50 values are in the range of 5-10%
As exemplarily shown for the sulphated β-(1,4)-tetragalactoside (5) in Fig. 2 the
inhibitory effect on the bovine testicular hyaluronidase and on the bacterial en-
zyme at optimum pH (BTH pH 3.6, hylB4755 pH 5.0) are in the micromolar range
and concentration dependent. Whereas the obtained IC50 values of compound
5 were similar for the bovine testicular and the bee venom hyaluronidase (BTH
35 µM and BVH 40 µM), the IC50 value for the hyaluronate lyase was only
Sulphated oligosaccharides
41
320 µM. The inhibitory effect on the bacterial hyaluronidase was 9-fold lower
than on the bovine testicular hyaluronidase and the bee venom enzyme.
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Fig. 2: Effect of the sulphated β-(1,4)-tetragalactoside 5 (structure cf. Table 1,
DS = 0.56) on the activities of the bovine testicular hyaluronidase (IC50 =
35 µM, pH 3.6) and the bacterial hyaluronidase (IC50 = 320 µM, pH 5.0)
The highest activities on the bovine testicular and the bee venom hyaluronidase
were found for the sulphated tri-, tetra- and pentasaccharides. The determined
IC50 values were 40 µM / 25 µM (3, n = 1, DS = 0.67); 35 µM / 40 µM (5, n = 2,
DS = 0.56); 20 µM / 20 µM (7, n = 3, DS = 0.59) (cf. Table. 1). The effect of the
sulphated β-(1,4)-octagalactoside (8, n = 6, DS = 0.35) on the bovine testicular
hyaluronidase was 15-fold lower than the effect of the sulphated compounds 3,
5 and 7.
The IC50 values of the sulphated tri-, tetra- and pentasaccharides determined
on the bacterial hyaluronidase ranged from 200 µM to 630 µM. These sul-
phated oligosaccharides had a 10- to 16-fold lower inhibitory effect on hylB4755
in comparison to the bovine testicular and the bee venom hyaluronidase. Sur-
prisingly the lowest IC50 value of 4 µM was measured for the sulphated β-(1,4)-
octasaccharide (8, DS = 0.35). The extension of the chain length from 3 to 8
monomer units resulted in a 160-fold increase of the inhibitory activity on the
hyaluronate lyase.
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No R DS
9 H 0
10 H or SO3Na 0.43
11 H or SO3Na 0.53
In conclusion, the optimal number of sugar residues seems to be 3, 4 and 5 for
the inhibition of the bovine testicular and the bee venom hyaluronidase. The
oligosaccharides with the chain length of 8 monomers showed the highest inhi-
bitory activity on the bacterial enzyme. Independent of the chain length of the
oligosaccharides, the sulphation was essential: all examined non-sulphated
β-(1,4)-galacto-oligosaccharides were inactive at all three hyaluronidases.
2.2 Influence of the degree of sulphation on the potency
The pentasaccharide verbascose 9 (structure cf. Fig. 3) and two sulphated de-
rivatives 10 and 11 which differed in the degree of sulphation (DS: 0.43 and
0.53) were selected to investigate the contribution of sulphation on the enzyme
activity of the three hyaluronidases.
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Fig. 3: Structure of the verbascose derivatives 9-11
The inhibitory effects of verbascose 9 and the sulphated derivatives 10 and 11
on the activity of the bovine testicular hyaluronidase are shown as concentra-
tion-response curves in Fig. 4. The IC50 value determined for the sulphated de-
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rivative 10 (DS = 0.43) and 11 (DS = 0.53) were  30 µM and 3 µM, respectively.
As expected, the non-sulphated pentasaccharide was ineffective on the bovine
testicular hyaluronidase and on the hyaluronidases from bee venom as well as
from S. agalactiae (data not shown). Obviously, a 20% increase in the degree
of sulphation resulted in about 10-fold enhancement of the inhibitory activity.
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Fig. 4: Effect of the three verbascose derivatives 9-11 on the activity of BTH
depending on the degree of sulphation (DS of 1 is equivalent to the sulphation
of all hydroxyl groups)
The effects of verbascose and its sulphated derivatives on the hyaluronate ly-
ase and on the bee venom hyaluronidase were similar to those on the bovine
testicular enzyme. The IC50 values determined on hylB4755 were 30 µM (DS =
0.43) and 1 µM (DS = 0.53) and for BVH 40 µM and 3 µM, respectively. An in-
crease by 20% in the degree of sulphation resulted in about 30-fold and 13-fold
enhancement of the inhibitory activity on the bacterial enzyme and the bee
venom hyaluronidase, respectively. In summary, the potency of the penta-
saccharides is dependent on the degree of sulphation: the higher the degree of
sulphation, the higher the inhibitory activity.
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No R DS
12 H 0
13 H or SO3Na 0.62
2.3 Inhibitory effects of neomycin and planteose derivatives on
the activity of the three hyaluronidases BTH, BVH and hylB4755
As oligosaccharides with three, four or five monomers and a high degree of
sulphation which appears to be the most promising derivatives, we examined
the antibiotic neomycin (12) and its sulphated derivative 13 as well as plante-
ose (14) and its sulphated derivative 15 – in order to confirm the aforemen-
tioned structure-activity relationships. The structures of the neomycin deriva-
tives 12 and 13 and the planteose derivatives 14 and 15 are shown in Fig. 5
and Fig. 7, respectively.
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Fig. 5: Structure of the neomycin derivatives 12-13
The non-sulphated tetrasaccharide 12 was inactive on the bovine testicular and
the bacterial hyaluronidase, whereas the sulphated compound showed a dose-
dependent inhibition of both enzymes. The inhibition curves of the sulphated
compound are depicted in Fig. 6. The IC50 value of the sulphated neomycin
derivative 13 (DS = 0.62) determined on BTH was 60 µM, the IC50 value on
hylB4755 was 500 µM. The sulphated tetrasaccharide 13 was an 8-fold more
potent inhibitor of the bovine testicular hyaluronidase than of the hyaluronate
lyase.
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No R DS
14 H 0
15 H, SO3Na ~ 1
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Fig. 6: Effect of the sulphated neomycin (13, DS = 0.62) on the activities of the
bovine testicular hyaluronidase and the hyaluronate lyase at optimum pH (BTH
pH 3.6; hylB4755 pH 5.0)
As expected the non-sulphated trisaccharide 14 was inactive on the bovine tes-
ticular, the bee venom hyaluronidase and on the hyaluronate lyase (data not
shown), whereas the sulphated derivative 15 showed concentration dependent
inhibitions of all three hyaluronidases.
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Fig. 7: Structure of the planteose derivatives 14-15
The inhibition curves of the sulphated planteose derivative 15 are depicted in
Fig. 8. The determined IC50 value of compound 15 on the bovine testicular
hyaluronidase of 4 µM was only 2-times lower than for the bee venom hyalu-
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ronidase (8 µM; not shown in Fig. 8) and 4-times lower than for the bacterial
enzyme (15 µM). In comparison to the sulphated neomycin analogue 13, the
sulphated trisaccharide 15 showed a 15-fold and a 30-fold higher inhibitory po-
tency on the bovine testicular hyaluronidase and on the bacterial enzyme, re-
spectively.
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Fig. 8: Activities of BTH and hylB4577 in the presence of the sulphated plante-
ose derivative 15 with a degree of sulphation of approximately 1
In summary, the results obtained with neomycin and planteose derivatives sup-
port the idea that small oligosaccharides with a high degree of sulphation are
the most promising compounds for further investigation.
2.4 Inhibition of hyaluronidases by the sulphates of hydrochi-
none digalactoside and 2-hydroxyphenyl monolactobioside
To investigate the influence of a planar ring system as spacer between mono-
saccharides or at the end of an oligosaccharide we tested the sulphated hy-
drochinone digalactoside (16) and the sulphated 2-hydroxyphenyl monolac-
tobioside (17) (cf. Fig. 9). Compound 16 is composed by an aromatic ring be-
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tween two galactose monomers, whereas compound 17 is composed by an
aromatic ring at the end of a lactose unit.
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Fig. 9: Structure of the sulphated hydrochinone digalactoside 16 and the sul-
phated 2-hydroxyphenyl monolactobioside 17 (R = H and/or SO3Na)
The degrees of sulphation of the examined derivatives were 0.81 and 0.67 for
compound 16 and 17, respectively. The inhibitory activities determined on the
bovine testicular, the bee venom and the bacterial hyaluronidase are summa-
rised in Table 2.
Table 2: Effect of the sulphated hydrochinone digalactoside 16 and the sul-
phated compound 17 on the activities of hyaluronidases
Compound
No           R                             DS
BTH
IC50 [µM]a
at pH = 3.6
BVH
IC50 [µM]a
at pH = 3.6
hylB4755
IC50 [µM]a
at pH = 5.0
16 R = H or SO3Na 0.81 15 6 80
17 R = H or SO3Na 0.67 25 n.d. 350
a the SEM values of the calculated IC50 values are in the range of 5-10%
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The lowest inhibitory effects on the hyaluronidases were obtained for the sul-
phated compound 17. The IC50 values of 2-hydroxyphenyl monolactobioside 17
were 25 µM determined on BTH and 350 µM on hylB4755. The inhibitory activi-
ties of the sulphated hydroxychinone digalactoside 16 were also in the micro-
molar range with IC50 values of 6 µM (BVH), 15 µM (BTH) and 80 µM (hylB4755).
Whereas the inhibition of the bovine testicular enzyme by the two sulphated
compounds were similar, the sugar derivative with the higher degree of sul-
phation (cf. compound 16 with DS = 0.81) showed a 4-fold increase of the in-
hibitory activity on the hyaluronate lyase.
The inhibitory activities of these two sulphated compounds, which possess a
phenyl ring as structural element, are of the same potency as the investigated
sulphated tri-, tetra- and pentasaccharides.
3. Summary
The results obtained in the present study suggest that sulphated sugar deriva-
tives are useful as inhibitors of hyaluronidase, whereas the basic structures
lacking sulphate groups are inactive. Furthermore, the degree of sulphation
plays an important role on the inhibitory effect: the higher the degree of sul-
phation the higher the inhibitory activity. The major problem with the sulphated
compounds is, that the sulphation results in mixture of reaction products, which
are extremely difficult to separate. The degree of sulphation is a mean value
and is not exactly known which hydroxy groups are sulphated and which are
free. Compounds with sulphate groups in defined positions would be necessary
for detailed structure-activity investigations.
As inhibitors of the bovine testicular and the bee venom hyaluronidase the sul-
phated oligosaccharides with three, four or five sugar units were the most active
compounds. About the same activity was achieved with compounds having two
sugar units and a phenyl ring. In summary, sulphated tri-, tetra-, pentasaccha-
rides and/or sulphated disaccharides with a phenyl moiety are the most prom-
ising compounds for further investigations as inhibitors of BTH and BVH.
By contrast, in case of the hyaluronate lyase, the highest activity was found for
the sulphated octasaccharide with a degree of sulphation of 0.35. It seems to
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be, that an increase in the chain length of the oligosaccharides favours the in-
hibition of the hyaluronan lyases compared to the investigated hyaluronate hy-
drolases. The investigated sulphated saccharides were 100-500 times more
active than the widely accepted hyaluronidase inhibitors apigenin (1) and
kaempferol (2). In conclusion, oligosaccharides with sulphate groups in defined
positions are necessary for further structure-activity studies.
4. Materials and Methods
4.1 Test compounds
The sulphated and non-sulphated oligosaccharides were kindly provided from
PD Dr. D. Paper and Dr. C. Käsbauer (Institute of Pharmacy, University of
Regensburg, Germany). The compounds were isolated, modified and analysed
as described elsewhere (Käsbauer 1999; Käsbauer et al. 2001).
4.2 Enzymes and chemicals
Hyaluronic acid (HA) from rooster comb and bovine serum albumin (BSA) were
purchased from Serva (Heidelberg, Germany). The investigated hyaluronidases
were enzyme preparation from different sources.
Hylase® “Dessau”, containing 1 500 IU (according to the declaration of the sup-
plier) of lyophilised bovine testicular hyaluronidase (BTH) per vial was a gift
from Pharma Dessau (Dessau, Germany).
Stabilised hyaluronate lyase, i.e., 200 000 IU (according to the declaration of
the supplier) of lyophilised hyaluronidase (0.572 mg) from Streptococcus aga-
lactiae, strain 4755 (hylB4755), plus 2.2 mg BSA and 37 mg Tris-HCl per vial was
kindly provided by id-Pharma (Jena, Germany).
Bee venom hyaluronidase (BVH) (Gmachl et al. 1993; Soldatova et al. 1998)
was a gift from Dr. Zora Marcovic-Housley, University of Basel (Switzerland).
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All other chemicals were of analytical grade and were purchased from Merck
(Darmstadt, Germany). Water was purified by a Milli-Q system (Millipore, Esch-
born, Germany).
4.3 Determination of enzyme inhibition
Hyaluronidase activity was quantified by the method of Reissig et. al. (Reissig
et al. 1955) based on the Morgan-Elson reaction, a reaction between N-acetyl-
D-glucosamine (NAG) at the reducing ends of sugars liberated from hyaluronic
acid and N,N-dimethylaminobenzaldehyde. The assay was performed as de-
scribed elsewhere in detail (Muckenschnabel et al. 1998; Muckenschnabel et
al. 1998). The test compounds, dissolved in DMSO (0.1 µM - 5 mM), were in-
cubated at 37 °C in an incubation mixture containing 60 µl of citrate-phosphate
buffer (solution A: 0.1 M Na2HPO4 / 0.1 M NaCl, solution B: 0.1 M citric acid /
0.1 M NaCl; solution A and B were mixed in appropriate portions to adjust the
required pH), 40 µl BSA (0.2 mg BSA per ml of water), 20 µl substrate solution
(5 mg hyaluronic acid from rooster comb per ml of water) and 20 µl enzyme
solution (equiactive concentration: 20 IU BTH, 1 IU hylB4755 and 19 IU BVH).
The pH of the incubation mixture was adjusted to the pH optimum of the en-
zymes (BTH and BVH pH = 3.6, hylB4755 pH = 5.0).
The enzyme reaction was stopped by addition of alkaline borate solution and
subsequent heating for 4.5 min in a boiling water bath. The alkaline borate so-
lution was prepared immediately before use from the borate solution (17.3 g
H3BO4 and 7.8 g KOH in 100 ml water) and the potassium carbonate solution
(8.0 g K2CO3 in 10 ml water). After cooling on ice for 1 min 600 µl of N,N-di-
methylaminobenzaldehyde (20.0 g N,N-dimethylaminobenzaldehyde dissolved
in 25 ml concentrated hydrochloric acid and 75 ml glacial acetic acid; the solu-
tion was diluted with 4 volumes of glacial acetic acid immediately before use)
was added and the mixture was incubated at 37 °C for 20 min. The solution
was transferred to cuvettes or 96 well plates and the absorbance of the col-
oured product was measured with an Uvicon 930 UV spectrophotometer (Kon-
tron, Eching, Germany) at 590 nm and with an automatised EL312E (BIO-TEKR
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Instruments INC., Highland Park, Winooski) microplate reader at 590 nm re-
spectively.
Enzyme activity was calculated from the formation of the red coloured product
measured at 586 nm. The effect of the inhibitors on the enzyme activity was
calculated according to the equation:
A % = (B - C) / (D - E)
A: calculated enzyme activity
B: absorbance of the incubation mixture containing inhibitor
C: absorbance of the incubation mixture containing inhibitor in absence of the
enzyme (enzyme solution replaced with buffer)
D: absorbance of the incubation mixture in absence of the inhibitor (inhibitor
solution replaced with DMSO)
E: absorbance of the incubation mixture in absence of both enzyme and in-
hibitor (enzyme solution replaced with buffer, inhibitor solution replaced with
DMSO)
The IC50 ± SEM values were calculated using the standard curves analysis of
SigmaPlotTM (version 8.0) and are the means of three independent experiments
performed in duplicate.
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Chapter 5
Design and synthesis of a substrate analogue
as a potential inhibitor of hyaluronate lyases
1. Introduction
By cleaving hyaluronan, bacterial hyaluronate lyases, e. g. that of S. agalactiae
(hylB4755), facilitate the spreading of the microorganisms and their toxins in in-
fectious diseases such as meningitis and septicaemia (Hynes et al. 2000). Po-
tent inhibitors of hyaluronan lyases could be useful in studying the role of hyalu-
ronan and hyaluronidases in bacterial infection. As part of our project on hyalu-
ronate lyase inhibitors, the design of a substrate analogue as a potential in-
hibitor was envisaged.
The degradation of hyaluronic acid by bacterial hyaluronate lyases occurs at
the β-1,4-glycosidic linkage between D-glucuronic acid and N-acetyl-D-glucos-
amine. The product of this elimination reaction is the unsaturated disaccharide
yield 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-D-glu-
cose (Kreil 1995; Pritchard et al. 2000). Recently, the mechanism of the elimi-
nation reaction by S. agalactiae strain 3502 hyaluronate lyase (hylB3502) was
revealed (Jedrzejas et al. 2000; Li et al. 2001; Jedrzejas 2002). The active
centre of hylB3502 is composed of two main parts, a catalytic group responsible
for the substrate degradation and an aromatic patch responsible for the selec-
tion of cleavage sites on the substrate chains (Li et al. 2000). The residues that
form the aromatic patch of the enzyme are Trp371, Trp372 and Phe423, those
of the catalytic group are His479, Tyr488 and Asn429.
The mechanism of the hyaluronan lyase reaction was postulated by S. Li and
M. J. Jedrzejas (Li et al. 2001) as follows: In the first step, the positively
charged cleft of the enzyme attracts and binds the negatively charged substrate
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chain, whereby three disaccharide units can be accommodated into the cleft
(cf. Fig. 1, only two of the three disaccharide units are drawn HA1 and HA2). In
the second step, the aromatic patch of the active site interacts with the sub-
strate chain and anchors it right position. In the third step, the glucuronic acid of
HA1 is deprotonated at C-5 by His479 (cf. Fig. 1). At the same time, Tyr488
donates a proton to the glycosidic oxygen O-4 connecting D-glucuronic acid of
HA1 and N-acetyl-D-glucosamine of HA2. The glycosidic bond is cleaved by
1,2-elimination forming the double bond of the unsaturated final product (fourth
step). Finally (fifth step), the catalytic triad is regenerated: His479 loses its ac-
quired proton and Tyr488 attracts a proton from the surrounding water mole-
cules. Thus, the enzyme returns to the original state and a next cycle of cataly-
sis can be started. All five steps of the mechanism are crucial for the degrada-
tion of hyaluronic acid. The protein acts as a proton exchanger, because the
protein accepts one proton from the substrate and donates one proton from
water molecules to the substrate to break the 1,4-β glycosidic bond in hyaluro-
nan.
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Fig. 1: Mechanism of the hyaluronan degradation by hyaluronate lyase
according to Li et al. (Li et al. 2001). Schematical representation of the hyalu-
ronic acid with HA1 and HA2 as disaccharide units and the position of the
amino acids residues Tyr488, His497 and Asn429 relative to the substrate.
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The S. agalactiae strain 4755 hyaluronate lyase (hylB4755) shows extensive se-
quence identity of 98 % to the homologous enzyme of S. agalactiae strain 3502
(Baker et al. 2000; Ponnuraj et al. 2000). Even the whole structural architecture
and the active site geometry are quite similar, thus the catalytic mechanism
suggested for hylB3502 is likely to be identical to that of hylB4755.
Based on this mechanistical study of the hyaluronan degradation, we designed
a substrate analogue as a potential inhibitor. One important step of this mecha-
nism is the removal of the proton at C-5 of the glucuronic acid by the amino
acid residues His479. By preventing the elimination of this proton, the cleavage
of the substrate would be blocked. This could be achieved by replacing the hy-
drogen atom with a fluorine atom. As known, such substitutions (F vs. H) are
commonly used for the development of enzyme inhibitors. To cleave the C-F
bond an extra energy is required compared to the cleavage of the C-H bond. By
introducing the fluorine atom at C-5 the binding properties of the whole mole-
cule should be comparable to those of the substrate. As only the first three
saccharide units of hyaluronan are directly involved in the cleavage, these three
units were chosen as basic structure of our approach. The structure of the pro-
posed inhibitor deduced from the hyaluronan structure in consideration of the
cleavage mechanism, is shown in Fig. 2.
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Fig. 2: Design of a fluorinated hyaluronan analogue as a potential sub-
strate-like inhibitor of hyaluronate lyase
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2. Synthetic strategies and chemistry
For the synthesis of the trisaccharide A, a general straightforward synthetic
route had to be developed. Flanked by two N-acetylglucosamine units (Ia and
Ib) D-glucuronic acid with a fluoro substituent in position 5 (II) is the central and
most important building block (cf. Fig. 3). To synthesise the substrate analogue,
it is necessary to protect the sugar monomers in specific positions, then to con-
nect the three compounds to the trisaccharide and finally to cleave the protect-
ing groups (PG) to get the desired product. To achieve the substantial structural
similarity to the substrate, the linkage should be β-1,4 between N-acetyl-D-
glucosamine and D-glucuronic acid and β-1,3 between D-glucuronic acid and
N-acetyl-D-glucosamine (cf. Fig. 2 and Fig. 3).
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Fig. 3: First retrosynthesis considerations of the substrate analogue 2-acetyl-
amino-2-deoxy-β-D-glucopyranosyl-(1→4)-5-fluoro-β-D-glucopyranuronosyl-
(1→3)-2-acetylamino-2-deoxy-D-glucupyranose
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2.1 Synthesis of the building blocks Ia and Ib
As the building block Ia has to be β-1,4 linked with the second monomer we
protected N-acetyl-D-glucosamine (1) in the positions 3, 4 and 6 and kept posi-
tion 1 unprotected for the linkage. The acetyl and the benzyl protecting groups
were selected for the protection of N-acetyl-D-glucosamine (1) groups. The ad-
vantages of these two protecting groups are synthetic feasibility, mild cleavage
conditions and stability during linkage reactions.
3,4,6-Tri-O-acetyl-2-acetylamino-2-deoxy-D-glucopyranose (3) was prepared in
two steps (cf. Scheme 1). First, N-acetyl-D-glucosamine (1) was totally acety-
lated with acetic anhydride and sodium acetate at high temperature. In the sec-
ond step, the acetyl group must be cleaved selectively in position 1 of com-
pound 2. This reaction was carried out with benzylamine in anhydrous tetrahy-
drofuran according to the method of M. Sim et al. (Sim et al. 1993).
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Scheme 1: Synthesis of 3,4,6-Tri-O-acetyl-2-acetylamino-2-deoxy-D-glucopyra-
nose (3); reaction conditions: i) Ac2O, NaOAc, ∆T; ii) BnNH2, THF
To synthesise 2-acetylamino-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (5) a
different strategy was used starting with allyl protection of the hydroxy group in
position 1, followed by benzylation of the remaining hydroxy groups and finally
cleavage of the allyl ether (cf. Scheme 2).
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Scheme 2: Synthesis of 2-acetylamino-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyra-
nose (5); reaction conditions: i) AllOH, BF3*Et2O; ii) BnBr, KOH, THF; iii) PdCl2,
AcOH, NaOAc;
The allylation of the hydroxy group in position 1 with allyl alcohol and BF3*Et2O
was carried out according to a method described by A. Vasella et al. (Vasella et
al. 1991) with some modifications. The subsequent benzylation of the residual
hydroxy groups was realised with benzyl bromide in anhydrous THF and potas-
sium hydroxide as base according to the general procedure described by of M.
Shaban et al. (Shaban et al. 1976). For the conversion of compound 4 to com-
pound 5 by cleaving the allyl ether different standard methods were tried. The
deprotection with tBuOK in DMSO at 60 °C and than I2 in a bi-phase system
(THF/H2O) (Granier et al. 1998) did not lead to the desired product. As de-
scribed by Mereyala et al. (Mereyala et al. 1993), the cleavage of the allyl ether
should be achieved with PdCl2 and CuCl, however, this reaction failed, too.
Finally, 2-acetylamino-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (5) was ob-
tained by the deprotection of compound 4 with PdCl2 under acidic conditions
based on the method described by S. Figueroa-Perez et al. (Figueroa-Perez et
al. 2000).
The building block Ib required for the preparation of the trisaccharide is again
N-acetyl-D-glucosamine which should be β-1,3 linked with the fluorinated glucu-
ronic acid II. Therefore, N-acetyl-D-glucosamine (1) should be protected in po-
sitions 1, 4 and 6, whereas the hydroxy group in position 3 should remain non-
protected for the linkage.
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The benzyl and the benzylidene groups were selected for the protection of
N-acetyl-D-glucosamine to get benzyl 2-acetylamino-4,6-O-benzylidene-2-de-
oxy-D-glucopyranoside (7) (cf. Scheme 3). The advantages of these two pro-
tecting groups are the synthetic feasibility, the mild cleavage conditions and the
stability during linkage reactions. The synthesis of compound 7 was carried out
in two steps as shown in Scheme 3. In the first step the semi-acetal in position
1 of N-acetyl-D-glucosamine (1) was quantitatively converted to the acetal with
benzyl alcohol in acetyl chloride according to the method of Sutherlin et al.
(Sutherlin et al. 1997). Subsequently, the 4,6-benzylideneacetal 7 was obtained
by treating compound 6 with PhCH(OCH3)2 and p-TsOH as catalyst in aceto-
nitrile according to the method of Aguilera et al. (Aguilera et al. 1997) with some
modifications.
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Scheme 3: Synthesis of benzyl 2-acetylamino-4,6-O-benzylidene-2-deoxy-D-
glucopyranoside (7); reaction condition: i) BnOH, AcCl; ii) PhCH(OCH3)2, ace-
tonitrile, p-TsOH
2.2 Synthesis of the fluorinated D-glucuronic acid II
As 5-fluoro-D-glucuronic acid has to be linked with two N-acetylglucosamine
molecules in position 1 and 4, the fluorinated compound should be protected in
the positions 2 and 3, whereas the hydroxy groups in the positions 1 and 4
should be ether free for linkage or protected with a group that can be selectively
cleaved before linkage (cf. structure II).
Two different strategies were envisaged for the synthesis of this building block
(cf. Fig. 4).
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Fig. 4: Retrosynthetic routes for the synthesis of the fluorinated D-glucuronic
acid
Starting from the commercially available methyl α-D-glucopyranoside according
to route A, the double bond between the carbon atoms 5 and 6 will be intro-
duced by an elimination reaction. By subsequent fluorination of this alkene, the
fluorine atom would be introduced in position 5. Finally, the oxidation of the
carbon atom in position 6 would lead to the desired fluorinated glucuronic acid,
which can be linked with both other carbohydrate monomers Ia and Ib.
According to route B, the fluorine atom would be introduced by fluorination of
an intermediate with C=C double bond in position 4. The pertinent alkene will
be synthesised by an elimination reaction starting from the commercially avail-
able methyl α-D-glucopyranoside, too. The carboxylic acid in position 6 should
be obtained by oxidation reaction.
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Synthetic route A
The key reactions of route A are elimination, fluorination and oxidation. The
elimination of HI on the protected 6-iodo-α-D-glucose derivative was the first
method tried to introduce an alkene function. Therefore, the hydroxy group in
position 6 of methyl α-D-glucopyranoside (8) was selectively substituted by io-
dine and the remaining hydroxy groups were subsequently acetylated or ben-
zoylated. The iodination of compound 8 was successfully performed by treating
the starting material with N-iodosuccinimide and triphenylphosphine in DMF
(Garegg et al. 1978) or with iodine, triphenylphosphine and imidazole in aceto-
nitrile (Garegg et al. 1982).  The subsequent acetylation or benzoylation of the
iodinated intermediate were carried out under standard conditions with acetic
anhydride and sodium acetate or benzoyl chloride and pyridine, respectively to
yield the products 9a and 9b (cf. Scheme 4).
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8 9a, b
Scheme 4: Synthesis of the protected methyl 6-deoxy-6-iodo-α-D-glucopyrano-
side 9a and 9b; reaction conditions: for 9a i) NIS, Ph3P, DMF; ii) Ac2O, NaOAc;
for 9b i) I2, Ph3P, imidazole; ii) BzCl, pyridine
Due to difficult separation of the product from starting materials and low yield,
an alternative route was envisaged: first protection of the hydroxy groups in the
positions 2, 3 and 4 and then substitution of position 6 with iodine. Several
methods were tried for this alternative route (Garegg et al. 1978; Garegg et al.
1982; Mirza et al. 1985), however, neither the acetylated glucose derivative nor
the benzoylated compound could be iodinated. Therefore, the route shown  in
Scheme 4 was applied despite the aforementioned disadvantages.
In the next step the elimination of HI was accomplished according to the
method described by Mirza et al. (Mirza et al. 1985) using 1,8-diazabicyclo-
R
a Ac
b Bz
Design and synthesis of a substrate analogue as a potential inhibitor of hylB4755
62
[5.4.0]undec-7ene (DBU) in THF. Compound 9a could be converted to com-
pound 10 by elimination and deacetylation, whereas the reaction did not work
with the compound 9b and could not be improved by variation of the reaction
conditions (cf. Scheme 5).
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Scheme 5: Synthesis of methyl 6-deoxy-α-D-xylo-hex-5-enopyranoside (10)
An alternative synthetic route for the synthesis of the alkene derivative started
from the 6-tosylated glucose derivative 11, which was prepared by treating
methyl α-D-glucopyranose (8) with tosyl chloride in pyridine (Cramer et al.
1959). Then, methyl 2,3,4-tri-O-benzoyl-6-O-tosyl-α-D-glucopyranoside (12)
was prepared by a benzoylation of compound 11 under standard conditions
with benzoyl chloride and pyridine (cf. Scheme 6).
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Scheme 6: Protection of methyl α-D-glucopyranoside (8) with the tosyl pro-
tecting group in position 6 and the benzoyl group in the positions 2, 3 and 4;
reaction conditions: i) TsCl, pyridine, 0 °C → RT; ii) BzCl, pyridine, RT
Finally, compound 12 was treated with sodium iodide, tetrabutylammonium io-
dide, molecular sieve and DBU in DMSO to give the unsaturated glucose de-
rivative 13 (cf. Scheme 7) (Sato et al. 1988; Sato et al. 1991; Mereyala et al.
1993; Sato et al. 1993).
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Scheme 7: Synthesis of methyl 2,3,4-tri-O-benzoyl-6-deoxy-α-D-xylo-hex-5-
enopyranoside (13)
Following this synthetic route, the elimination product 13 could be obtained in a
three step reaction instead of a four step reaction compared to the first stra-
tegy. Furthermore, the handling and the purification of the synthesised product
were much more convenient.
The crucial step of the synthetic route A is the introduction of the fluorine atom
in position 5 of the D-xylo-hex-5-eno-pyranoside 13. In the literature, several
methods are published for the introduction of a fluorine atom by an addition
reaction. From the list of commercially available reagents 1-fluoropyridinium
tetrafluoroborate, 1-fluoro-2,4,6-trimethylpyridinium triflate, N-fluorobenzene-
sulfonimide, selectfluorTM and silver fluoride were the most common fluorinating
agents (Maguire et al. 1993; Burkart et al. 1997; Albert et al. 1998; Vincent et
al. 1999). With exception of silver fluoride, all other fluorination agents intro-
duce the fluorine atom in position 6 instead of position 5, i.e. not adjacent to the
oxygen atom. Maguire et al. (Maguire et al. 1993) reported the iodofluorination
of an adenosine derivative with silver fluoride and iodine in acetonitrile at
- 40 °C. All attempts to transfer this method to the preparation of the 5-fluo-
rinated hexose derivative were unsuccessful. Variation of the reaction tem-
perature from – 20 °C over – 10 °C to 0 °C or room temperature did not lead to
the fluorinated compound.
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Synthetic route B
In parallel to route A, the synthesis of the fluorinated D-glucuronic acid II via
route B was explored. The hydroxy groups in position 4 and 6 of methyl α-D-
glucopyranoside (8) were protected with benzaldehyde dimethyl acetal and
camphorsulphonic acid in DMF according to a method of Mallet et al. (Mallet et
al. 1993) with some modifications. The subsequent protection of the remaining
hydroxy groups was carried out with benzyl bromide and sodium hydroxide to
give methyl 2,3-di-O-benzyl-4,6-O-benzyliden-α-D-glucopyranoside (14) (cf.
Scheme 8).
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Scheme 8: Formation of the 4,6-benzylidene acetal and subsequent benzyla-
tion of positions 2 and 3; reaction conditions: i) PhHC(OCH3)2, DMF, camphor-
sulfonic acid; ii) BnBr, DMF, NaH
The reductive opening of benzylidene acetals using lithium aluminium hydride-
aluminium chloride or sodium cyanoborohydrate has been reported
(Bhattacharjee et al. 1969; Liptak et al. 1975; Garegg et al. 1981; Gelas 1981;
Johansson et al. 1984). For 4,6-benzylidene acetals with bulky substituents
such as benzyl groups at position 3, the regioselectivity of the dioxane ring
opening is dependent on the reducing agents. By the reaction with LiAlH4/AlCl3
the benzyl group is directed to position 4 and position 6 remains free (Liptak et
al. 1975), whereas with NaCNBH3/HCl and NaCNBH3/TFA the inverse result is
achieved (Garegg et al. 1981; Garegg et al. 1982; Johansson et al. 1984).
To synthesise the sugar derivative 15 with the benzyl group in position 6, the
NaCNBH3 method was chosen. According to Johansson et al. (Johansson et al.
1984) the regioselective reductive ring-opening of the benzylidene acetals
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should be achieved with NaCNBH3/TFA. Unfortunately, this reaction failed.
However, a modified procedure (Garegg et al. 1981; Garegg et al. 1982) work-
ing at room temperature instead of 0 °C, changing the 3 Å molecular sieve from
powdered to spherical shape and by extending the reaction time from 10 min to
16 h, gave compound 15 (cf. Scheme 9).
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Scheme 9: Regioselective deprotection at position 4 by cleavage of the ben-
zylidene acetal NaCNBH3 under acidic conditions
With respect to the introduction of a C=C double bond, the hydroxy group in
position 4 was mesylated to obtain an efficient leaving group. Methyl 2,3,6-tri-O-
benzyl-α-D-glucopyranoside (15) was treated with mesyl chloride and triethyla-
mine in anhydrous dichloromethane according to a method described by Bernet
et al. (Bernet et al. 1979) with some modifications (cf. Scheme 10).
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Scheme 10: Synthesis the methane sulphonate 16
For the subsequent elimination, methyl 2,3,6-tri-O-benzyl-4-mesyl-α-D-gluco-
pyranoside (16) was heated with sodium benzoate in hexamethylphosphoric tri-
amide (Gill et al. 1971) to give methyl 2,3,6-tri-O-benzyl-4-deoxy-β-L-threo-hex-
4-enopyranoside (17).
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Scheme 11: Synthesis of methyl 2,3,6-tri-O-benzyl-4-deoxy-β-L-threo-hex-4-
enopyranoside (17)
The crucial step of the synthetic route B is similar to that of route A: the intro-
duction of the fluorine atom in position 5. The fluorinated compound should be
synthesised by fluorination of the double bond of compound 17. The application
of the fluorination methods described for route A, failed again. Obviously, the
introduction of a fluorine atom at the carbon atom 5 adjacent to an oxygen atom
is impossible by an addition reaction with fluorination agents.
3. Summary
Based on mechanistical studies of the hyaluronan degradation by hyaluronate
lyases, we designed a substrate analogue consisting of three carbohydrate
units including a fluorinated glucuronic acid as central building block as a po-
tential inhibitor. The synthesis of the pertinent protected N-acetylglucosamine
was successful, whereas the attempts to synthesise the fluorinated glucuronic
acid failed. As the problems with the fluorination of hex-4-enopyranoside and
hex-5-enopyranoside derivatives were not conquerable an alternative strategy
should be envisaged, for instance, the synthesis of mechanism-based non-
carbohydrate hyaluronidase inhibitors.
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4. Experimental section
4.1 General conditions
• Starting materials and solvents were purchased from Acros Organics (Bel-
gium), Lancaster Synthesis GmbH (Germany), Maybridge Chemical Com-
pany (United Kingdom), Sigma-Aldrich Chemie GmbH (Germany), Merck
(Germany).
• Column chromatography was carried out using Merck Kieselgel 60 (0.063-
0.200) and thin layer chromatography (TLC) was performed with Merck Kie-
selgel 60 F254 aluminium.
• Melting points (Mp) were determined on a BÜCHI 510 electrically heated
copper block apparatus using an open capillary and are uncorrected.
• Elemental analysis were carried out by the department of microanalysis Re-
gensburg. Compounds were dried in vacuo (0.1-1 Torr) at room temperature
or with heating up to 80 °C for at least of 24 h prior to submission for ele-
mental analysis.
• Infrared spectra (IR) were recorded on a BRUKER TENSOR 27 spectropho-
tometer. The wave number is given in cm-1.
• Mass spectrometry analysis (MS) were performed on a Varian MAT 112 (PI-
EIMS 70 eV) and on a Varian MAT 95 (⊕FAB-MS: methanol, glycerin, xe-
non) spectrometer. The peak-intensity is indicated relatively to the strongest
signal in %.
• Nuclear Magnetic Resonance (1H-NMR and 13C-NMR) spectra were re-
corded using a Bruker AC-250 or ARX-300 or ARX-400 NMR spectrometer
with per-deuterated dimethyl sulphoxide (DMSO-d6) or deuterated chloro-
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form (CDCl3). The chemical shift δ is given in parts per million (ppm) with
reference to the chemical shift of the residual protic solvent compared to tet-
ramethylsilane (TMS, δ = 0 ppm). "s" indicates a singlet, "d" a doublet, “dd”
a doublet of doublet, "t" a triplet, “q” a quartet, "m" a multiplet and "br" a
broad peak. The multiplicity of carbon atoms (13C-NMR) were determined by
DEPT 135 and DEPT 90 (distortionless enhancement by polarisation trans-
fer): “+” primary and tertiary carbon atom (positive DEPT 135 signal), “-“
secondary carbon atom (negative DEPT 135 signal), “Cquart” quaternary car-
bon atom.
4.2 Chemistry
1,3,4,6-Tetra-O-acetyl-2-acetylamino-D-glucopyranoside (2)
A solution of N-acetyl-D-glucosamine (5.0 g, 22.60 mmol), sodium acetate
(2.22 g, 27.12 mmol) and acetic anhydride (22 ml) was stirred and heated at
110 °C for 30 min. After cooling to 60 °C, the reaction mixture was carefully
poured into ice water (50 ml) and extracted with chloroform (3 x 30 ml). The
combined organic layers were washed three times with a saturated solution of
sodium hydrogen carbonate (30 ml) and three times with water (30 ml), dried
over sodium sulphate, and the solvent was removed under reduced pressure.
The product was purified by column chromatography on silica gel eluting with a
1:1 (v/v) mixture of petroleum ether 60-80 °C and ethyl acetate to give a white
crystalline solid.
Yield: 8.55 g (21.96 mmol, 97 %, white crystalline solid)
1H-NMR (CDCl3):
δ [ppm] = 1.92 (s, 3H, CH3), 2.05 (s, 3H, CH3), 2.10 (s, 3H, CH3), 2.13 (s, 3H,
CH3), 2.24 (s, 3H, CH3), 3.96-4.12 (m, 2H, CH2OH), 4.18-4.30 (m, 1H, H-5),
(4.40-4.55 (m, 1H, H-4), 5.15-5.28 (m, 2H, H-2, H-3), 5.60 (d, 1H, 3J = 7.4 Hz,
NH), 6.20 (d, 1H, 3J = 3.5 Hz, H-1)
C16H23NO10 (389.35)
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3,4,6-Tri-O-acetyl-2-acetylamino-2-deoxy-D-glucopyranose (3)
A solution of compound 2 (1.0 g, 2.57 mmol), benzylamine (0.41 g, 3.86 mmol)
and anhydrous tetrahydrofuran (15 ml) was stirred at ambient temperature for
16 h. The reaction mixture was diluted with water (30 ml) and extracted three
times with chloroform (50 ml). The combined organic layers were washed with
diluted hydrochloric acid (1N, 1 x 50 ml), a saturated solution of sodium hydro-
gencarbonate (1 x 50 ml), a saturated solution of sodium chloride (1 x 50 ml)
and water (1 x 50 ml) and dried over sodium sulphate. The solvent was re-
moved in vacuo. The product was purified by column chromatography on silica
gel eluting with ethyl acetate to give a colourless oil.
Yield: 0.23 g (0.66 mmol, 26 %, colourless oil)
1H-NMR (CDCl3):
δ [ppm] = 1.97 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.04 (s, 3H, CH3), 2.10 (s, 3H,
CH3), 4.11-4.17 (m, 1H, H-5), 4.18-4.29 (m, 2H, CH2OH), 4.30-4.45 (m, 1H, H-
2), 5.10-5.17 (m, 1H, H-3), 5.26-5.27 (m, 1H, H-1), 5.30-5.34 (m, 1H, H-4), 5.94
(d, 1H, 3J = 7.4 Hz, NH)
C14H21NO9 (347.32)
1-O-Allyl-2-acetylamino-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranoside (4)
To a solution of N-acetyl-2-amino-α-D-glucopyranoside (5.0 g, 22.60 mmol) in
allyl alcohol (44.15 g, 0.76 mol), BF3*Et2O (5.13 g, 36.16 mmol) was added in
one portion and stirred under a nitrogen atmosphere at 95 °C for 4.5 h. After
evaporation of the solvent in vacuo, the residue was diluted with N,N-dimethyl-
formamide (50 ml), treated with benzyl bromide (13.92 g, 81.36 mmol) and
cooled with an ice bath to 0 °C. Sodium hydride (60 % in mineral oil, 2.98 g cor-
responding to 74.58 mmol NaH) was added in small portions, then the reaction
mixture was stirred at room temperature for 15 h, treated with methanol
(100 ml) and again stirred for 1 h. After the reaction mixture was concentrated
and the residue was purified by chromatography on a silica gel column eluting
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with a 1:2 (v/v) mixture of petrol ether 60-80 °C and ethyl acetate to give a col-
ourless oil.
Yield: 1.44 g (2.71 mmol, 12 %, colourless oil)
1H-NMR (CDCl3):
δ [ppm] = 2.06 (s, 3H, CH3), 3.54-3.86 (m, 5H, H-2, H-4, H-5, CH2OH), 3.90-
4.02 (m, 1H, H-3), 4.02-4.20 (m, 2H, CH2CH=CH2), 4.23-4.34 (m, 1H, H-1),
4.50-4.98 (m, 6H, C6H5CH2), 5.15-5.22 (m, 1H, NH), 5.23-5.38 (m, 2H,
CH2CH=CH2), 5.76-5.91 (m, 1H, CH2CH=CH2), 7.14-7.40 (m, 15H, C6H5)
C32H37NO6 (531.65)
2-Acetylamino-3,4,6-tri-O-benzyl-2-deoxy-D-glucopyranose (5)
To a solution of compound 4 (0.40 g, 0.83 mmol) and sodium acetate (0.53 g,
6.44 mmol) in acetic acid (95 %, 17 ml) palladium(II)-chloride (0.94 g,
5.28 mmol) was added. The reaction mixture was stirred at room temperature
for 60 h, filtered through. Celite and diluted with dichloromethane (100 ml). The
organic solution was washed with water (1 x 50 ml), saturated sodium hydro-
gencarbonate solution (1 x 50 ml) and again with water (1 x 50 ml), dried over
sodium sulphate and concentrated in vacuo. The product was purified by chro-
matography on a silica gel column eluting with a 1:2 (v/v) mixture of petrol ether
60-80 °C and ethyl acetate to give a white solid.
Yield: 0.10 g (0.20 mmol, 25 %, white solid)
1H-NMR (CDCl3):
δ [ppm] = 2.06 (s, 3H, CH3), 3.48-3.82 (m, 5H, H-4, H-5, CH2OH), 4.00-4.31 (m,
2H, H-2, H-3), 4.48-4.90 (m, 4H, C6H5CH2), 4.72-4.90 (m, 2H, C6H5CH2), 5.08-
5.12 (m, 1H, H-1), 5.45-5.50 (m, 1H, NH), 7.10-7.42 (m, 15H, C6H5)
C29H33NO6 (491.58)
Design and synthesis of a substrate analogue as a potential inhibitor of hylB4755
71
2-Acetylamino-1-O-benzyl-2-deoxy-D-glucopyranoside (6)
A solution of N-acetyl-D-glucosamine (8.76 g, 39.60 mmol), benzyl alcohol
(100 ml) and acetyl chloride (2.43 g, 30.90 mmol) was stirred at 72 °C for 16 h.
After cooling, the mixture was diluted with diethyl ether until a white solid pre-
cipitated. The solid was filtered and washed with diethyl ether and dried in
vacuo.
Yield: 11.35 g (39.5 mmol, 100 %, white solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 1.85 (s, 3H, CH3), 3.44-3.76 (m, 3H, H-3, H-4, H-5), 4.44-4.48 (m, 1H,
H-2), 4.53 (s, 2H, CH2OH), 4.67 (s, 1H, H-1), 4.72-4.75 (m, 2H, C6H5-CH2),
7.20-7.46 (m, 5H, C6H5), 7.88 (d, 1H, 3J = 7.4 Hz, NH)
C13H21NO6 (287.32)
Benzyl 2-acetylamino-4,6-O-benzylidene-2-deoxy-D-glucopyranoside (7)
To a solution of compound 6 (5.00 g, 17.40 mmol) in acetonitrile (150 ml)
PhCH(OCH3)2 (6.89 g, 45.24 mmol) and p-toluenesulphonic acid (0.83 g, 4.36
mmol) were added. After the mixture was stirred at room temperature for 14 h,
Et3N (4 ml), hexane (100 ml) and methanol (100 ml) were added. The precipi-
tated product was collected, washed with a warm 10:1:2 (v/v/v) mixture of hex-
ane, dichloromethane and diethyl ether and dried in vacuo.
Yield: 4.37 g (10.94 mmol, 63 %, white solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 1.85 (s, 3H, NCOCH3), 3.46-3.58 (m, 1H, H-5), 3.83 (m, 1H, 1H, H-2),
3.66-3.80 (m, 3H, H-4, CH2), 4.15 (dd, 1H, 3J = 3.6 Hz, 2J = 5.5, H-3), 4.48 (d,
1H, 2J = 12.5 Hz, C6H5CH2 ), 4.71 (d, 1H, 2J = 12.5 Hz, C6H5CH2), 4.79 (d, 1H,
3J = 3.2 Hz, H-1), 5.20 (d, 1H, 2J = 5.5 Hz, OH), 5.62 (s, 1H, C6H5CH), 7.28-
7.48 (m, 10H, C6H5), 8.06 (d, 3J = 7.9 Hz, NH)
C22H25NO6 (399.44)
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Methyl 2,3,4-tri-O-acetyl-6-deoxy-6-iodo-α-D-glucopyranoside (9a)
A solution of methyl-α-D-glucopyranoside (1.0 g, 5.15 mmol), N-iodosuccin-
imide (2.32 g, 10.30 mmol, 2eq) and triphenylphosphine (2.70 g, 10.30 mmol)
in N,N-dimethylformamide (50 ml) was stirred at 50 °C for 2 h. After cooling to
room temperature, the reaction mixture was diluted with water (30 ml) and ex-
tracted with chloroform (3 x 30 ml). The aqueous solution was concentrated
under reduced pressure to give a brown viscose liquid (1.57 g). To the residue,
sodium acetate (2.11 g, 25.75 mmol) and acetic acid anhydride (20 ml) were
added and the mixture was stirred and heated for 40 min at 110 °C. After cool-
ing to 60 °C, the reaction mixture was carefully poured into ice water (100 ml)
and extracted with chloroform (3 x 30 ml). The combined organic layers were
extracted three times with a saturated solution of sodium hydrogencarbonate
(30 ml) and three times with water (30 ml), dried over sodium sulphate and the
solvent was removed under reduced pressure. The product was purified by col-
umn chromatography on silica gel eluting with a 1:1 (v/v) mixture of petrol ether
60-80 °C and ethyl acetate to give a white solid.
Yield: 0.91 g (2.12 mmol, 41 %, white solid)
1H-NMR (CDCl3):
δ [ppm] = 2.01 (s, 3H, CH3), 2.06 (s, 3H, CH3), 2.08 (s, 3H, CH3), 3.13-3.18 (m,
1H, CH2), 3.28-3.32 (m, 1H, CH2), 3.48 (s, 3H, OCH3), 3.75-3.85 (m, 1H, H-5),
4.84-4.87 (m, 1H, H-4), 4.90-4.91 (m, 1H, H-2), 4.96-4.97 (m, 1H, H-3), 5.43-
5.51 (m, 1H, H-1)
13C-NMR (CDCl3):
δ [ppm] = 3.6 (-, ICH2), 20.6 (+, CH3), 20.7 (+, CH3), 20.8 (+, CH3), 55.8 (+,
OCH3), 68.6 (+, CH), 69.7 (+, CH), 70.9 (+, CH), 72.5 (+, CH), 96.7 (+, CH),
169.7 (Cquart, C=O), 170.0 (Cquart, C=O), 170.1 (Cquart, C=O)
C13H19IO8 (430.19)
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Methyl 2,3,4-tri-O-benzoyl-6-deoxy-6-iodo-α-D-glucopyranoside (9b)
Iodine (27.18 g, 107.12 mmol) was added in small portions to a solution of
methyl-α-D-glucopyranoside (10.00 g, 51.50 mmol), triphenylphosphine
(30.26 g, 115.36 mmol), imidazole (15.88 g, 233.30 mmol), toluene (100 ml)
and acetonitrile (200 ml) and the reaction mixture was stirred at 90 °C for 2 h.
After evaporation of the solvent, water (300 ml) was added and shaken vigor-
ously. The solution was extracted with toluene (3 x 100 ml) and the aqueous
phase was concentrated under reduced pressure. The residue was dissolved in
pyridine (70 ml), treated with benzoyl chloride (23.89 g, 0.17 mol) and stirred at
ambient temperature for 16 h. The reaction mixture was diluted with dichlo-
romethane (300 ml), washed with water (2 x 50 ml), a solution of potassium
hydrogensulphate (3 x 50 ml, 1M) and again water (2 x 50 ml), dried over so-
dium sulphate and evaporated. The product was purified by column chromatog-
raphy on silica gel eluting with a 3:1 (v/v) mixture of petroleum ether 60-80 °C
and ethyl acetate to give a white solid.
Yield: 3.81 g (6.18 mmol, 12 %, white solid)
1H-NMR (CDCl3):
δ [ppm] = 3.46 (s, 3H, OCH3), 3.82-3.91 (m, 1H, H-5), 3.94-3-95 (m, 2H, CH2),
3.99-4.07 (m, 1H, H-4), 5.15 (d, 1H, 3J = 3.7 Hz, H-1), 5.30 (dd, 1H, 3J = 3.7 Hz,
3J = 10.1 Hz, H-2), 5.70 (dd, 1H, 3J = 8.9 Hz, 3J = 10.1 Hz, H-3), 7.34-8.15 (m,
15H, C6H5)
C28H25IO8 (616.41)
Methyl 6-deoxy-α-D-xylo-hex-5-enopyranoside (10)
To a solution of compound 9a (1.00 g, 2.32 mmol) in anhydrous tetrahydrofuran
(50 ml) 1,8-diazabizyclo[5.4.0]undec-7-ene (DBU, 2.12 g, 13.92 mmol) was
added. The reaction mixture was stirred and heated under reflux for 12 h. After
removal of the solvent, the obtained oil was dissolved in methanol and shacked
with a solution of NaOMe in MeOH (10 ml, 0.1M). The reaction mixture was
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neutralised with acetic acid, concentrated under reduced pressure and purified
by column chromatography on silica gel eluting with a 6:3:1 (v/v/v) mixture of
diethyl ether, dichloromethane and ethanol to give a yellow oil.
Yield: 0.26 g (1.48 mmol, 64 %, yellow oil)
1H-NMR ([D6]acetone):
δ [ppm] = 3.38 (s, 3H, OCH3), 3.50-3.97 (m, 3H, H-2, H-3, H-4), 4.56 (d, 1H, 2J
= 2.2 Hz, =CH2), 4.74 (d, 1H, 3J = 3.3 Hz, H-1), 4.77 (d, 1H, 2J = 2.2 Hz, =CH2)
C7H12O5 (176.17)
Methyl 6-O-tosyl-α-D-glucopyranoside (11)
To an ice-cold solution of methyl α-D-glucopyranoside (10.0 g, 51.50 mmol) in
pyridine (90 ml), a solution of tosyl chloride (10.50 g, 55.07 mmol) in pyridine
(25 ml) was added dropwise, and the mixture was stirred at ambient tempera-
ture for 48 h. After evaporation, the residue was diluted with chloroform
(100 ml), washed with a solution of potassium hydrogensulphate (2 x 50 ml,
1M), a solution of sodium hydrogencarbonate (2 x 50 ml, 5 %) and water (1 x
50 ml), dried over sodium sulphate, and the solvent was removed under re-
duced pressure. The product was used without further purification.
Yield: 17.60 g (50.52 mmol, 98 %, white solid)
C14H20SO8 (348.37)
Methyl 2,3,4-tri-O-benzoyl-6-O-tosyl-α-D-glucopyranoside (12)
To a solution of compound 11 (18.79 g, 53.94 mmol) in pyridine (50 ml), ben-
zoyl chloride (25.02 g, 178.0 mmol) was added dropwise at 0 °C. Afterwards
the reaction mixture was stirred at room temperature for 48 h, concentrated
under reduced pressure and diluted with chloroform (200 ml). The solution was
extracted with a solution of KHSO4 (3 x 100 ml, 1M), a solution of NaHCO3 (2 x
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100 ml, 5 %) and water (2 x 100 ml), dried over sodium sulphate and the sol-
vent was removed under reduced pressure. The product was purified by col-
umn chromatography on silica gel eluting with a 2:1 (v/v) mixture of petroleum
ether 60-80 °C and ethyl acetate to give a white solid.
Yield: 15.35 g (23.23 mmol, 43 %, white solid)
1H-NMR (CDCl3):
δ [ppm] = 2.34 (s, 3H, C6H4CH3), 3.46 (s, 3H, OCH3), 4.02-4.09 (m, 1H, H-5),
4.14-4.21 (m, 2H, CH2), 4.52 (dd, 1H, 3J = 3.6 Hz, 3J = 10.0 Hz, H-2), 5.02 (d,
1H, 3J = 3.6 Hz, H-1), 5.27 (t, 1H, 3J = 9.6 Hz, H-3), 5.82 (t, 1H, 3J = 9.6 Hz, H-
4), 6.92-7.77 (m, 20H, C6H5)
MS (PI-DCIMS (NH3)): m/z (%) = 678 ([M+NH4]+, 100), 524 ([M-C6H4CH3]+, 69)
C35H32SO11 (660.70)
Methyl 2,3,4-tri-O-benzoyl-6-deoxy-α-D-xylo-hex-5-enopyranoside (13)
A mixture of compound 12 (5.0 g, 8.33 mmol), sodium iodide (6.24 g, 41.65
mmol), tetrabutylammonium iodide (1.54 g, 4.17 mmol) and molecular sieve 4 Å
in DMSO (100 ml) was stirred under nitrogen at 100 °C. After 2 h, DBU (1.52 g,
100.0 mmol, 1.50 ml) was added and stirred for additional 2 h at 80 °C. The
reaction mixture was poured into water and extracted with ethyl acetate (6 x
50 ml). The combined organic layers were dried over sodium sulphate and the
solvent was removed under reduced pressure. The product was purified by col-
umn chromatography on silica gel eluting with a 2:1 (v/v) mixture of petroleum
ether 60-80 °C and ethyl acetate to give a colourless oil.
Yield: 2.99 g (6.12 mmol, 73 %, colourless oil)
1H-NMR (CDCl3):
δ [ppm] = 3.62 (s, 3H, OCH3), 4.72 (s, 1H, =CH2), 4.90 (s, 1H, =CH2), 5.22-5.31
(m, 1H, H-1), 5.33-5.46 (m, 1H, H-2), 5.92-6.00 (m, 1H, H-3), 6.10-6.23 (m, 1H,
H-4), 7.24-7.61 (m, 10H, C6H5), 7.79-8.09 (m, 5H, C6H5)
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MS (PI-DCIMS (NH3)): m/z (%) = 506 ([M+NH4]+, 100), 489 ([MH]+, 35)
C28H24O8 (488.50)
Methyl 2,3-di-O-benzyl-4,6-O-benzyliden-α-D-glucopyranoside (14)
A mixture of methyl-α-D-glucopyranoside (50.0 g, 257.45 mmol), benzaldehyde
dimethyl acetal (48.96 g, 321.70 mmol), catalytic amounts (80 mg) of camphor-
sulphonic acid (0.70 g, 3.01 mmol) and N,N-dimethylformamide (200 ml) was
stirred at 100 °C in vacuo (water aspirator) for 2 h. The remaining solution was
cooled with an ice bath to 0 °C and benzyl bromide (100.80 g, 0.59 mol) and
N,N-dimethylformamide (300 ml) were added, followed by sodium hydride
(60 % in mineral oil, 24 g corresponding to 0.6 mol NaH) in small portions. After
stirring at ambient temperature for 15 h, methanol (100 ml) was added and stir-
ring was continued for 1 h. The reaction mixture was concentrated in vacuo and
diluted with dichloromethane (500 ml) and water (500 ml) and shaken vigor-
ously. The aqueous phase was extracted with dichloromethane (3 x 50 ml) and
the combined organic layers were washed with water (3 x 50 ml), dried over
sodium sulphate and the solvent was removed under reduced pressure. The
product was purified by column chromatography on silica gel eluting with a 3:1
(v/v) mixture of petrol ether 60-80 °C and ethyl acetate to give a white solid.
Yield: 80.84 g (174.78 mmol, 68 %, white solid)
1H-NMR (CDCl3):
δ [ppm] = 3.42 (s, 3H, OCH3), 3.50-3.87 (m, 4H, H-2, H-5, CH2), 4.02-4.10 (m,
1H, H-3), 4.20-4.32 (m, 1H, H-4), 4.56-4.60 (m, 1H, H-1), 4.65-4.98 (m, 4H,
C6H5CH2), 5.05 (s, 1H, C6H5CH), 7.20-7.51 (m, 15H, C6H5)
MS (PI-DCIMS (NH3)): m/z (%) = 480 ([M+NH4]+, 100), 463 ([MH]+, 39)
C28H30O6 (462.54)
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Methyl 2,3,6-tri-O-benzyl-α-D-glucopyranoside (15)
To a mixture of compound 14 (1.0 g, 2.16 mmol), NaCNBH3 (1.7 g, 27.0 mmol),
and molecular sieve 3 Å (spherical shape) in anhydrous THF (30 ml), a solution
of hydrogenchloride in ether (2M) was added dropwise until the generation of
gas ceased. Afterwards, the reaction mixture was stirred at room temperature
for 16 h. After dilution with dichloromethane (150 ml) and water (150 ml), the
organic phase was washed with 50 ml water and with a saturated solution of
sodium hydrogencarbonate (2 x 50 ml), dried over sodium sulphate and evapo-
rated under reduced pressure. The product was purified by column chromatog-
raphy on silica gel eluting with a 2:1 (v/v) mixture of petroleum ether 60-80 °C
and ethyl acetate to give a white solid.
Yield: 1.83 g (3.94 mmol, 36 %, white solid)
MS (PI-DCIMS (NH3)): m/z (%) = 482 ([M+NH4]+, 100)
C28H32O6 (464.56)
Methyl 2,3,6-tri-O-benzyl-4-mesyl-α-D-glycopyranoside (16)
To a solution of compound 15 (0.25 g, 0.54 mmol) in anhydrous dichlo-
romethane (30 ml), triethylamine (330 µl, 2.38 mmol) and mesyl chloride
(170 µl, 2.11 mmol) were added at 0 °C and stirred for 2 h. After dilution with a
saturated solution of NaHCO3 (100 ml), the reaction mixture was extracted with
dichloromethane (3 x 50 ml). The combined organic layers were washed with a
solution of KHSO4 (1M, 50 ml), dried over MgSO4 and the solvent was removed
under reduced pressure. The product was purified by column chromatography
on silica gel eluting with a 10:1 (v/v) mixture of chloroform and ethyl acetate to
give a white solid.
Yield: 0.17 g (0.31 mmol, 56 %, white solid)
Design and synthesis of a substrate analogue as a potential inhibitor of hylB4755
78
1H-NMR (CDCl3):
δ [ppm] = 3.01 (s, 3H, SCH3), 3.39 (s, 3H, OCH3), 3.68-4.01 (m, 5H, H-2, H-4,
H-5, CH2), 4.27-4.35 (m, 1H, H-3), 4.53-4.76 (m, 6H, C6H5CH2), 5.06-5.10 (m,
1H, H-1), 7.24-7.40 (m, 15H, C6H5)
MS (PI-DCIMS (NH3)): m/z (%) = 560 ([M+NH4]+, 100)
C29H34O8S (542.64)
Methyl 2,3,6-tri-O-benzyl-4-deoxy-β-L-threo-hex-4-enopyranoside (17)
A solution of compound 16 (170 mg, 0.32 mmol), PhCO2Na (172 mg,
1.19 mmol) and HMPT (3 ml) was stirred at 90 °C for 95 min. After cooling, the
reaction mixture was carefully poured into water (50 ml) and extracted with
ether (3 x 50 ml). The combined organic layers were dried over MgSO4 and the
solvent was removed under reduced pressure. The product was purified by col-
umn chromatography on silica gel eluting with a 5:2 (v/v) mixture of petroleum
ether 60-80 °C and ethyl acetate to give a white solid.
Yield: 90 mg ( 0.2 mmol, 67 %, white solid)
MS (CI-MS (NH3)): m/z (%) = 464 ([M+NH4]+, 3), 230 ([M-2CH2C6H5-OCH3]+,
100)
C28H30O5 (446.54)
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Chapter 6
Flavone and chalcone derivatives as inhibitors of
hyaluronidases – synthesis and pharmacological
investigations
1. Introduction
Flavonoids are a group of naturally occurring low molecular weight benzo-γ-py-
ranone derivatives. The immediate family members of flavonoids include flav-
ones, flavanes, flavonols, isoflavones, anthocyanidines and catechins (cf. Fig.
1). The flavonoids all consist of a benzene ring (A) condensed with a heterocy-
clic six-membered ring (B) which carries a phenyl ring (C) in position 2 (flav-
onoids) or 3 (isoflavonoids) and a keto group in position 4.
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Fig. 1: Structure of chalcone, flavone and flavone related compounds
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The difference between the flavane and the flavone structure is the lack of the
double bond between C-2 and C-3. The structures of anthocyanidin and cate-
chin are closely related to the flavone structure. The 2-hydroxychalcone struc-
ture correspond to a flavone with an opened ring B. The ortho-hydroxylated
chalcone may be converted to flavone by intramolecular nucleophilic addition of
the hydroxy group to the enone group.
Flavonoids are ubiquitous in vegetables, fruits, teas and other plants (Havsteen
1983; Hollman 2000). They exhibit a great variety of pharmacological and
pharmaceutical functions which have been reviewed by Havsteen in 1983
(Havsteen 1983). It was reported that some flavone and flavone derivatives had
anticancer, antiischemic, antiallergic, anti-inflammatory and several other acti-
vities (Harborne 1986; Deschner et al. 1991; Ferrandiz et al. 1991; van Acker et
al. 2000). Furthermore, it was also reported that several structurally related fla-
vonoids were potent hyaluronidase inhibitors. The inhibitory effect of the most
important flavone compounds on hyaluronidases are summarised in the fol-
lowing.
In 1990, the group of Kuppusamy examined the effect of 31 flavonoids, sylibin
(1) and condensed tannin (2) on the activity of the bovine testicular hyaluro-
nidase (BTH) (Kuppusamy et al. 1990). From all investigated flavonoids only six
compounds (apigenin, kaempferol, luteolin, morin, myricetin and quercetin)
showed inhibitory activity on the enzyme between 29 % and 76 % at a concen-
tration of 250 µM. Furthermore, the effect of sylibin (1) on BTH was 48 % at a
concentration of 250 µM. Of the investigated compounds only condensed tan-
nin (2) showed a complete inhibition of the bovine testicular enzyme at a con-
centration of 50 µM. Kuppusamy et al. (Kuppusamy et al. 1990) suggested a
competitive inhibition for all active compounds. On the basis of these results,
they concluded that the double bond between the positions 2 and 3 was crucial
for the inhibitory activity. Also the keto group in position 4 and different sub-
stituents seem to be important for the inhibitory effect of the compounds. The
introduction of hydroxy groups in the positions 5, 7 and 4’ increase the potency,
whereas the presence of a glycoside substituent completely reverses the in-
hibitory effect of the flavonoids on the bovine testicular hyaluronidase.
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Fig. 2: Sylibin (1) and condensed tannin (2)
In 1991, the same working group investigated the effect of sylibin (1) and 12
flavone derivatives on the activities of five hyaluronidases from the venom of
honey bee, scorpion, two rattle snakes and malayan cobra (Kuppusamy et al.
1991). The inhibition of the flavone compounds on the venom hyaluronidase
was determined by a turbidimetric method. Additionally, the survival time of
mice after the injection of the venom plus a flavonoid was measured. Narin-
genin, catechin and the four flavone-glycosides apiin, luteolin-7-glucoside, my-
ricitrin and quercitrin were inactive on all five hyaluronidases. Apigenin,
kaempferol, luteolin, myricetin, phloretin (chalcone) and quercetin showed vari-
able inhibitions ranging from 30 % - 89 % at a concentration of 250 µM. Under
these conditions, silybin (1) was the only compound that inhibited the activity of
the bee and the scorpion venom hyaluronidases by 100 %. The authors con-
cluded that flavones, flavonols and chalcones possess the general ability to
inhibit venom hyaluronidases.
In 1992, the inhibitory effect of some natural products and synthetic anti-allergic
drugs on the activation of bovine testicular hyaluronidase were investigated by
Kakegawa et al. (Kakegawa et al. 1992). The structure of the examined com-
pounds DSCG (3, disodium cromoglycate (Cox 1967)), traxanox (6), tranilast
(8) (Koda et al. 1976), two chalcones 4 and 5 and three flavone derivatives 7, 9
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and 10 are shown in Fig. 3. The IC50 values of liquiritigenin (10), tranilast (8),
baicalein (7), traxanox (6), isoliquiritigenin (5) and DSCG (3) were 0.74 mM,
0.35 mM, 0.165 mM, 85 µM, 64 µM and 29 µM respectively. The two glycosides
4 and 9 were not active on the bovine testicular hyaluronidase.
ONaO2C
O O CH2CHCH2
OH
O
O
O
CO2Na
OH
O
HO
OR
3 Disodium cromoglycate 4 Isoliquiritin: R = glucose
(DSCG) 5 Isoliquiritigenin: R = H
N O
N
N
NNO
Cl
Na
O
OOH
HO
HO
6 Traxanox 7 Baicalein
CONH
OCH3H3CO
HO2C
OHO
O
OR
8 Tranilast 9 Liquiritin: R = glucose
10 Liquiritigenin: R = H
Fig. 3: Structures of the investigated natural products and synthetic anti-allergic
drugs
The inhibitory effect of apigenin, kaempferol, luteolin, quercetin and tannic acid
on the activity of venom hyaluronidase from Crotalus adamenteus (Kuppusamy
et al. 1993) and on the activity of monkey sperm hyaluronidase (Li et al. 1997)
were also investigated. The assayed compounds showed a very low inhibitory
activity and never a complete inhibition of the enzymes.
The latest results on the inhibition of hyaluronidases by flavones and flavone
related compounds were published by Pessini et al. in 2001 (Pessini et al.
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2001). They investigated the effect of natural flavonoids (e. g. eupatorin, des-
methoxycentaureidine, pinostrobin) on the activity of scorpion venom hyaluroni-
dase. Among the examined compounds, only desmethoxycentaureidine 11, a
flavone derivative with three methoxy groups in the positions 3, 4’ and 6 and
three hydroxy groups in the positions 3’, 5 and 7 reduced the activity of the
scorpion venom hyaluronidase in a dose-dependent manner and induced an
inhibition by 90 % at a concentration of 50 µM.
HO O
OOH
OCH3H3CO
OH
OCH3
11
Fig. 4: Desmethoxycentaureidine
The published data, i.e. the inhibition given in % and the IC50 values of all
aforementioned compounds, are not comparable with each other because of
the differences in the applied test systems (e.g. incubation condition, enzymes
and substrate concentrations).
Taken together the published results show that, in principle, flavones and re-
lated compounds are suitable to inhibit hyaluronidases. However, the inhibitory
activities of the compounds described in literature are only in the millimolar
range. This is also true for the widely accepted hyaluronidase inhibitors api-
genin and kaempferol which have activities in the mM range, too.
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2. Chemistry
As the flavonoid structure appeared to be a promising skeleton for the develop-
ment of hyaluronidase inhibitors, new flavonoid compounds were synthesised
and tested for their activity on the bovine testicular hyaluronidase.
To synthesise the desired flavone compounds we started with published proce-
dures. Costantino et al. (Costantino et al. 1996) reported a one step synthesis
of 5,7-dihydroxy-4’-methoxyflavone from 2,4,6-trihydroxyacetophenone and
4-methoxybenzaldehyde which were treated at first with lithium
bis(trimethyl)silyl amide in THF at – 78 °C and then with glacial acetic acid and
sulphuric acid at 100 °C. Following this procedure, the products could only be
obtained in very low yields. Furthermore, the isolation of the product and the
separation of the by-products was not possible by standard methods.
The next reaction tried was described by the group of Jain and Saxena (Jain et
al. 1982; Saxena et al. 1985) (cf. Scheme 1). In this synthesis a substituted hy-
droxyacetophenone 12 was treated with an excess of an aroyl chloride 13 in a
benzene/aqueous potassium carbonate biphase to get an O-aroylation. By the
subsequent Baker-Vankatarama reaction with tetrabutylammonium hydrogen-
sulphate a rearrangement to an o-hydroxydibenzoylmethane 14 takes place.
The final cyclocondensation to the flavone 15 was achieved by using concen-
trated sulphuric acid or aqueous potassium carbonate followed by treatment
with acetic acid. Following this synthesis, it was possible to synthesise the
diketo derivatives but the final ring closure reaction failed. Different substituents
at both phenyl rings may explain the failure of known synthesis.
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Scheme 1: Strategy of flavone synthesis reported by (Jain et al. 1982; Saxena
et al. 1985); reagents used: i) 1. K2CO3, H2O, C6H6, 60 °C; 2. (n-C4H9)4N+
HSO4+; ii) H2SO4, 0 °C; iii) 1. K2CO3, H2O, ∆T, 2. AcOH
To synthesise the flavone derivatives a new synthetic strategy was developed
which is illustrated in Scheme 2. In the first step 2,4,6-trihydroxyacetophenone
(16) was protected by O-methylation in the positions 4 and 6, to increase the
solubility of the compounds in organic solvents. The protection was prepared
under alkaline conditions according to the method described by Maurer (Maurer
1976) with slight modifications.
Starting from the protected compound 17 the synthesis of the propan-1,3-dione
and the chalcone derivatives as precursor of flavone compounds was per-
formed according to two approaches. Following the first route, the esters 18
were synthesised from the protected hydroxyacetophenone 17 and the corre-
sponding aroyl chloride under alkaline conditions as described by Schnetzer
(Schnetzer 1991) and Gratzfeld (Gratzfeld 1978) with slight modifications. The
final step, the rearrangement to the corresponding propan-1,3-dione 20 was
accomplished via the Baker-Vankatarama reaction by a modified method de-
scribed by Maurer (Maurer 1976). Following the second route, a one step reac-
tion, the propenones 19 were synthesised from the acetophenone 17 and the
corresponding benzaldehydes by an aldol condensation with potassium hy-
droxide in ethanol in good yields (cf. Scheme 2). The advantages of this syn-
thetsis are the smaller number of reaction steps and the higher yields. Thus, we
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decided to synthesise our chalcone derivative as precursore of flavone com-
pounds.
OHHO
HO O
OHH3CO
CH3O O
(CH3O)2SO2
Na2S2O4 / K2CO3
16 17
X
O R2
R1
R3 KOH / EtOHPyridine
O
O
O
CH3O
H3CO H3CO
CH3O
OH
O
R1
R2
R3
R1
R2
R3
18a 19b-k
O
OH
O
R3
H3CO
CH3O
KOH / EtOH
R1
R2
20a
Scheme 2: Synthesis of compounds 19b-k and 20a
No R1 R2 R3
a 4’-CN H H
b 4’-OCH3 H H
c 3’-OCH3 4’-OCH3 H
d 4’-N(CH3)2 H H
e [3,4]-benzo-annelated H H
f 4’-CO2H H H
g 2’-OSO2H 4’-OSO2H H
h 4’-Cl H H
i 2’-Cl 3’-OCH3 4’-OCH3
j 2’-Cl 4’-Cl 6’-OCH3
k 4’-F H H
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The chalcone derivatives 23a-d were also synthesised in one step, starting
from the fluorinated 2-hydroxyacetophenones 21a and 21b under strong alka-
line conditions (cf. Scheme 3).
OH
O
H O
+
OH
O
R2R1
R3
KOH / EtOH
R2
R3
R1
21a-b 22a-c 23a-d
Scheme 3: Synthesis of the fluorinated chalcone derivatives 23a-d
Starting from the synthesised chalcone derivatives 19b-k and 23a-d several
published methods were tried to accomplished the ring closure. The cyclisation
with copper (II) chloride in dimethylsulphoxide at high temperature described by
Saharabhuddhe et al. (Sahasrabhuddhe et al. 1990) as well as the method us-
ing iodine in dimethylsulphoxide described by different authors (Doshi et al.
1986; Kitagawa et al. 1991; Silva et al. 1993; Silva et al. 1994; Silva et al. 1994;
Pinto et al. 1996) did not lead to a successful synthesis of the flavone deriva-
tives. Even modifications of these methods did not yield any flavone deriva-
tives. Different substituents at both phenyl rings may explain the failure of
known synthesis. Nevertheless, it was possible to synthesise the flavone de-
rivatives 14a-e and 25a-i by following three different methods as shown in
Scheme 4.
No R1 R2 R3
a 4-F 3’-OCH3 4’-OCH3
b 4-F 4’-OCH3 H
c 5-F 4’-OCH3 H
d 5-F 4’-F H
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Scheme 4: Synthesis of the flavone derivatives 24a-e and 25a-i
Table 1: Substitution patterns of the synthesised flavone compounds
No R1 R2 R3 R4 R5
24a 5-OCH3 7-OCH3 4’-OCH3 H H
24b 5-OCH3 7-OCH3 2’-Cl 4’-Cl 6’-OCH3
24c 5-OCH3 7-OCH3 4’-N(CH3)2 H H
24d 5-OCH3 7-OCH3 4’-Cl H H
24e 5-OCH3 7-OCH3 2’-Cl 3’-OCH3 4’-OCH3
25a 5-OCH3 7-OCH3 4’-OCH3 H H
25b 5-OCH3 7-OCH3 3’-OCH3 4’-OCH3 H
25c 5-OCH3 7-OCH3 [3,4]-naphthyl H H
25d 5-OCH3 7-OCH3 4’-Cl H H
25e 5-OCH3 7-OCH3 4’-F H H
25f 6-F H 4’-OCH3 H H
25g 6-F H 4’-F H H
25g 7-F H 3’-OCH3 4’-OCH3 H
25i 7-F H 4’-OCH3 H H
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The synthesis of the flavone derivatives 24a-e (cf. Table 1) were carried out by
treating the chalcone derivatives dissolved in ethanol with a sodium hydroxide
solution and an aqueous solution of hydrogen peroxide at under reflux (cf.
Method A in Scheme 4). According to this procedure an additional hydroxy
group was introduced in position 3 – the obtained compounds are so-called
flavonols. To synthesise the flavone derivatives via method A as described by
different authors (De Meyer et al. 1991; Hariprasad et al. 1998; van Acker et al.
2000) some modifications were necessary. The problems of this synthesis were
the low yield and the difficult separation of the product from by-products and
starting material. To circumvent these problem, the flavone derivatives were
prepared according to method B. This reaction was described by Khan et al.
(Khan et al. 1990) and Chang et al. (Chang et al. 1961). The ring closure was
achieved with selenium dioxide in isopropylalcohol and heated to reflux (cf.
Method B in Scheme 4). The advantages were the facile practicability of the
method, the short reaction time and the convenient purification of the product.
Following this method most of the flavones 25a-c and 25e- i (cf. Table 1) could
be obtained in good yields.
4’-Chloro-5,7-dimethoxyflavone (25d) could not be synthesised from the chal-
cone derivative 19h, neither via method A nor by method B. Obviously, the re-
action conditions of method A were too severe, as only decomposed products
could be isolated. Following method B, the starting material was recovered
completely; obviously, the reaction conditions were too mild to force the ring
closure. Finally, it was possible to convert the chalcones to flavones by treat-
ment with sodium periodate in dimethylsulphoxide according to a method de-
scribed by Naresh et al. (Naresh et al. 1993) (cf. Method C in Scheme 4) with
slight modifications.
Of all synthesised chalcone derivatives only the compounds 19f and 19g could
not be converted into the corresponding flavone derivatives according to pub-
lished methods with and without modifications.
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To increase the solubility of the flavones the introduction of hydroxy and/or sul-
phate groups should be useful. Moreover, these polar substituents could inter-
act with functional groups in the active site of the hyaluronidase thereby in-
creasing the affinity of the potential enzyme inhibitors. To prove this hypothesis,
one hydroxyflavone and its sulphated derivative were synthesised as shown in
Scheme 5.
O
O
F O
O
F
OCH3 OH
BBr3, CH2Cl2
25i 26
O
O
F
OSO3
- Bu4N
+
1) Pyridine*SO3
DMF, Pyridine
2) Bu4N
+HSO4
-
CH3OH
27
Scheme 5: Synthesis of the hydroxyflavone 26 and the sulphated derivative 27
4’-Methoxy-7-fluoroflavone 25i was deprotected with boron tribromide in anhy-
drous dichloromethane at room temperature to give the hydroxyflavone 26 (cf.
Scheme 5). The subsequent sulphation of the compound 27 was carried out
according to the method described by Böddeker (Böddeker 1995) with pyri-
dine*SO3 in dimethylformamide and pyridine at 100 °C. Disadvantages of this
last step were the incomplete removal of the inorganic salt and the difficult
separation of the product from the starting material by crystallisation and
column chromatography.
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3. Pharmacological investigations
Due to the inconsistent published results, we investigated several assumed in-
hibitors like disodium cromoglycate (DSCG, 3), apigenin (28), kaempferol (29)
and silybinin (30) on the bovine testicular hyaluronidase to obtain comparable
data determined under the same conditions (cf. Fig. 5).
ONaO2C
O O CH2CHCH2
OH
O
O
O
CO2Na
O
O
HO
HO
R
OH
3 DSCG 28 Apigenin R = H
29 Kaempferol R = OH
O
O
OH
OH
HO
O
O CH2OH
OCH3
OCH3
30 Silybinin
Fig. 5: Structure of several assumed hyaluronidase inhibitors
The inhibitory effects on the activities of hyaluronidases were determined in an
optimised colorimetric assay (Morgan-Elson assay) as described in chapter 3.
The compounds 28-30 could not be tested at concentrations above 1 mM or
10 mM due to poor solubility.
The widely accepted hyaluronidase inhibitors apigenin (28) and kaempferol (29)
showed only weak inhibitory effects on the bovine testicular enzyme (inhibition
by 56 % and 36 %, respectively, at a concentration of 1 mM). Moreover, the
effects of these two compounds were not dose-dependent. The obtained
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results are depicted in Fig. 6. Silybinin (30), a flavanol-related compound, in-
duced an inhibition of the enzyme activity by 40 % at a concentration of 10 mM.
From the four purported inhibitors only disodium cromoglycate (3) showed a
dose-dependent and nearly complete inhibition of the enzyme. The calculated
IC50 value of 1.24 mM for DSCG was higher those that reported in the literature
(IC50 = 30 µM) (Sakamoto et al. 1980; Kakegawa et al. 1985; Kakegawa et al.
1992).
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Fig. 6: Inhibitory effects of DSCG (3), apigenin (28), kaempferol (29) and
sylibinin (30) on the activity of the bovine testicular hyaluronidase
To get more information about the structural requirements of flavone derivatives
(e.g. substitution, functional groups, planarity) for hyaluronidase inhibitory activ-
ity, we investigated a series of flavones and related compound. The obtained
results for the flavones 33-36, the flavonols 37-41, the flavanes 42-46, the iso-
flavones 47 and 481 are presented in the following (cf. Table 2 and Table 3).
1 The compounds 33-48 were kindly provided from PD Dr. C. Paper, Institute of Pharmacy, Uni-
versity of Regensburg, Germany
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Table 2: Inhibitory effects of the flavone derivatives 31-41
O
O
356
7 8 1 2
4
2'
3' 4'
5'
6'
1'
R
R'
31-41
No Substitution % Inhibition a at Concentration
31 ⎯ 11 % 10 mM
inactive ≤ 2 mM
32 5-OH inactive ≤10mM
33 6-OH 17 % 10 mM
10 % 2 mM
34 7-OH 28 % 10 mM
inactive ≤ 2 mM
35 [2’,3’]-benzo-annelated 21 % 5 mM
inactive ≤ 2 mM
36 [3’,4’]-benzo-annelated inactive ≤ 5 mM
37 3-OH 58 % 10 mM
inactive ≤ 2 mM
38 3-OH, 6-OCH3 inactive ≤ 5 mM
39 3-OH, 7-OCH3 13 % 10 mM
13 % 2 mM
40 3,3’,4’,5,5’,7-hexy-OH 34 % 2 mM
41
3’,4’,5,7-tetra-OH,
3-O-rutinose
BTH: 15 %
hylB4755: 46 %
7.7 mM
BTH: 11 %
hylB4755: inactive
2 mM
a % inhibition of BTH at an inhibitor concentration unless otherwise indicated
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Table 3: Inhibitory effects of the compounds 42-48
O ∗
O
356
7
8 1 2
4
2'
3' 4'
5'
6'
1'
R
R'
R'
O
O
356
7 8 1 2
4 2'
3'
4'5'
6'
1'
R
42-46 47-48
No Substitution % Inhibition a at Concentration
42 4’-OH 32 % 10 mM
21 % 2 mM
43 4’,5,7-tri-OH 45 % 10 mM
10 % 2 mM
44 3’,4’,5,7-tetra-OH 23 % 2 mM
45 4’,5,7-tri-OH, 3’-OCH3 17 % 2 mM
46 3,3’,4’,5,7-penta-OH 30 % 2 mM
47 4’,5,7-tri-OH
BTH: inactive
hylB4755: 61 %
1.7 mM
48 3’,4’,7-tri-OH
BTH: inactive
hylB4755: 17 %
2 mM
a % inhibition of BTH at an inhibitor concentration unless otherwise indicated
The 5-hydroxyflavone 32 and the β-naphthoflavone 36, two of the six flavone
compounds, were ineffective as inhibitors of the bovine testicular hyaluroni-
dase. The compounds 33-35 induced only very weak inhibition of the enzyme
at millimolar concentrations (cf. Table 2). Compounds 33 and 34 which are hy-
droxylated in the positions 6 and 7, respectively, are more active than the un-
substituted flavone 31. By contrast, a hydroxylation in position 5 (cf. compound
32) results in a loss of the inhibitory activity.
Within the series of flavonols 37-41, the compounds 37 and 39-41 showed a
weak inhibitory activity, whereas 6-methoxyflavon-3-ol (38) was inactive on the
bovine testicular hyaluronidase (cf. Table 2). The highest inhibitory activity was
found for flavon-3-ol 37 (58 % inhibition at the concentration of 10 mM). A de-
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crease in activity was induced by an additional methoxy group in position 7
(39), whereas the isomer with a methoxy group in position 6 (38) was com-
pletely inactive. Myricetin 40, which is hydroxylated in the positions 3’, 4’, 5, 5’
and 7 of the flavone skeleton, induced 34 % inhibition of the bovine testicular
hyaluronidase at a concentration of 2 mM. The inhibitory effect of the glycosyl-
ated flavonol (+)-rutin (41) on BTH was similar to that reported in the literature
(15 % inhibition at a concentration of 2 mM) (Kuppusamy et al. 1990). Com-
pound 41 was also tested on the bacterial hyaluronidase from S. agalactiae.
The inhibition oh the hylB4755 by 41 at a concentration of 7.7 mM was 46 % cor-
responding to about 3-fold the percentual inhibition found on the bovine tes-
ticular hyaluronidase.
Furthermore, we investigated the flavanes 42-46 for bovine testicular hyaluro-
nidase inhibitory activity (Table 3). The hydroxylated flavane 42 induced  32 %
at a concentration of 10 mM. Additional hydroxylations in the positions 5 and 7
(43) led to an increase in activity (45 % inhibition at a concentration of 10 mM).
Due to poor solubility, the compounds 44-46 were tested at a concentration of
2 mM, so that a comparison of the results with those found for the compound
42 and 43 are only reasonable at this lower concentration. Of all flavane de-
rivatives, the penta hydroxylated compound (46) induced the highest inhibition
of BTH by 30 %. Taxifolin 46 (flavan) as well as myricetin 40 (flavone) induced
an inhibition of approximately 30 % at a concentration of 2 mM. Thus, the C=C
double bond of the flavone seems to be less important than reported in the lit-
erature (Kuppusamy et al. 1990; Kuppusamy et al. 1991).
Isoflavones are a group of flavone analogues which have been neglected so far
concerning investigation for inhibition of hyaluronidases. Only a few compounds
like diadzein (4’,7-dihydroxyisoflavone) and tectorigenin (4’,7-dihydroxy-6-
methoxyisoflavone) were tested on hyaluronidases (Matsuda 1985; Matsuda
1985; Kuppusamy et al. 1990). In this project, two isoflavones (47 and 48) were
instigated for inhibition of BTH and hylB4755. Both compounds were inactive on
the bovine testicular enzyme but active on the bacterial hyaluronidase.
Whereas compound 47 induced an inhibition of 61 % at a concentration of
1.7 mM, compound 48 was only weakly active (17 % at a concentration of
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2 mM) (cf. Table 3). Obviously, a hydroxy group in position 5 is more favourable
than a hydroxy group in position 3’ of the phenyl ring.
In addition to the aforementioned flavones, the sulphated flavone derivatives
49-522 were investigated (Table 4). The sulphate groups are suitable to im-
prove the solubility of flavones. Moreover, it is conceivable that these polar
substituents could interact similar to the carboxylates of the hyaluronic acid with
amino acid residues in the active site of the hyaluronidase.
Whereas the flavone derivative 49 with the sulphate group in position 3 was
inactive, compound 51 with an additional methoxy group in position 7 induced
an inhibition of BTH by 37 % at a concentration of 2 mM.
Table 4: Inhibitory effect of the sulphated flavone derivatives 49-52
O
O
R1
R2
R3
No R1 R2 R3
IC50 [µM] or
(% Inhibition) a
49 OSO3
− Na+ H H inactiveb
50 H H OSO3
− Na+ 690
51 OSO3
− Na+ H OCH3 (37 %)c
52 H OH OSO3− Na+ BTH:   190hylB4755:   290
a determination on BTH unless otherwise indicated
b at concentrations ≤ 2 mM
c % inhibition of BTH at an inhibitor concentration of 2 mM
The sulphated flavone 50 and chrysin-7-sulphate (52) induced a concentration-
dependent inhibition of the bovine testicular hyaluronidase in the submillimolar
range (IC50 values of 660 µM (50) and 190 µM (52)) (cf. Fig. 7). The introduc-
2 The compounds 49-52 were kindly provided from PD Dr. C. Paper, Institute of Pharmacy, Uni-
versity of Regensburg, Germany
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tion of an additional  hydroxy group in position 5 (cf. compound 52) led to a
3.5-fold increase in inhibitory potency. Additionally, on the S. agalactiae hyalu-
ronate lyase an IC50 value of 290 µM was determined for chrysin-7-sulphate.
The concentration-dependent inhibitory effect of compound 52 on hylB4755 is
depicted in Fig. 7, too.
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Fig. 7: Effect of the sulphated flavones 50 and 52 on the activity of BTH and
hylB4755 at optimum pH (BTH: pH 3.6, hylB4755: pH 5.0)
In summary, the first investigations revealed that flavone, flavonol and flavane
derivatives have some inhibitory activity on the bovine testicular hyaluronidase,
but only in the millimolar range. Furthermore, in the most cases the inhibitory
effects were not concentration-dependent. The highest inhibitory activities were
obtained with the sulphated flavones 50 and 52, i.a. the introduction of an
acidic group not only contributed to a better solubility of the compounds but
also to an increase in potency.
Starting from these results a series of chalcones (19b-f , 19h-k and 23a-d) and
flavones (25a-e, 25f-i and 26) with different substituents, e.g. COO- and OSO3-,
OH, N(CH3)2, OCH3, Cl and F was synthesised (cf. section 2 of this chapter)
and tested for inhibition of BTH and hylB4755. The inhibitory activities of these
chalcone derivatives on the bovine testicular hyaluronidase (pH 3.6 and 7.4)
and bacterial hyaluronidase (pH 5.0 and 7.4) are summarised in Table 5.
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Table 5: Inhibitory activities of compounds 19b-f, 19h-k and 23a-d on BTH
and hylB4755
H3CO
CH3O
OH
O
R3
R2
R1
R4 OH
O
R1
R2
R3
R4
19b-f, 19h-k 23a-d
No Substitution BTH hylB4755
IC50 [µM] or (% Inhibition)
R1 R2 R3 R4 pH 3.6 pH 7.4 pH 5.0 pH 7.4
19b H H OCH3 H 4000 (70 %)a (28 %)a (66 %)a
19c H OCH3 OCH3 H inactiveb inactiveb (44 %)c 660
19d H H NMe2 H (71 %)d (49 %)d 310 380
19e H benzo-annelated H inactive
b (15 %)c (41 %)c (80 %)c
19f H H CO2H H (55 %)c (72 %)c 110 220
19h H H Cl H 660 720 (54 %)c 70
19i Cl OCH3 OCH3 H inactivee inactivee (38 %)f (44 %)f
19j Cl H Cl OCH3 inactiveb (20 %)c (24 %)c (83 %)c
19k H H F H (48 %)c (40 %)c 200 250
23a F H OCH3 OCH3 inactiveb inactiveb inactiveb 190
23b F H H OCH3 (21 %)c (16 %)c (34 %)c 220
23c H F H OCH3 inactivee inactivee inactivee inactivee
23d H F H F (69 %)c 1000 500 (80 %)c
a % inhibition of the enzyme at an inhibitor concentration of 7 mM; b at concentrations ≤ 2 mM;
c % inhibition of the enzyme at an inhibitor concentration of 2 mM; d % inhibition of the enzyme
at an inhibitor concentration of 3.3 mM; e at concentrations of ≤100 µM; f % inhibition of the
enzyme at an inhibitor concentration of 100 µM
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Both methoxylated chalcones 19b and 19c induced different inhibition of the
bovine testicular hyaluronidase. Whereas the IC50 value of compounds 19b on
BTH was 4 mM, the chalcone 19c with an additional methoxy group in position
3’ was inactive. By contrast, the inhibitory effect of the compound 19c on the
hyaluronate lyase was stronger than that of compound 19b. The IC50 value de-
termined for the chalcone 19c on hylB4755 was 660 µM at pH 7.4 (cf. Table5).
The chalcone derivative 19d with a dimethylamino substituent in position 4’ and
two methoxy groups in the positions 4 and 6 inhibited both hyaluronidases in
the millimolar range. The percentual inhibition of BTH by compound 19d at a
concentration of 3.3 mM was 71 % at optimum pH (3.6) and 49 % at physio-
logical pH (7.4). The IC50 value of compound 19d determined on hylB4755 was
310 µM at pH 5.0 and 380 µM at pH 7.4. The concentration-dependent inhibi-
tion curves are depicted in Fig. 8.
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Fig. 8: Enzyme activity of hyaluronate lyase from S. agalactiae in the presence
of the chalcone derivative 19d
The chalcone derivative 19e was almost inactive on the bovine testicular hyalu-
ronidase and induced an inhibition of the bacterial hyaluronidase in the milli-
molar range (cf. Table 5).
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Due to the results obtained with the sulphated flavones 50 and 52, the
4‘-carboxylated compound 19f was expected to be also rather potent. However,
the inhibition of BTH by the flavone 19f was only 55 % at pH 3.6 and 72 % at
pH 7.4 at a concentration of 2 mM. By contrast, the inhibitory effects on the
bacterial hyaluronidase were concentration-dependent (cf. Fig. 9) and in the
same order of magnitude as those of the sulphated flavones (IC50 values:
110 µM at pH 5.0 and 220 µM at pH 7.4).
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Fig. 9: Inhibitory effect of the chalcone derivative 19f on the activity of the bac-
terial hyaluronidase from S. agalactiae at optimum and physiological pH
Within the series of chloro substituted derivatives 19h, 19i and 19j, the mono-
chlorinated compound 19i (2’-Cl) was only active on the bacterial hyaluronidase
(cf. Table 5), whereas the  chalcone derivative 19j, with two chloro substituents
in the positions 2’ and 4’ inhibited both hyaluronidases. Surprisingly, the highest
inhibitory effect was formed with compound 19h, the chalcone derivative with
p-chloro substituent and lacking the additional methoxy group(s) at the phenyl
ring compared to the compounds 19i and 19j . The IC50 values of compound
19h determined on BTH were 660 µM (pH 3.6) and 720 µM (pH 7.4). The po-
tency of compound 19h on hylB4755 (IC50 of 70 µM) was 4-fold higher compared
to chrysin-7-sulphat, the flavone derivative with a polar substituent. The con-
centration-dependent inhibition of BTH and hylB4755 by compound 19h are de-
picted in Fig. 10.
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Fig. 10: Inhibition of the bovine testicular and the bacterial hyaluronidase by the
chlorinated chalcone derivative 19h
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Fig. 11: Enzyme activity of hylB4755 in the presence of the fluorinated chalcone
derivatives 23a and 23b at physiological pH (7.4)
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Of all fluorinated chalcone derivatives (19k, 23a-d), the compounds 23c and
23a were inactive on the bovine testicular hyaluronidase and 23c was inactive
on the bacterial enzyme, too. The chalcone derivatives 19k, 23b and 23d in-
duced only a very weak inhibition of the BTH at millimolar concentration (cf.
Table 5). Whereas the chalcone derivatives 23a and 23b showed no effect or a
very weak effect on the bovine testicular hyaluronidase, the obtained inhibitory
effects on the hyaluronate lyase at physiological pH were concentration-
dependent (cf. Fig. 11). The calculated IC50 values of 23a and 23b were
190 µM and 200 µM, respectively.
The IC50 values of compound 19k determined on the bacterial enzyme were
200 µM at pH 5.0 and 250 µM at pH 7.4, whereas BTH was inhibited by only
about 40 % at a concentration of 2 mM. In comparison to chrysin-7-sulphate
(52), the fluorinated chalcone 19k induced a lower inhibition of BTH, whereas
the potencies on hylB4755 were similar.
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The inhibitory effects of the synthesised flavones 25a-i and 26 on the bovine
testicular hyaluronidase and the hyaluronate lyase from S. agalactiae at differ-
ent pH values are summarised in Table 6.
Table 6: The effects of the synthesised flavone derivatives 25a-i and 26 on the
bovine testicular hyaluronidase and the S. agalactiae hyaluronate lyase
O
O
H3CO
CH3O
R1
R2
O
O
R1
R2
R3
7
6
25a-e 25f-i, 26
No Substitution BTH hylB4755
IC50 [µM] or ( % Inhibition)
R1 R2 R3 pH 3.6 pH 7.4 pH 5.0 pH 7.4
25a H OCH3 ⎯ inactivea inactivea (13 %)b (33 %)b
25b OCH3 OCH3 ⎯ inactivea inactivea inactivea (45 %)b
25c benzo-annelated ⎯ (26 %)b inactive
a (26 %)b (83 %)b
25d H Cl ⎯ (12 %)b inactivea (18 %)b (66 %)b
25e H F ⎯ inactivea inactivea (64 %)b (78 %)b
25f 6-F H OCH3 (33 %)b (36 %)b (65 %)b (77 %)b
25g 6-F H F inactivec inactivec inactivec inactivec
25h 7-F OCH3 OCH3 inactivea inactivea (24 %)b (56 %)b
25i 7-F H OCH3 inactivea inactivea (63 %)b 250
26 7-F H OH 970 1600 380 260
a at concentrations ≤ 2 mM; b % inhibition of the enzyme at an inhibitor concentration of 2
mM; c at concentrations ≤ 100 µM
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Comparing the inhibitory effects of the investigated flavone compounds 25a-i
and 26 on the bovine testicular enzyme, all compounds except 7-fluoro-4’-
hydroxyflavone (26) showed either very weak inhibition or no effects at all. At
millimolar concentrations the flavones 25c, 25d and 25f induced about 12 % -
36 % inhibition of the bovine testicular hyaluronidase at (cf. Table 6). Only
compound 26 was sufficiently active to determine IC50 values on both enzymes
(BTH: 970 µM (pH 3.6) and 1.6 mM (pH 7.4) and hylB4755: 380 µM (pH 5.0) and
260 µM (pH 7.4)). As expected the replacement of the p-methoxy group in
compound 25i with a hydroxy group (26) led to an increase in affinity on the
bovine testicular hyaluronidase. The inhibition curves on BTH are depicted in
Fig. 12.
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Fig. 12: Inhibitory effect of the 7-fluoro-4’-hydroxyflavone (26) on BTH at opti-
mum pH (3.6) and physiological pH (7.4)
In contrast to the results for BTH, on the bacterial enzyme nine out of ten syn-
thesised flavones induced inhibition at millimolar concentrations (cf. Table 6).
The difluorinated flavone 25g was inactive, whereas the compounds 25a-f and
25h induced partial inhibition of the hyaluronate lyase. The inhibitory effects on
hylB4755 at physiological pH were always stronger at pH 5.0, the optimum pH of
the enzyme.
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The highest inhibitory activities on the hyaluronate lyase were measured for the
compounds 25i and 26. The IC50 values were 350 µM for 25i at physiological
pH, 380 µM and 260 µM for 26 at pH 5.0 and pH 7.4, respectively (cf. Table 6).
The inhibition curves of the compounds 25i and 26 are depicted in Fig. 13.
Surprisingly, the replacement of the methoxy group by a hydroxy group did not
increase the potency on the bacterial hyaluronidase.
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Fig. 13: Enzyme activity of the hyaluronate lyase hylB4755 at physiological pH
(7.4) in the presence of the fluorinated flavone derivatives 25i and 26
4. Summary
The inhibitory effects of some purported hyaluronidase inhibitors like apigenin,
kaempferol and disodium chromoglycate (DSCG) on the bovine testicular hya-
luronidase (BTH) were investigated. Of these compounds, disodium chromo-
glycate was the most potent inhibitor of BTH with an IC50 value of 1.24 mM.
Furthermore, the inhibitory effects of some flavones (natural compounds) and
sulphated flavones were measured. Sodium flavone-7-sulphate (50) and so-
dium 5-hydroxyflavone-7-sulphate (52) were more active BTH inhibitors (IC50:
690 µM and 190 µM) than DSCG. Additionally, compound 52 was a hyaluro-
nate lyase inhibitor with submillimolar activity (IC50: 290 µM).
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Starting from these results, a series of chalcone and flavone derivatives was
synthesised and subsequently tested on the bovine testicular and the bacterial
hyaluronidase. The chalcone derivatives 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-
(4-methoxyphenyl)propenone (19b) and 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-
(4-chlorophenyl)propenone (19h) and the flavone 7-fluoro-4’-hydroxyflavone
(26) induced a concentration-dependent inhibition of the bovine testicular en-
zyme in the millimolar range. The IC50 values were comparable to those of the
sulphated flavone 50 (690 µM), but higher than that of compound 52 (190 µM).
In general, the increase in activity on BTH seems to be dependent on the pres-
ence of acidic functional groups.
Five chalcone derivatives and the two flavone derivatives were found to have
inhibitory activity in the millimolar range on the bacterial hyaluronidase. The IC50
values of the most active compound were about 250 µM, that is comparable to
that of  the sulphated flavone 52. Apparently, the presence of acidic groups is
not that important for inhibition of hyaluronate lyase in comparison to the bovine
testicular enzyme. 4’-Chloro-4,6-dimethoxychalcone (19h) was the most potent
hyaluronate lyase inhibitor (IC50 = 70 µM) of all compounds described in this
chapter.
5. Experimental section
5.1 General conditions
For a detailed description of the general procedures, equipments and chemi-
cals used in the chemistry part, see section 4.1 of chapter 5.
5.2 Chemistry
1-(2-Hydroxy-4,6-dimethoxyphenyl)ethanone (17)
A solution of 1-(2,4,6-trihydroxyphenyl)ethanone ( 26.57 g, 142.52 mmol), po-
tassium carbonate (59.17 g, 428.16 mmol), dimethyl sulphate (50.40 g, 399.62
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mmol) and Na2S2O4 (1.0 g, 5.74 mmol) in anhydrous acetone (800 ml) was
stirred at room temperature for 2 h and then heated under reflux for two addi-
tional hours. After cooling to room temperature, the solution was diluted in small
portion with water until a white solid precipitated. The product was collected and
dried in vacuo at 55-60 °C.
Yield: 24.37 g (124.20 mmol, 87 %, white crystalline solid)
MP: 81 °C
1H-NMR (CDCl3):
δ [ppm] = 2.61 (3H, CCH3), 3.82 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 5.92 (d, 1H,
4J = 2.4 Hz, H-3), 6.06 (d, 1H, 4J = 2.4 Hz, H-5), 14.04 (s, 1H, OH)
MS (PI-EIMS (70 eV)): m/z (%) = 196 ([M•+], 33), 181 ([M-CH3]+, 100), 166 ([M-
2CH3]+, 8)
IR [cm-1]: 3210 (O-H), 3000 (C-H) aromatic, 2927 (C-H) aliphatic, 1612 (C=O),
1422, 1366 (C-H), 1268 (C-H), 1202 (C-O), 1155, 1110, 940, 834, 804
C10H8O4 (196.2)
1-[2-(4-Cyanobenzoyloxy)-4,6-dimethoxyphenyl]ethanone (18a)
A solution of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (2.0 g, 10.20 mmol)
and p-cyanobenzoyl chloride (2.03 g, 12.24 mmol) in pyridine (20 ml) was
stirred and heated under reflux for 90 min. Afterwards, the mixture was poured
into diluted hydrochloric acid (40 ml, 5 %) and extracted three times with chlo-
roform (50 ml). The combined extracts were washed with water (2 x 30 ml),
dried over sodium sulphate and evaporated under reduced pressure to obtain a
yellow solid.
Yield: 2.30 g (7.0 mmol, 67 %, yellow solid)
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1H-NMR ([D6]DMSO):
δ [ppm] = 2.39 (s, 3H, CCH3), 3.83 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 6.61 (d,
1H, 4J = 2.3 Hz, H-3), 6.66 (d, 1H, 4J = 2.3 Hz, H-5), 7.84-7.87 (m, 2H, H-3, H-
5), 8.16-8.19 (m, 2H, H-2, H-6)
MS (PI-EIMS (70 eV)): m/z (%) =325 ([M•+], 27), 310 ([M-CH3]+, 61), 282 ([M-
CH3-CO]+, 2), 130 ([CNC6H4CO]+, 100), 102 ([CNC6H4]+, 35)
IR [cm-1]: 2989 (C-H) aromatic, 2861 (C-H) aliphatic, 2200 (C≡N), 1738-1657
(C=O), 1605 (C=C), 1407 (C-H), 1248 (C-O), 1154, 1105, 862, 838, 779, 686
C18H15NO5 (325.32)
1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(4-cyanophenyl)propan-1,3-dione
(20a)
To a solution of compound 18a (1.0 g, 3.07 mmol) in ethanol (30 ml), a potas-
sium hydroxide solution (15 ml, 60 %) was added dropwise and the mixture was
stirred at room temperature for 24 h. After cooling with an ice bath, the reaction
mixture was acidified with concentrated hydrochloric acid and diluted in small
portion with water. The yellow precipitate was collected, washed with water and
dried in vacuo over silica gel. The product was used without further purifica-
tions.
Yield: 0.96 g (yellow solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 3.81 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 6.08 (d, 1H, 4J = 2.4 Hz, H-
3), 6.11 (d, 1H, 4J = 2.4 Hz, H-5), 7.97-8.01 (m, 4H, ph), 8.04-8.07 (m, 1H,
=CH), 13.35 (br, 1H, OH), 13.79 (s, 1H, OH)
C18H15NO5 (325.32)
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General procedure for the preparation of the chalcone deriva-
tives 19b-k and 23a-d
To a solution of the pertinent substituted (2-hydroxyphenyl)ethanone and sub-
stituted benzaldehyde in ethanol (30-100 ml), an aqueous potassium hydroxide
solution (15-30 ml, 60 %) was added dropwise and the mixture was stirred at
room temperature for 24 h. After cooling with an ice bath, the reaction mixture
was acidified with concentrated hydrochloric acid and diluted in small portion
with water until a solid precipitated. The product was collected, dried over silica
gel and recrystallised.
1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)propenone (20b)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (2.0 g, 10.19 mmol)
and 4-methoxybenzaldehyde (3.06 g, 22.48 mmol); recrystallisation from
DMSO;
Yield: 3.17 g (10.08 mmol, 99 %, orange crystalline solid)
Mp: 94 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.82 (s, 6H, OCH3), 3.90 (s, 3H, OCH3), 6.10 (d, 1H, 4J = 2.3 Hz, H-
3), 6.13 (d, 1H, 4J = 2.3 Hz, H-5), 7.00 (d, 2H, 3J = 8.8 Hz, H-3’, H-5’), 7.67 (d,
2H, 3J = 8.8 Hz, H-2’, H-6’), 7.66-7.71 (m, 2H, =CH), 13.61(s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.3 (+, OCH3), 55.6 (+, OCH3), 56.1 (+, OCH3),  91.1 (+, ph), 93.9
(+, ph), 106.3 (Cquart, ph), 114.5 (+, ph), 124.9 (+, =CH), 127.4 (Cquart, ph), 130.4
(+, ph), 142.6 (+, =CH), 161.3 (Cquart, ph), 161.9 (Cquart, ph), 165.4 (Cquart, ph),
165.6 (Cquart, ph), 192.2 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 314 ([M•+], 100), 313 ([M-H]+, 72), 207 ([M-
C6H4OMe]+, 38), 134 ([MeOC6H4CH=CH2]+, 51), 121 ([MeOC6H4CH2]+, 58)
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IR [cm-1]: 3084 (C-H) aromatic, 2843 (C-H) aliphatic, 1580, 1512, 1439 (C-H),
1344 (C-H), 1255 (C-O), 1177, 1114, 972, 900, 821, 615
Analysis:
calculated C: 68.78 H: 5.77
found C: 68.40 H: 5.77
C18H18O5 (314.34)
(E) 1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(3,4-dimethoxyphenyl)propenone
(19c)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (3.0 g, 15.29 mmol)
and 3,4-dimethoxybenzaldehyde (5.59 g, 33.64 mmol); recrystallisation from a
1:1 (v/v) mixture of toluene and acetone;
Yield: 5.08 g (14.75 mmol, 96 %, orange crystalline solid)
MP: 107-110°C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.82 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.89 (s,
3H, OCH3), 6.12 (d, 1H, 4J = 2.3 Hz, H-3), 6.16 (d, 1H, 4J = 2.3 Hz, H-5), 7.00-
7.04 (m, 1H, ph), 7.27-7.32 (m, 2H, ph), 7.60 (d, 1H, 3J = 15.7 Hz, =CH), 7.67
(d, 1H, 3J = 15.7 Hz, =CH), 13.41 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.5 (+, OCH3), 55.6 (+, OCH3), 55.6 (+, OCH3), 56.1 (+, OCH3), 91.0
(+, ph), 93.9 (+, ph), 106.5 (Cquart, ph), 110.8 (+, ph), 111.8 (+, ph), 122.8 (+,
ph), 125,2 (+, =CH), 127.6 (Cquart, ph), 143.0 (+, =CH), 149.0 (Cquart, ph), 151.1
(Cquart, ph), 161.7 (Cquart, ph), 165.2 (Cquart, ph), 165.2 (Cquart, ph), 192.3 (Cquart,
C=O)
MS (PI EI 70 eV): m/z (%) = 344 ([M•+], 100), 164 ([MeO)2C6H4CH=CH2]+, 73),
151 ([MeO)2C6H4CH2]+, 93)
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HR-MS: calculated: 344.12550 amu
found: 344.12599 amu
IR [cm-1]: 3000 (C-H) aromatic, 2838 (C-H) aliphatic, 1618 (C=O), 1509, 1441
(C-H), 1303 (C-H), 1218 (C-O), 1145, 1110,1022, 815, 760, 615
C19H20O6 (344.36)
(E) 1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(4-dimethylaminophenyl)propen-
one (19d)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (1.0 g, 5.10 mmol)
and 4-N,N-dimethylaminobenzaldehyde (1.68 g, 11.22 mmol);
Yield: 1.59 g (4.87 mmol, 96 %, red solid)
Mp: 160 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.01 (s, 3H, NCH3), 3.05 (s, 3H, NCH3), 3.81 (s, 3H, OCH3), 3.90 (s,
3H, OCH3), 6.10 (d, 1H, 4J = 2.4 Hz, H-3), 6.14 (d, 1H, 4J = 2.4 Hz, H-5), 6.67-
6.81 (m, 2H, H-3’, H-5’), 7.54-7.72 (m, 2H, H-2’, H-6’), 7.58 (d, 1H, 3J = 15.5 Hz,
=CH), 7.67 (d, 1H, 3J = 15.5 Hz, =CH), 14.0 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 39.7 (+, NCH3), 39.7 (+, NCH3), 55.6 (+, OCH3), 56.1 (+, OCH3), 91.0
(+, ph), 93.9 (+, ph), 106.2 (Cquart, ph), 111.9 (+, ph), 121.2 (+, =CH), 122.0
(Cquart, ph), 130.5 (+, ph), 144.4 (+, =CH), 152.0 (Cquart, ph), 161.8 (Cquart, ph),
165.1 (Cquart, ph), 165.9 (Cquart, ph), 191.8 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 327 ([M•+], 52), 174 ([Me2NC6H4CH=CHCO]+, 7),
147 ([Me2NC6H4CH=CH2]+, 83), 134 ([Me2NC6H4CH2]+, 100)
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IR [cm-1]: 3000 (C-H) aromatic, 2832 (C-H) aliphatic, 1587, 1527, 1480 (C-H),
1346 (C-H), 1209 (C-O), 1153 (C-N), 1030, 985, 919, 808, 764, 615
Analysis:
calculated C: 69.71 H: 6.47 N: 4.28
found C: 69.34 H: 6.50 N: 4.44
C19H21NO4 (327.38)
1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(naphth-2-yl)propenone (19e)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (3.0 g, 15.29 mmol)
and naphthalene-2-carbaldehyde (5.25 g, 33.64 mmol); recrystallisation from
dimethylsulphoxide
Yield: 3.20 g (9.57 mmol, 63 %, yellow solid)
Mp: 92 - 95 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.84 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 6.14 (d, 1H, 4J = 2.3 Hz, H-
3), 6.17 (d, 1H, 4J = 2.3 Hz, H-5), 7.56-7.60 (m, 2H, naphthyl), 7.83 (s, 1H,
=CH), 8.23 (s, 1H, =CH), 7.86-8.00 (m, 5H, naphthyl), 13.41 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.7 (+, OCH3), 56.3 (+, OCH3), 91.1 (+, ph), 93.91 (+, ph), 106.4
(Cquart, ph), 123.9 (+, naphthyl), 126.8 (+, naphthyl), 127.4 (+, naphthyl), 127.7
(+, naphthyl), 127.8 (+, naphthyl), 128.6 (+, naphthyl), 128.7 (+, naphthyl),
130.4 (+, =CH), 132.4 (Cquart, naphthyl), 133.0 (Cquart, naphthyl), 133.8 (Cquart,
naphthyl), 142.5 (+, =CH), 161.9 (Cquart, ph), 165.4 (Cquart, ph), 165.5 (Cquart, ph),
192.3 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) =334 ([M•+], 100), 333 ([M-H]+, 62), 207 ([M-
naphthyl]+, 58), 181 ([M-naphthyl-C2H2]+, 26), 153 ([M- naphthyl-C2H2-CO]+, 25)
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IR [cm-1]: 3399 (H-O), 3009 (C-H) aromatic, 2921 (C-H) aliphatic, 1619 (C=O),
1556, 1436 (C-H), 1361 (C-H), 1212 (C-O), 1157, 1112, 952, 856, 818, 761
C21H18O4 (334.37)
(E) 4-[3-(2-Hydroxy-4,6-dimethoxyphenyl)-3-oxopropenyl]benzoic acid (19f)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (2.0 g, 10.19 mmol)
and sodium 4-formylbenzoate (3.68 g, 22.42 mmol); recrystallisation from di-
methylsulphoxide
Yield: 3.01 g (9.17 mmol, 90 %, orange solid)
Mp: 218 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.84 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 6.13 (d, 1H, 4J = 2.2 Hz, H-
3), 6.15 (d, 1H, 4J = 2.2 Hz, H-5), 7.66 (d, 1H, 3J = 15.8 Hz,  =CH), 7.84 (d, 1H,
3J = 15.8 Hz,  =CH), 7.70-7.88 (m, 2H, ph), 7.94-8.05  (m, 2H, ph), 11.50-13.30
(br, 1H, COOH), 13.36 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.6 (+, OCH3), 56.2 (+, OCH3), 91.1 (+, ph), 93.8 (+, ph), 106.3
(Cquart, ph), 128.4 (+, ph), 129.6 (+, =CH), 129.8 (+, ph), 131.8 (Cquart, ph), 138.9
(Cquart, ph), 140.5 (+, =CH), 161.9 (Cquart, ph), 165.5 (Cquart, ph), 165.7 (Cquart,
ph), 166.7 (Cquart, COOH), 192.0 (Cquart, C=O)
MS (PI-EIMS (70 eV): m/z (%) = 328 ([M•+], 72), 329 ([M-H]+, 52), 207 ([M-
C6H4CO2H]+, 100), 181 ([M - CH=CHC6H4CO2H]+, 31)
IR [cm-1]: 3008 (C-H) aromatic, 2832 (C-H) aliphatic, 1682 (C=O), 1556, 1408
(C-H), 1341 (C-H), 1211 (C-O), 1156, 1108, 935, 847, 751, 608
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Analysis:
calculated C: 65.49 H: 4.91
found C: 65.16 H: 4.92
C18H16O6 • 0.1 H2O (328.32)
(E) 4-[3-(2-Hydroxy-4,6-dimethoxyphenyl)-3-oxopropenyl]benzene-1,3-di-
sulphonic acid (19g)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (1.0 g, 5.10 mmol)
and disodium 4-formylbenzene-1,3-disulphonate monohydrate (3.68 g, 11.22
mmol); after filtration the solvent was removed under reduced pressure; The
purification by standard methods failed.
Yield: 0.66 g (yellow solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 3.83 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 6.13 (d, 1H, 4J = 2.4 Hz, H-
3), 6.16 (d, 1H, 4J = 2.4 Hz, H-5), 7.61 (m, 1H, H-5’), 7.68 (d, 1H, 3J = 15.2 Hz,
=CH), 7.74 (d, 1H, 3J = 8.3 Hz, H-6’), 8.14 (d, 1H, 4J = 2.0 Hz, H-3’), 8.74 (d,
1H, 3J = 15.2 Hz, =CH), 13.77 (s, 1H, OH)
MS (ESI): m/z (%) = 443 ([M-H]-, 48), 227 ([M-2TFA-H]-, 100)
C17H16O10S2 (444.31)
(E) 1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(4-chlorophenyl)propenone (19h)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (3.0 g, 15.29 mmol)
and 4-chlorobenzaldehyde (4.58 g, 33.64 mmol); recrystallisation from dimeth-
ylsulphoxide
Yield: 4.48 g (14.25 mmol, 93 %, yellow crystalline solid)
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Mp: 153 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.83 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 6.14 (d, 1H, 4J = 2.4 Hz, H-
3), 6.16 (d, 1H, 4J = 2.4 Hz, H-5), 7.48-7.53 (m, 2H, H-3’, H-5’), 7.75-7.78 (m,
2H, H-2’, H-6’), 7.62 (d, 1H, 3J = 15.8  Hz, =CH), 7.76 (d, 1H, 3J = 15.8 Hz,
=CH), 14.00 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.7 (+, OCH3), 56.2 (+, OCH3), 91.3 (+, ph), 93.9 (+, ph), 106.3
(Cquart, ph), 128.2 (+, =CH), 129.1 (+, ph), 130.1 (+, ph), 133.8 (Cquart, ph), 134.9
(Cquart, ph), 140.7 (+, =CH), 161.9 (Cquart, ph), 165.5 (Cquart, ph), 165.7 (Cquart,
ph), 192.2 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 318 ([M•+], 76), 317 ([M-H]+, 60), 207
([(CH3O)2C6H3COCH=CH2]+, 100), 181 ([(CH3)2C6H4CO]+, 52), 165 ([ClC6H4CH2
=CHCO]+, 13), 138 ([ClC6H4CH2=CH]+, 16)
IR [cm-1]: 3414 (O-H), 3021 (C-H) aromatic, 2947 (C-H) aliphatic, 1565, 1487,
1440 (C-H), 1337 (C-H), 1213 (C-O), 1024 (C-Cl), 970, 818, 788, 757
Analysis:
calculated C: 64.06 H: 4.74
found C: 63.65 H: 4.80
C17H15ClO4 (318.76)
(E) 1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(2-chloro-3,4-dimethoxyphenyl)-
propenone (19i)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (3.0 g, 15.29 mmol)
and 2-chloro-3,4-dimethoxybenzaldehyde (6.72 g, 33.64 mmol); recrystallisa-
tion from dimethylsulphoxide
Yield: 4.38 g (11.56 mmol, 76 %, orange crystalline solid)
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Mp: 152 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.77 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.91 (s,
3H, OCH3), 6.13 (d, 1H, 4J = 2.3 Hz, H-3), 6.15 (d. 1H, 4J = 2.3 Hz, H-5), 7.15
(d, 1H, 3J = 8.9 Hz, H-5’), 7.69 (d, 1H, 3J = 15.6 Hz, =CH), 7.70 (d, 1H, 3J = 8.9
Hz, H-6’), 7.89 (d, 1H, 3J = 15.6 Hz, =CH), 13.33 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.7 (+, OCH3), 56.2 (+, OCH3), 56.3 (+, OCH3), 60.1 (+, OCH3), 91.1
(+, ph), 93.9 (+, ph), 106.3 (Cquart, ph), 112.0 (+, ph), 123.8 (+, ph), 125.3 (Cquart,
ph), 128.1 (+, =CH), 128.6 (Cquart, ph), 137.4 (+, =CH), 145.0 (Cquart, ph), 155.0
(Cquart, ph), 161.9 (Cquart, ph), 165.4 (Cquart, ph), 165.6 (Cquart, ph), 191.9 (Cquart,
C=O)
MS (PI-EI 70 eV): m/z (%) = 378 ([M•+], 18), 343 ([M-Cl]+, 100)
IR [cm-1]: 3100 (C-H) aromatic, 2843 (C-H) aliphatic, 1626-1549 (C=O), 1489,
1421 (C-H), 1299 (C-H), 1209 (C-O), 1035 (C-Cl), 976, 884, 821, 796, 649
Analysis:
calculated C: 60.24 H: 5.06
found C: 60.00 H: 4.95
C19H19ClO6 (378.80)
(E) 1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(2,4-dichloro-6-methoxyphenyl)-
propenone (19j)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (5.0 g, 25.48 mmol)
and 2,4-dichloro-6-methoxybenzaldehyde (11.49 g, 56.06 mmol); recrystallisa-
tion from dimethylsulphoxide;
Yield: 9.56 g (24.95 mmol, 98 %, yellow solid)
Mp: 145-147°C
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1H-NMR ([D6]DMSO):
δ [ppm] = 3.83 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.99 (s, 3H, OCH3), 6.12 (d,
1H, 4J = 2.3 Hz, H-3), 6.14 (d, 1H, 4J = 2.3 Hz, H-5), 7.26 (d, 1H, 4J = 2.0 Hz, H-
5’), 7.33 (d, 1H, 4J = 2.0 Hz, H-3’), 7.88 (d, 1H, 3J = 15.9 Hz, =CH), 8.18 (d, 1H,
3J = 15.9 Hz, =CH), 13.50 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.7 (+, OCH3), 56.1 (+, OCH3), 56.9 (+, OCH3), 91.2 (+, ph), 93.9 (+,
ph), 106.2 (Cquart, ph), 111.8 (+, ph), 120.2 (Cquart, ph), 121.7 (+, ph), 132.6 (+,
=CH), 133.2 (Cquart, ph), 135.5 (Cquart, ph), 135.9 (+, =CH), 160.3 (Cquart, ph),
162.1 (Cquart, ph), 165.9 (Cquart, ph), 166.1 (Cquart, ph), 192.5 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 382 ([M•+], 76), 347 ([M-Cl]+, 100)
HR-MS: calculated: 382.03754 amu
found: 382.03747 amu
IR [cm-1]: 2988 (C-H) aromatic, 2860 (C-H) aliphatic, 1632 (C=O), 1548, 1448
(C-H), 1341 (C-H), 1220 (C-O), 1110-1037 (C-Cl), 979, 873, 833, 816, 621
C19H18O6 (382,22)
(E) 1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-(4-fluorophenyl)propenone (19k)
Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone (3.0 g, 15.29 mmol)
and 4-fluorobenzaldehyde (4.18 g, 33.68 mmol); recrystallisation from dimeth-
ylsulphoxide
Yield: 4.46 g (14.74 mmol, 96 %, orange solid)
Mp: 121 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.45 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.12 (d, 1H, 4J = 2.4 Hz, H-
3), 6.14 (d, 1H, 4J = 2.4 Hz, H-5), 7.27 (d, 1H, 3J = 8.9 Hz, H-3’), 7.29 (d, 1H, 3J
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= 8.9 Hz, H-5’), 7.62 (d, 1H, 3J = 15.8 Hz,  =CH), 7.71 (d, 1H, 3J = 15.8 Hz,
=CH), 7.77 (d, 1H, 3J = 8.8 Hz, H-2’),7.80 (d, 1H, 3J = 8.8 Hz, H-6’), 13.43 (s,
1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.7 (+, OCH3), 56.2 (+, OCH3), 91.1 (+, ph), 93.9 (+, ph), 106.3
(Cquart, ph), 115.9 (+, ph), 116.2 (+, ph), 127.3 (+, =CH), 130.7 (+, ph), 130.8 (+,
ph), 131.5 (Cquart, 4JC,F = 3.2 Hz, C-F), 141.1 (+, =CH), 161.9 (Cquart, ph), 165.2
(Cquart, 1JC,F = 248.6 Hz, C-F), 165.5 (Cquart, ph), 165.6 (Cquart, ph), 192.2 (Cquart,
C=O)
MS (PI-EI 70 eV): m/z (%) = 302 ([M•+], 84), 301 ([M-H]+, 77), 207 ([M- C6H4F]+,
100), 181 ([MeO)2C6H4(OH)CO]+, 60)
IR [cm-1]: 3012 (C-H) aromatic, 2944 (C-H) aliphatic, 1626 (C=O), 1505, 1443
(C-H), 1341 (C-H), 1276 (C-F), 1213 (C-O), 1154, 1112, 986, 822, 760, 614
Analysis:
calculated C: 67.54 H: 5.00
found C: 67.42 H: 4.88
C17H15FO4 (302.30)
(E) 1-(4-Fluoro-2-hydroxyphenyl)-3-(3,4-dimethoxyphenyl)propenone (23a)
Reaction of 1-(4-fluoro-2-hydroxyphenyl)ethanone (0.70 g, 4.54 mmol) and
3,4-dimethoxybenzaldehyde (1.17 g, 7.14 mmol); recrystallisation from dimeth-
ylsulphoxide
Yield: 1.08 g (3.57 mmol, 79 %, orange crystalline solid)
Mp: 145 °C
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1H-NMR ([D6]DMSO):
δ [ppm] = 3.84 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 6.83-6.92 (m, 2H, ph), 7.03
(d, 1H, 3J = 8.4 Hz, H-5’), 7.43 (dd, 1H, 4J = 2.0 Hz, 3J = 8.4 Hz, H-6’), 7.56 (d,
1H, 4J = 2.0 Hz, H-2’), 7.81 (d, 1H, 3J = 15.4 Hz, =CH), 7.90 (d, 1H, 3J = 15.4
Hz,  =CH), 8.40-8.46 (m, 1H, ph), 13.30 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.6 (+, OCH3), 55.7 (+, OCH3), 104.2 (+, 2JC,F = 23.5 Hz, C-F), 106.8
(+, 2JC,F = 22.3 Hz, C-F), 110.9 (+, ph), 111.5 (+, ph), 117.7 (Cquart, 4JC,F = 2.5
Hz, C-F), 118.6 (Cquart, ph), 124.7 (+, =CH), 127.1 (Cquart, ph), 133.6 (+, 3JC,F =
12.1 Hz, C-F ), 145.8 (+, =CH), 148.9 (Cquart, ph), 151.7 (Cquart, ph), 164.6
(Cquart, 3JC,F = 13.9 Hz, C-F ), 166.4 (Cquart, 1JC,F = 253.7 Hz, C-F), 192.5 (Cquart,
C=O)
MS (PI-EI 70 eV): m/z (%) = 302 ([M•+], 71), 301 ([M-H]+, 23), 164 ([MeO)2
C6H4CH=CH2]+, 47), 151 ([MeO)2C6H4CH2]+, 100), 139 ([FC6H4(OH)CO]+, 26),
121 ([MeOC6H4CH2]+, 6)
IR [cm-1]: 3017 (C-H) aromatic, 2841 (C-H) aliphatic, 1632-1560 (C=O), 1508,
1464 (C-H), 1359 (C-H), 1263 (C-F),1206 (C-O), 1140, 989, 974, 845, 798, 608
Analysis:
calculated C: 67.54 H: 5.00
found C: 67.59 H: 4.92
C17H15FO4 (302.30)
1-(4-Fluoro-2-hydroxyphenyl)-3-(4-methoxyphenyl)propenone (23b)
Reaction of 1-(4-fluoro-2-hydroxyphenyl)ethanone (0.50 g, 3.25 mmol) and
4-methoxybenzaldehyde (0.97 g, 7.14 mmol); recrystallisation from dimethyl-
sulphoxide;
Yield: 0.84 g (3.09 mmol, 95 %, yellow solid)
Mp: 126 °C
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1H-NMR ([D6]DMSO):
δ [ppm] = 3.84 (s, 3H, OCH3), 6.83-6.91 (m, 2H, ph), 7.03-7.06 (m, 2H, ph),
7.81-7.88 (m, 2H, ph), 7.88-7.94 (m, 2H, =CH), 8.83-8.44 (m, 1H, ph), 13.23 (s,
1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.4 (+, OCH3), 104.2 (+, 2JC,F = 23.5 Hz, C-F ), 106.9 (+, 2JC,F = 22.3
Hz, C-F ), 114.4 (+, ph), 117.7 (Cquart, 1JC,F = 2.5 Hz, C-F ), 118.7 (Cquart, ph),
126.9 (+, =CH), 131.2 (+, ph), 133.6 (+, 3JC,F = 12.1 Hz, C-F ), 145.2 (+, =CH),
161.7 (Cquart, ph), 164.5 (Cquart, 2JC,F = 13.9 Hz, C-F), 166.4 (Cquart, 1JC,F = 253.0
Hz, C-F), 192.4 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 272 ([M•+], 73), 271 ([M-H]+, 53), 139 ([FC6H4
(OH)CO]+, 37), 134 ([MeOC6H4CH=CH2]+, 99), 121 ([MeOC6H4CH2]+, 100)
IR [cm-1]: 3406 (O-H), 2949 (C-H) aromatic, 2848 (C-H) aliphatic, 1634 (C=O),
1548, 1416 (C-H), 1352 (C-H), 1280 (C-F),1255 (C-O), 1173, 1122, 1016, 843,
820, 609
Analysis:
calculated C: 70.58 H: 4.81
found C: 70.38 H: 4.88
C16H13FO3 (272.27)
(E) 1-(5-Fluoro-2-hydroxyphenyl)-3-(4-methoxyphenyl)propenone (23c)
Reaction of 1-(5-fluoro-2-hydroxyphenyl)ethanone (2.32 g, 15.05 mmol) and
4-methoxybenzaldehyde (4.51 g, 33.11 mmol); recrystallisation from dimethyl-
sulphoxide
Yield: 4.03 g (14.80 mmol, 98 %, orange crystalline solid)
Mp: 104 °C
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1H-NMR ([D6]DMSO):
δ [ppm] = 3.84 (s, 3H, OCH3), 6.99-7.02 (m, 1H, H-3), 7.03-7.07 (m, 2H, ph),
7.41-7.49 (m, 1H, H-4), 7.81 (d, 1H, 3J = 15.5 Hz, =CH), 7.88 (d, 1H, 3J = 15.5
Hz, =CH), 8.11 (dd, 3J = 3.12 Hz, 3JH,F = 9.8 Hz, H-F), 12.42 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.4 (+, OCH3), 114.4 (+, 2ph), 115.7 (+, 2JC,F = 23.8 Hz, C-F), 118.9
(+, =CH), 119.1 (+, 3JC,F = 7.6 Hz, C-F), 120.9 (Cquart, 3JC,F = 6.6 Hz, C-F), 123.3
(+, 2JC,F = 23.8 Hz, C-F), 126.9 (Cquart, ph), 131.3 (+, ph), 154.7 (Cquart, 1JC,F =
235.6 Hz, C-F), 158.0 (Cquart, 4JC,F = 1.4 Hz, C-F), 161.8 (Cquart, ph), 192.6
(Cquart, 2JC,F = 2.5 Hz, C-F)
MS (PI-EI 70 eV): m/z (%) = 272 ([M•+], 56), 271 ([M-H]+, 35), 257 ([M-CH3]+, 5),
255 ([M-OH]+, 7), 134 ([CH3OC6H4CH=CH]+, 100)
IR [cm-1]: 2972 (C-H) aromatic, 2850 (C-H) aliphatic, 1640-1565 (C=O), 1510,
1416 (C-H), 1346 (C-H), 1247 (C-O), 1164 (C-F), 1023, 985, 819, 781, 674
Analysis:
calculated C: 70.58 H: 4.81
found C: 70.35 H: 4.54
C16H13FO3 (272.27)
(E) 1-(5-Fluoro-2-hydroxyphenyl)-3-(4-fluorophenyl)propenone (23d)
Reaction of 1-(5-fluoro-2-hydroxyphenyl)ethanone (2.0 g, 12.98 mmol) and
4-fluorobenzaldehyde (3.54 g, 28.56 mmol); recrystallisation from dimethylsul-
phoxide
Yield: 3.29 g (12.64 mmol, 97 %, yellow crystalline solid)
Mp: 157 °C
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1H-NMR ([D6]DMSO):
δ [ppm] = 7.04 (dd, 1H, 4JH,F = 5.9 Hz, 3J = 8.9 Hz, H-3, ), 7.34 (m, 2H, ph), 7.46
(ddd, 1H, 4J = 3.1 Hz, 3JH,F = 8.51 Hz, 3J = 8.9 Hz, H-4, ), 7.85 (d, 3J = 15.6 Hz,
=CH), 7.98 (d, 1H, 3J = 15.6 Hz, =CH), 8.03 (m, 2H, ph), 8.11 (dd, 1H, 4J = 3.1
Hz, 3JC,F = 9.7 Hz, H-6, ), 12.20 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 115.9 (+, ph), 115.9 (+, ph), 115.9 (+, ph), 119.2 (Cquart, ph), 121.04
(+, ph), 121.7 (+, =CH), 123.4 (+, ph), 131.1 (Cquart, ph), 131.7 (+, ph), 131.7 (+,
ph), 144.1 (+, =CH), 154.7 (Cquart, 1JF,C = 235.5 Hz, C-F), 157.8 (Cquart,, ph),
163.7 (Cquart, 1JF,C = 250.2 Hz, C-F), 192.6 (Cquart, 4JC,F = 2.5 Hz, C=O)
MS (PI-EI 70 eV): m/z (%) = 260 ([M•+], 100), 259 ([M-H]+, 65), 243 ([M-OH]+,
14), 241 ([M-F]+, 5)
HR-MS: calculated: 260.064800 amu
found: 260.064886 amu
IR [cm-1]: 3054 (C-H) aromatic, 1645-1578 (C=O), 1510-1484 (C=C), 1230 (C-
O), 1165 (C-F), 1021, 943, 830, 782, 741, 674
C15H10F2O2 (260.24)
General procedures for the preparation of the flavone deriva-
tives 24a-e and 25a-i
Method A
A solution of the chalcone derivative (1 eq), hydrogen peroxide (0.22 eq, 30 %),
a sodium hydroxide solution (1.2 eq, 5-7 %) and ethanol (5-15 ml) was stirred
and heated under reflux for 1-2 h. After cooling to ambient temperature a so-
dium hydroxide solution (6.6 %) was added dropwise and stirred at room tem-
perature for two additional hours. The reaction mixture was diluted with water
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and carbon dioxide was induced until a solid precipitated. The solid was filtered
off, washed with water and dried in vacuo over silica gel.
Method B
A solution of the chalcone derivative, selenium dioxide and pentyl alcohol (20-
100 ml) was stirred and heated under reflux for 10-16 h. Insoluble material was
filtered off from the hot solution and washed with hot ethanol. Than ¾ of the
solvent was removed under reduced pressure. After cooling in the refrigerator,
the precipitated product was collected and dried in vacuo.
Method C
The chalcone derivative was dissolved in anhydrous dimethylsulphoxide and
was stirred and heated at 100 - 120 °C with sodium periodate for 48 h. After
cooling to room temperature, a solution of sodium thiosulphate (10 %) was
added slowly to the reaction mixture. The precipitate was collected, washed
with a solution of sodium thiosulphate and dried in vacuo over phosphorus
pentoxide.
4’,5,7-Trimethoxyflavon-3-ol (24a)
Method A: Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphen-
yl)propenone 19b (0.50 g, 1.59 mmol), a sodium hydroxide solution (5.1 ml,
5.4 %) and a hydrogen peroxide solution (0.7 ml, 30 %). The obtained solid was
a mixture of starting material and product; it was not possible to separate the
two solids using standard methods.
1H-NMR ([D6]DMSO): [ppm] = 3.83 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.92 (s,
3H, OCH3), 6.34 (s, 1H, OH), 6.70 (s, 2H, ph), 7.04 (m, 2H, ph), 7.88 (m, 2H,
ph)
C18H16O6 (328.32)
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2’,4’-Dichloro-5,6’,7-trimethoxyflavon-3-ol (24b)
Method A: Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(2’,4’-dichloro-6-
methoxyphenyl)propenone 19j (1.0 g, 2.62 mmol), a sodium hydroxide solution
(4.5 ml, 17 %) and a hydrogen peroxide solution (24 ml, 6.6 %). The obtained
solid was a mixture of the starting material and product, which was identified by
MS analysis. The separation of the two solids by standard methods failed.
MS (PI-EI 70 eV): m/z (%) =292 ([M•+], 3), 345 ([M-Cl-H]+, 100)
C19H14Cl2O6 (396.21)
4’-Dimethylamino-3-hydroxy-5,7-dimethoxyflavone (24c)
Method A: Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-dimethylamino-
phenyl)propenone 19d (1.0 g, 3.05 mmol), a hydrogen peroxide solution
(4.40 ml, 30 %) and a sodium hydroxide solution (24 ml, 6.60 %). The obtained
orange solid was a mixture of starting material and product; it was not possible
to separate the two solids by standard methods.
Yield: 0.49 g (orange solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 3.35 (s, 6H, N(CH3)2), 3.82 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 6.48
(s, 1H, ph), 6.70-6.92 (m, 3H, chromen and ph), 8.00-8.15 (m, 2H, ph), 8.60 (s,
1H, OH)
C19H19NO5 (341.36)
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2’-Chloro-3-hydroxy-3’,4’,5,7-tetramethoxyflavone (24e)
Method A : Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(2-chloro-3,4-di-
methoxyphenyl)propenone 19i (1.0 g, 2.64 mmol), a hydrogen peroxide solu-
tion (4.5 ml, 17 %) and a sodium hydroxide solution (24 ml, 6.6 %). The ob-
tained solid was a mixture of product, starting material and by-product. It was
not possible to separate the product using standard methods. The product was
identified by MS analysis.
Yield: 115 mg (0.29 mmol, 11 %, yellow solid)
MS (PI-EI 70 eV): m/z (%) =392 ([M•+], 4), 341.5 ([M-OH-Cl]+, 36), 181
([(CH3O)2Ph(OH)CO]+, 100)
C19H17ClO7 (392.79)
4,5,7-Trimethoxyflavone (25a)
Method B: Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphen-
yl)propenone 19b (3.0 g, 9.54 mmol) and selenium dioxide (2.59 g,
23.38 mmol). The product was purified by column chromatography on silica gel
eluting with a 5:5:1 (v/v/v) mixture of petroleum ether 60-80 °C, ethyl acetate
and methanol.
Yield: 1.92 g (6.15 mmol, 64 %, orange solid)
Mp: 143-145°C [Lit. 150-155 °C (Chauhan et al. 1996)]
1H-NMR ([D6]DMSO):
δ [ppm] = 3.87 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 6.59 (s,
1H, H-3), 6.36 (d, 1H, 3J = 2.3 Hz, H-6), 6.55 (d, 1H, 3J = 2.3 Hz, H-8), 6.99 (d,
2H, 3J = 8.9 Hz, H-2’, H-6’), 7.81 (d, 2H, 3J = 8.9 Hz, H-3’, H-5’)
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13C-NMR ([D6]DMSO):
δ [ppm] = 55.5 (+, OCH3), 55.7 (+, OCH3), 56.4 (+, OCH3), 92.8 (+, chromen),
96.1 (+, chromen), 107.6 (+, chromen), 109.2 (Cquart, chromen), 114.3 (+, ph),
123.8 (Cquart, ph), 127.6 (+, ph), 159.8 (Cquart, ph), 160.7 (Cquart, chromen),
160.9 (Cquart, chromen), 162.1 (Cquart, chromen), 163.9 (Cquart, chromen), 177.7
(Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 312 ([M•+], 100), 311 ([M-H]+, 63), 283 ([M-CH3-
CH3]+, 41)
IR [cm-1]: 2934 (C-H) aromatic, 2825 (C-H) aliphatic, 1639-1601 (C=O), 1510,
1466 (C-H), 1346 (C-H), 1253 (C-O), 1213, 1193, 1160, 1055, 828, 769
Analysis:
calculated C: 68.83 H: 5.14
found C: 68.78 H: 5.14
C18H16O5 (312.12)
3’,4’,5,7-Tetramethoxyflavone (25b)
Method B: Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(3,4-dimethoxy-
phenyl)propenone 19c (1.0 g, 2.90 mmol) and selenium dioxide (0.79 g,
7.11 mmol). The product was purified by column chromatography on silica gel
eluting with a 5:5:1 (v/v/v) mixture of petroleum ether 60-80 °C, ethyl acetate
and methanol.
Yield: 0.26 g (0.76 mmol, 26 %, yellow solid)
Mp: 192-194°C [Lit. 190-191 °C (Nunez-Alarcon 1971)]
1H-NMR ([D6]DMSO):
δ [ppm] = 3.92 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 3.98 (s,
3H, OCH3), 6.38 (d, 1H, 4J = 2.0 Hz, H-8), 6.56 (d, 1H, 4J = 2.3 Hz, H-2’), 6.62
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(s, 1H, H-3), 6.96 (d, 1H, 3J = 8.6 Hz, H-5’), 7.32 (d, 1H, 4J = 2.0 Hz, H-6), 7.51
(dd, 1H, 4J = 2.3 Hz, 3J = 8.6 Hz, H-6’)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.8 (+, OCH3), 56.1 (+, OCH3), 56.1 (+, OCH3), 56.5 (+, OCH3), 92.8
(+, chromen), 96.1 (+, chromen), 107.9 (+, chromen), 108.6 (+, ph), 109.2
(Cquart, chromen), 111.1 (+, ph), 119.5 (+, ph), 124.1 (Cquart, ph), 149.2 (Cquart,
ph), 151.7 (Cquart, ph), 159.9 (Cquart, chromen), 160.7 (Cquart, chromen), 160.9
(Cquart, chromen), 163.9 (Cquart, chromen), 177.7 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 342 ([M•+], 58), 296 ([M-OCH3-CH3]+, 24), 57 ([M-
PhOCH3-OCH3-PhOCH3]+,100)
IR [cm-1]: 2924 (C-H) aromatic, 2839 (C-H) aliphatic, 1644-1600 (C=O), 1514,
1456 (C-H), 1354 (C-H), 1253 (C-O), 1157, 1138, 1016, 870, 831, 804, 766
Analysis:
calculated C: 66.66 H: 5.30
found C: 66.46 H: 5.64
C19H18O6 (342.34)
5,7-Dimethoxy[3,4]benzoflavone (25c)
Method B: Reaction solution of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(naph-
thalen-2-yl)propenone 19e (1.0 g, 2.99 mmol) and selenium dioxide (1.66 g,
14.95 mmol). The product was purified by column chromatography on silica gel
eluting with a 5:5:1 (v/v/v) mixture of petroleum ether 60-80 °C, ethyl acetate
and methanol.
Yield: 0.52 g (1.57 mmol, 52 %, orange solid)
Mp: 128-130°C
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1H-NMR (CDCl3):
δ [ppm] = 3.95 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 6.39 (d, 1H, 4J = 2.3 Hz, H-
8), 6.65 (d, 1H, 4J = 2.3 Hz, H-6), 6.91 (s, 1H, H-3), 7.54-7.60 (m, 2H, naph-
thyl), 7.84-7.96 (m, 4H, naphthyl), 8.42 (s, 1H, naphthyl H2)
13C-NMR (CDCl3):
δ [ppm] = 55.9 (+, OCH3), 56.5 (+, OCH3), 92.9 (+, chromen), 96.4 (+,
chromen), 109.1 (+, chromen), 114.6 (Cquart, chromen), 122.4 (+, naphthyl),
126.5 (+, naphthyl), 127.0 (+, naphthyl), 127.9 (+, naphthyl), 128.6 (+, naph-
thyl), 128.9 (+, naphthyl), 128.1 (Cquart, naphthyl), 128.9 (+, naphthyl), 132.9
(Cquart, naphthyl), 134.6 (Cquart, naphthyl), 160.1 (Cquart, chromen), 160.9 (Cquart,
chromen), 160.9 (Cquart, chromen), 165.3 (Cquart, chromen), 177.7 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) =332 ([M•+], 100), 331 ([M-H]+, 50), 303 ([M-H-CO]+,
27), 152 ([M-naphthyl-C2H2-CO]+, 38)
IR [cm-1]: 2924 (C-H) aromatic, 2853 (C-H) aliphatic, 1641 (C=O), 1598 (C=C),
1461 (C-H), 1328 (C-H), 1206 (C-O), 1109, 870, 850, 823, 762, 669
Analysis:
calculated C: 75.89 H: 4.85
found C: 75.64 H: 4.84
C21H16O4 (332.35)
4’-Chloro-5,7-dimethoxyflavone (25d)
Method C: Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-chlorophenyl)-
propenone 19h (0.59 g, 1.84 mmol) and sodium periodate (2.0 g, 9.34 mmol).
Yield: 0.18 g (0.56 mmol, 30 %, light yellow solid)
Mp: 181 °C [Lit. 180-182 °C (Hsue 1959)]
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1H-NMR (CDCl3):
δ [ppm] = 3.91 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 6.36 (d, 1H, 4J = 2.3 Hz, H-
6), 6.54 (d, 1H, 4J = 2.3 Hz, H-8), 6.65 (s, 1H, H-3), 7.44-7.46 (m, 2H, H-2’, H-
6’), 7.75-7.79 (m, 2H, H-3’, H-5’)
13C-NMR (CDCl3):
δ [ppm] = 55.8 (+, OCH3), 56.4 (+, OCH3), 92.8 (+, chromen), 96.2 (+,
chromen), 109.0 (+, chromen), 109.1 (Cquart, chromen), 127.1 (+, ph), 129.2 (+,
ph), 120.9 (Cquart, ph), 137.4 (Cquart, ph), 159.5 (Cquart, chromen), 159.7 (Cquart,
chromen), 160.9 (Cquart, chromen), 164.2 (Cquart, chromen), 177.3 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 316 ([M•+], 100), 287 ([(M-CH3)-CH3]+, 55)
HR-MS: calculated: 316.050100 amu
found: 316.050237 amu
IR [cm-1]: 3011 (C-H) aromatic, 2838 (C-H) aliphatic, 1639 (C=O), 1489, 1466
(C-H), 1339 (C-H), 1217 (C-O), 1104 (C-Cl), 1058, 952, 904, 837, 820
C17H13ClO4 (316.74)
4’-Fluoro-5,7-dimethoxyflavone (25e)
Method B: Reaction of 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-fluorophenyl)-
propenone 19k (2.11 g, 6.98 mmol) and selenium dioxide (1.90 g, 17.1 mmol).
Yield: 1.38 g (4.60 mmol, 66 %, yellow solid)
Mp: 165 °C
1H-NMR (CDCl3):
δ [ppm] = 3.91 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 6.36 (d, 1H, 4J = 2.3 Hz, H-
6), 6.54 (d, 1H, 4J = 2.3 Hz, H-8), 6.64 (s, 1H, H-3), 7.13-7.27 (m, 2H, H-2’, H-
6’), 7.82-7.80 (m, 2H, H-3’, H-5’)
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13C-NMR (CDCl3):
δ [ppm] = 55.8 (+, OCH3), 56.5 (+, OCH3), 92.8 (+, chromen), 96.3 (+,
chromen), 108.7 (+, chromen), 109.1 (Cquart, chromen), 116.0 (+, ph), 116.4 (+,
ph), 127.72 (Cquart, 4JC,F = 3.2 Hz, C-1’), 128.1 (+, ph), 128.2 (+, ph), 159.8
(Cquart, chromen), 159.8 (Cquart, chromen), 160.9 (Cquart, chromen), 164.2 (Cquart,
chromen), 164.5 (Cquart, 1JC,F = 252.4 Hz, C-F), 177.5 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 300 ([M•+], 100), 299 ([M-H]+, 56), 271 ([(M-CH3-
CH3]+, 45)
IR [cm-1]: 3000 (C-H) aromatic, 2960 (C-H) aliphatic, 1644-1604 (C=O), 1508,
1466 (C-H), 1344 (C-H), 1216 (C-O), 1162 (C-F), 1116, 873, 838, 686
Analysis:
calculated C: 67.19 H: 4.38
found C: 67.02 H: 4.44
C17H13FO4 (300.88)
6-Fluoro-4’-methoxyflavone (25f)
Method B: Reaction of 1-(5-fluoro-2-hydroxyphenyl)-3-(4-methoxyphenyl)pro-
penone 23c (1.00 g, 3.67 mmol) and selenium dioxide (1.00 g, 8.99 mmol);
Yield: 0.52 g (1.92 mmol, 52 % (77 %), yellow solid)
Mp: 136-138 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.92 (s, 3H, OCH3), 6.74 (s, 1H, H-3), 7.00-7.05 (m, 2H, H-2’, H-6’),
7.38-7.43 (m, 1H, chromen), 7.54-7.57 (m, 1H, chromen), 7.86-7.88 (m, 1H,
chromen), 7.86-7.89 (m, 2H, H-3’, H-5’)
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13C-NMR ([D6]DMSO):
δ [ppm] = 55.5 (+, OCH3), 105.5 (+, C-3), 110.6 (+, 2JC,F = 23.7 Hz, C-5), 114.5
(+, ph), 120.0 (+, 3JC,F = 8.0 Hz, C-8), 121.7 (+, 2JC,F = 25.4 Hz, C-7), 123.7
(Cquart, ph), 125.2 (Cquart, 3JC,F = 7.4 Hz, C-9), 128.0 (+, ph), 152.4 (Cquart, 4JC,F =
1.8 Hz, C-9), 159.6 (Cquart, 1JC,6 = 296.6 Hz, C-F), 162.6 (Cquart, ph), 163.7
(Cquart, C-2), 177.5 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 270 ([M•+], 100), 239 ([M-OCH3]+, 23), 138
([FC6H4(=O)(=C=O]+, 6), 132 ((CH3OC6H4CCH]+, 95)
IR [cm-1]: 3076 (C-H) aromatic, 2928 (C-H) aliphatic, 1639-1604 (C=O), 1512,
1478 (C-H), 1362 (C-H), 1267 (C-O), 1176-1117 (C-F), 908, 895, 825, 777, 719
Analysis:
calculated C: 71.11 H: 4.10
found C: 71.26 H: 4.24
C16H11FO3 (270.25)
4’,6-Difluoroflavone (25g)
Method B: Reaction of 1-(5-fluoro-2-hydroxyphenyl)-3-(4-fluorophenyl)propen-
one 23d (1.0 g, 3.84 mmol) and selenium dioxide (1.05 g, 9.41 mmol).
Yield: 0.32 g (1.24 mmol, 32 %, yellow solid)
Mp: 149 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 6.78 (s, 1H, H-3), 7.20-7.28 (m, 2H, H-2’, H-6’), 7.41-7.45 (m, 1H,
chromen), 7.44-7.48 (m, 1H, chromen), 7.85-7.89 (m, 1H, chromen), 7.91-7.96
(m, 2H, H-3’, H-5’)
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13C-NMR ([D6]DMSO):
δ [ppm] = 108.8 (+, C-3), 112.9 (+, 2JC,F = 23.8 Hz, H-5), 118.4 (+, ph), 118.7 (+,
ph), 122.3 (+, 3JC,F = 8.1 Hz, C-8), 124.2 (+, 2Jc,F = 25.6 Hz, C-7), 127.2 (Cquart,
3JC,F = 7.4 Hz, C-9), 129.9 (Cquart, 4JC,F = 3.3 Hz, C-1’), 130.7 (+, ph), 130.8 (+,
ph), 154.5 (Cquart, 4JC,F = 1.8 Hz, C-10), 161.8 (Cquart, 1JC,F = 247.2 Hz, C-F),
164.9 (Cquart, chromen), 167.0 (Cquart, 1JC,F = 253.8 Hz, C-F), 179.6 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 258 ([M•+], 58), 138 ([FC6H4(=O)(=C=O)]+, 100)
IR [cm-1]: 3063 (C-H) aromatic, 1663 (C=O), 1593, 1348 (C-H), 1229 (C-O),
1166 (C-F), 1032, 907, 834, 814
Analysis:
calculated C: 69.77 H: 3.12
found C: 69.43 H: 3.13
C15H8F2O2 (258.22)
7-Fluoro-3’,4’-dimethoxyflavone (25h)
Method B: Reaction of 1-(4-fluoro-2-hydroxyphenyl)-3-(3,4-dimethoxyphenyl)-
propenone 23a (0.50 g, 1.65 mmol) and selenium dioxide (0.45 g, 4.05).
Yield: 0.46 g (1.53 mmol, 93 %, green-yellow solid)
Mp: 159 °C
1H-NMR (CDCl3):
δ [ppm] = 3.97 (s, 3H, OCH3), 3.99 (s, 3H, OCH3), 6.76 (s, 1H, H-3), 6.99 (d,
1H, 3J = 8.9 Hz, H-5’), 7.15 (ddd, 1H, 4J = 2.4 Hz, 3JH,F = 8.2 Hz, 3J = 8.9 Hz, H-
6), 7.26 (ddd, 1H, 5J = 0.4 Hz, 4J = 2.4 Hz, 3JH,F = 9.1 Hz, H-8), 7.36 (d, 1H, 4J =
2.2 Hz, H-2’), 7.55 (dd, 1H, 4J = 2.2 Hz, 3J = 8.6 Hz, H-6’), 8.24 (ddd, 1H, 5J =
0.4 Hz, 4JH,F = 6.4 Hz, 3J = 8.9 Hz, H-5)
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13C-NMR (CDCl3):
δ [ppm] = 56.1 (+, OCH3), 56.1 (+, OCH3), 104.7 (+, 2JC,F = 25.4 Hz, C-8), 106.3
(+, ph), 108.7 (+, ph), 111.2 (+, ph), 113.9 (+, 2JC,F = 22.7 Hz, C-6), 120.1 (+,
chromen), 120.6 (Cquart, 4JC,F = 2.4 Hz, C-10), 123.7 (Cquart, ph), 128.1 (+, 3JC,F =
10.5 Hz, C-5), 149.3 (Cquart, ph), 152.3 (+, ph), 157.1 (Cquart, 3JC,F = 13.4 Hz, C-
9), 163.8 (Cquart, chromen), 165.6 (Cquart, 1JC,F = 254.8 Hz, C-7), 177.3 (Cquart,
C=O)
MS (PI-EI 70 eV): m/z (%) = 300 ([M•+], 100), 285 ([M-CH3]+, 14)
HR-MS: calculated: 300.079900 amu
found: 300.079787 amu
IR [cm-1]: 3075 (C-H) aromatic, 2838 (C-H) aliphatic, 1653 (C=O), 1515, 1422
(C-H), 1322 (C-H), 1230 (C-O), 1143 (C-F), 1027, 974, 870, 799 748
C17H13FO4 (300.28)
7-Fluoro-3’-methoxyflavone (25i)
Method B: Reaction of 1-(4-fluoro-2-hydroxyphenyl)-3-(4-methoxyphenyl)pro-
penone 23b (3.0 g, 11.02 mmol) and selenium dioxide (3.0 g, 27.0 mmol,
2.45 eq).
Yield: 1.15 g (4.26 mmol, 39 %, yellow-green solid)
Mp: 189 °C
1H-NMR (CDCl3):
δ [ppm] = 3.87 (s, 3H, OCH3), 6.98 (s, 1H, H-3), 7.13 (d, 2H, 3J = 9.1 Hz, H-2’,
H-6’), 7.14 (ddd, 1H, 4J = 2.4 Hz, 3JH,F = 8.2 Hz, 4J = 8.9 Hz, H-6), 7.24 (ddd,
1H, 5J = 0.4 Hz, 4J = 2.4 Hz, 3JH,F = 9.1 Hz, H-8), 8.07 (d, 2H, 3J = 9.1 Hz, H-3’,
H-5’), 8.24 (ddd, 1H, 5J = 0.4 Hz, 4JH,F= 6.4 Hz, 3J = 8.9 Hz, H-5)
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13C-NMR (CDCl3):
δ [ppm] = 55.6 (+, OCH3), 104.7 (+, 2JC,F = 25.4 Hz, C-8), 106.1 (+, chromen),
113.9 (+, 2JC,F = 22.9 Hz, C-6), 114.6 (+, ph), 123.6 (Cquart, chromen), 128.1 (+,
ph), 128.3 (Cquart, ph), 129.8 (+, 3JC,F = 23.2 Hz, C-5), 157.2 (Cquart, 3JC,F = 13.4
Hz, C-9), 162.7 (Cquart, ph), 163.9 (Cquart, chromen), 163.7-167.7 (Cquart, 1JC,7 =
254.9 Hz, C-F ), 177.4 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 270 ([M•+], 100), 255 ([M-CH3]+, 8)
HR-MS: calculated: 270.069300 amu
found: 270.069222 amu
IR [cm-1]: 3087 (C-H) aromatic, 2844 (C-H) aliphatic, 1649 (C=O), 1510, 1439
(C-H), 1364 (C-H), 1312 (C-F), 1256 (C-O), 1186, 1013, 817, 757, 635
C16H11FO3 (270.26)
7-Fluoro-4’-hydroxyflavone (26)
To a stirred solution of 7-fluoro-4’-methoxyflavone 25i (0.50 g, 1.85 mmol) in
anhydrous methylene chloride (40 ml), a solution of BBr3 (2.32 g, 9.25 mmol,
5 eq) in methylene chloride (9.25 ml) was added dropwise at 0 °C under a ni-
trogen atmosphere. After stirring at room temperature for 24 h the reaction
mixture was cooled again to 0°C and water and ice were added. The precipi-
tated product was collected, washed with water, dried in vacuo over silica gel
and purified by column chromathography on silica gel eluting with a 5:5:1 (v/v/v)
mixture of petroleum ether 60-80 °C, ethyl acetate and methanol.
Yield: 0.46 g (1.80 mmol, 97 %, brown solid)
Mp: 280°C
1H-NMR ([D6]DMSO):
δ [ppm] = 4.32 (br, 1H, OH), 6.88 (s, 1H, H-3), 6.93 (d, 2H, 3J = 8.9 Hz, H-2’, H-
6’), 7.36 (ddd, 1H, 4J = 2.5 Hz, 3JH,F = 8.5 Hz, 3J = 8.9 Hz, H-6), 7.72 (dd, 1H, 4J
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= 2.5 Hz, 3JH,F = 9.7 Hz, H-8), 7.94 (d, 2H, 3J = 8.9 Hz, H-3’, H-5’), 8.09 (dd,
3JH,F = 6.5 Hz, 3J = 8.9 Hz, H-5)
13C-NMR ([D6]DMSO):
δ [ppm] = 104.8 (+, chromen), 105.2 (+, 2JC,F = 25.8 Hz, C-8), 113.8 (+, 2JC,F =
23.1 Hz, C-6), 115.9 (+, ph), 120.5 (Cquart, 4JC,F = 2.2 Hz, chromen), 121.3
(Cquart, ph), 127.5 (+, 3JC,F = 10.9 Hz, C-5), 128.4 (+, ph), 156.6 (Cquart, 4JC,F =
14.0 Hz, chromen), 161.1 (Cquart, ph), 163.4 (Cquart, 5JC,F = 1.1 Hz, chromen),
164.9 (Cquart, 1JC,7 = 251.3 Hz, C-F), 176.1 (Cquart, C=O)
MS (PI-EI 70 eV): m/z (%) = 256 ([M•+], 100), 239 ([M-OH]+, 13)
IR [cm-1]: 3137 (O-H), 3069 (C-H) aromatic, 2832 (C-H) aliphatic, 1576, 1502,
1443 (C-H), 1371 (C-H), 1254 (C-O), 1179-1151 (C-F), 908, 878, 823, 758, 661
Analysis:
calculated C: 50.99 H: 2.85
found C: 50.42 H: 3.06
C15H9FO3 (256.23)
Tetrabutylammonium 7-fluoroflavon-4’-ylsulphate (27)
To a stirred solution of 7-fluoro-4’-hydroxyflavone 26 (200 mg, 0.78 mmol) and
dimethylformamide (10 ml), pyridine*SO3 (249 mg, 1.56 mmol) and pyridine
(124 mg, 1.56 mmol) were added dropwise at room temperature under a nitro-
gen atmosphere. The reaction mixture was stirred and heated for 30 min at
100 °C. After cooling to room temperature, a saturated sodium hydrogencar-
bonate solution was added until the generation of gas ceased. Afterwards, the
solvent was removed under reduced pressure and the oily residue was treated
with an aqueous acetic acid solution (5 %) to adjust the pH 7 to and Bu4N+
HSO4- (1.06 g, 3.12 mmol) was added. The obtained mixture was diluted with
methanol, filtrated and reconcentrated. The residue was again diluted with a
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mixture of 1:1 (v/v) methanol and water and concentrated in vacuo. The ob-
tained yellow solid was analysed by MS spectroscopy.
MS (ESI (H2O/MeOH + 1 % NH4OH): m/z (%) =335 ([M-Bu4N+]-, 58), 255 ([M-
SO3-], 100)
C16H36N • C15H8FO6S (577,76)
5.3 Pharmacological methods
The inhibitory effect of the examined compounds on the activity of hyaluroni-
dases were determined by a colorimetric method (Muckenschnabel et al. 1998;
Muckenschnabel et al. 1998) and a turbidimetric (Di Ferrante 1956) as de-
scribed in chapter 3.
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Chapter 7
Structure-based design, synthesis and pharma-
cological investigations of hyaluronate lyase
inhibitors
1. Introduction
Bacterial hyaluronan lyases (EC 4.2.2.1) differ from hyaluronidases from other
sources by their mode of action. The two best known hyaluronate lyases, the
Streptococcus pneumoniae and Streptococcus agalactiae hyaluronate lyase,
cleave hyaluronan to yield 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranos-
yluronic acid)-D-glucose (∆Di-HA) as end product (for a review about hyaluro-
nan and hyaluronidases cf. http://www.glycoforum.gr.jp). By cleaving hyaluro-
nan, bacterial hyaluronate lyases, e. g. that of S. agalactiae (hylB4755), facilitate
the spreading of the microorganisms and their toxins in infectious diseases
such as meningitis and septicaemia (Hynes et al. 2000). Potent inhibitors of
hyaluronan lyases are not known so far. Such compounds could be useful in
studying the role of hyaluronan and hyaluronidases in bacterial infections.
Some small compounds like arginine and guanidine derivatives and vitamin C
with IC50 values in the range of 150 to 0.150 mM for inhibition of the bacterial
hyaluronidase have been described to date (Li et al. 2001; Akhtar et al. 2003).
For the development of a new class of bacterial hyaluronidases inhibitors, the
primary goal of the present study was the identification of simple chemical
structures as first lead compounds. A crucial issue for improving binding affinity,
selectivity or bioavailability in an interactive approach is the quick synthetic ac-
cessibility of the target compounds, for example by modifications of the chemi-
cal lead. Until now, several computational methods like GROW (Moon et al.
1991), LEGEND (Nishibata et al. 1991) and LUDI (Böhm 1992; Böhm 1992)
have been described enabling the rational design of new ligands using the 3D
Structure-based design
142
structure of a target protein (Böhm 1996; Böhm 1996; Schneider et al. 2002).
Most of these programmes perform a detailed analysis of the amino acid resi-
dues constituting the binding pocket and extract the spatial binding features
which potential ligands have to fulfil. After this initial step, these favourable in-
teraction sites are converted into a complex pharmacophore model of the active
site of the enzyme. In consideration of this pharmacophore, large databases of
small molecules can be computationally screened resulting in the identification
of complementary ligands in terms of geometrical and physicochemical proper-
ties. Putative screening hits are selected with respect to a rough affinity predic-
tion estimated by a scoring function. The scoring of the proposed ligand binding
mode reflects the favourable interaction between the functional moieties of the
ligand and the amino acid residues of the binding pocket (Klebe et al. 2000;
Gohlke et al. 2002). Rational design includes several design cycles with appro-
priate structural modifications, synthesis and testing of the new candidate
structures resulting in ligands with improved binding affinities.
As a pilot scheme for hyaluronidase inhibitor design in general, we started a
structure-based ligand design programme to discover  hylB4755 inhibitors based
on the crystal structures of both aforementioned streptococcal lyases using the
de novo design software LUDI (Böhm 1992; Böhm 1992). The streptococcal
hyaluronan lyase hylB4755 shows extensive sequence identity to the homolo-
gous enzymes encoded by genes from group B Streptococcus (S. agalactiae)
strain 3502 (98 % amino acid sequence identity) and Streptococcus pneumo-
niae (53 % amino acid sequence identity) characterised previously. The three-
dimensional X-ray crystal structures of two hyaluronate lyases from Streptococ-
cus species, one from S. pneumonia (hylSpn) and the other one from S. aga-
lactiae strain 3502 (hylB3502) were determined recently (Li et al. 2000; Li et al.
2001). Additionally, a complex of the hyaluronan hexasaccharide with hylB3502
could be elucidated by means of X-ray crystallography. These results reveal the
progressive mode of the catalytic process, including the identification of specific
residues mechanistically involved in the degradation of hyaluronan by hylB3502
(Mello et al. 2002). In this chapter the design, synthesis and identification of first
promising leads as inhibitors of S. agalactiae strain 4755 hyaluronate lyase with
micromolar activities are reported.
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2. Structure-based lead discovery by LUDI calculations
with the hylB4755 model1
2.1 HylB4755 model construction
Necessary conditions for comparative protein structure modelling are a detect-
able or significant similarity between the target sequence and the template
structures and the construction of an accurate sequence alignment between
them (Sanchez et al. 2000). The sequence identity of the crystallised hyaluro-
nate lyases from S. pneumoniae (hylSpn, pdb code 1egu) (Li et al. 2000) and
from S. agalactiae (hylB3502, pdb code 1f1s) (Li et al. 2001) is 53 % whereas it
is even 98 % between the streptococcal enzymes hylB3502 and S. agalactiae
strain 4755 hyaluronan lyase (hylB4755). Thus, the crystal structures of the
streptococcal hyaluronidases hylSpn and hylB3502 have provided the first possi-
bility to construct a reliable comparative model of the parent bacterial enzymes
group B streptococcal hyaluronidase hylB4755.
As a first step, a multiple sequence alignment of hylB4755, hylB3502 and hylSpn
was generated using ClustalW (Higgins et al. 1988; Thompson et al. 1994).
Due to the very high overall identity of the amino acid sequences of the strepto-
coccal enzymes (85 % for hylB4755 vs. hylSpn and 99 % for hylB4755 vs. hylB3502
with respect to the active sites), the homology modelling approach should result
in a very reliable comparative model of hylB4755. Additionally, the structurally
conserved regions (SCR) of both crystal structures could easily be extracted
since almost all insertions in the hylB3502 sequence occur in the βII-domain
surface loop areas (Li et al. 2001). Given that the primary structures of hylB3502
and hylB4755 are almost identical, the question arose whether to directly use the
X-ray structure of S. agalactiae strain 3502 hyaluronan lyase as starting point
for the structure-based ligand design instead of constructing a homology model
of S. agalactiae strain 4755 hyaluronan lyase.
The crystal structure of the bacterial hyaluronan lyases from S. pneumoniae
(hylSpn) was used as a template for model construction, since its conformation
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is supposed to be catalytically active whereas the crystallised conformation of
hylB3502 is more open, therefore not optimal for catalysis (Li et al. 2001). Fur-
thermore, it was observed that the α- and βII-domains were rotated by a small
angle around the linker II in the hylB3502 structure as compared to hylSpn. As a
result, the hylB3502 structure is more open than is the hylSpn structure. Conse-
quently, corresponding subdomaines of hylSpn and hylB3502 were superim-
posed using Sybyl 6.8 (Tripos Inc., St. Louis, MO). A full model of hylB4755 was
constructed by starting from the hylB3502 α− and βII-domains with lowest root
mean square (rms) deviation to hylSpn, inserting joining loops from hylB3502,
and mutating eight amino acids to achieve the hylB4755 amino acid sequence.
The resulting model was protonated and energetically minimised. The energy
minimised model of hylB4755 is shown in Fig. 1.
βI-domain
α-domain
βII-domain
cleft
Fig. 1: Schematic representation of hylB3502 model. α-helices, β-sheets and
loop regions are coloured in purple, yellow and cyan, respectively (Botzki
2004).
1 The construction of the hylB4755 model and the LUDI calculations have been carried out by
Alexander Botzki (Botzki  2004) as part of his PhD project.
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2.2 Search for molecular fragments using the computer pro-
gram LUDI
Using the de novo design program LUDI, small and fairly rigid molecules were
retrieved from a 3D-structure database by positioning them into the protein-
binding site. For each successfully docked ligand, LUDI estimates the expected
binding affinity by an empirical scoring function (Böhm 1998). Based on the
homology model of hylB4755, we screened entries from the LeadQuest® Data-
bases Vol. 1&2 (Tripos 2000) with LUDI. Prior to the search, the molecules
from the LeadQuest® databases were processed using CONVERTER (Accelrys
2000) to generate reasonable 3D structures. Using standard parameters for
LUDI calculations, all 3D structures are treated as rigid bodies independent of
the existence of rotatable bonds on the molecules. The generated 3D database
was reprocessed by GENFRA, a module of the LUDI programme suite, to clas-
sify all molecules in terms of their hydrogen-bonding and lipophilic properties
and to calculate the fraction of solvent-accessible-surface of their functional
groups. Appropriate fit centres were assigned to all functional moieties of the
ligands to be screened and saved in a supplementary database by GENFRA.
Subsequently, for all functional groups of the enzyme exposed to the active
site, LUDI generates putative interaction sites in space according to rules de-
rived from composite crystal-field environments compiled with appropriate small
molecule crystal data (Cambridge Structural Database) (Böhm 1992). The pro-
gramme tries to fit each database molecule onto the previously calculated in-
teraction sites in the pre-defined binding pocket. The centre of this pocket was
defined as the geometric mean of all atom positions of the active site amino
acids Arg409, Trp460, Tyr576, Val579 and Arg634. All residues within a sphere
of 5 Å around this centre were included into the LUDI calculation.
After four days calculation time, 122 hits were retrieved by the described pro-
cedure and were ranked on a relative scale in terms of their expected binding
affinity using the scoring function described by Böhm (Böhm 1998). Since
neither ligand nor protein flexibility is taken into account when using the pa-
rameters described above, a subsequent LUDI run with slightly altered pa-
rameters was accomplished. To allow for a larger search space and for more
interaction possibilities, the radius of the sphere was enlarged to 8 Å and one
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rotatable bond at a time was treated flexible. Besides, the hit database was
combined with the original LUDI database as supplied by Accelrys because the
size of the screened database should be enlarged in order to retrieve new
compounds. A LUDI run with these adapted parameters on the whole Lead-
Quest database would have taken far too long to be completed in a reasonable
time. 212 structures from this combined database were retrieved by LUDI and
ranked in terms of their expected binding affinity with a predicted Ki value lower
than 1 mM (LUDI score higher than 300).
In parallel to these investigations, an additional database with commercially
available compounds has been constructed starting from the ChemACX data-
base Version 5.5 from CambridgeSoft Corp. For the sake of reasonable calcu-
lation time, the applied parameters were altered with respect to the sphere ra-
dius (6 Å instead of 5 Å) and the density of lipophilic and polar interaction sites.
Around 196908 compounds were screened in 5.5 days with LUDI resulting in
1063 hits.
Subsequently, both obtained hit lists were inspected visually. The final selection
of compounds for purchase, synthesis and enzyme testing included the follow-
ing criteria: (a) a predominantly high LUDI score until 325, (b) commercial
availability, (c) efficient synthetic feasibility. All nineteen selected compounds
are depicted with their calculated LUDI scores in Table 1.
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Table 1: Selected test compounds suggested by LUDI with calculated LUDI
score and quoted position (A = Accelrys, C = ChemACX and LQ = LeadQuest® Database)
No Structure LUDI Score Database
1
O
O2N
O
687 C
2
CO2H
HO2C
579 A
3
CO2H
CO2H
555 A
4
O
NO2O2N
505 C
5
N
OCH3
452 A
6
N
S
O
OCH3
441 LQ
7 CO2HHO2C 436 A
8
N
CH3
O2N
CH3
H3C O
429 LQ
9
N CO2H
OH
426 A
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10 N
NN
O
407 C
11
N
CO2CH3
405 A
12 N N
OCH3 O
CH3
392 LQ
13
NC
NC O OC4H9
391 LQ
14
S
NO2
Cl
O
384 LQ
15
O
CO2H
382 A
16
O
O
N
364 LQ
17
N
N
S
O
O
363 LQ
18 N
O
357 LQ
19 N
H
CO2H 328 A
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3. Chemistry
The furanyl derivative 1 was easily prepared in a one step reaction from 4-nitro-
benzaldehyde (20) and 2-acetylfurane (21). The aldol condensation has been
carried out in ethanol under strong basic conditions at ambient temperature (cf.
Scheme 1).
CHO
NO2
O
O
+
O2N
O
OKOH
EtOH
20 21 1
Scheme 1: Synthesis of 1-furan-2-yl-3-(4-nitrophenyl)propenone (1)
For the synthesis of 2,8-dinitro-dibenzofurane (4) different published proce-
dures were tried. The most successful method was the method described by
Borsche et al. (Borsche et al. 1908). Compound 4 was prepared by a nitration
reaction of dibenzofuran (22) with a mixture of acetic anhydride and vitriolic
acid (conc. HNO3) at room temperature (cf. Scheme 2).
O O
NO2O2N
conc. HNO3
(CH3CO)2O
22 4
Scheme 2: Nitration of dibenzofuran
The O-methyl-oxime 5 was prepared in good yield from the commercially avail-
able benzophenone (23) with methoxyamine hydrochloride in ethanol and pyri-
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dine under reflux. The synthesis was based on a method described by Kawase
et al. (Kawase et al. 1979) with some modifications (cf. Scheme 3).
O N OCH3
CH3ONH3
+Cl-
Pyridine / EtOH
23 5
Scheme 3: Synthesis of diphenylmethanone-O-methyl-oxime (5)
The piperazine derivative 12 can be obtained by a acetylation of piperazine 24
with 3-methylbenzoic acid 25. For this synthesis, several standard methods are
published. One very common method is the activation of the carboxylic acid
with EDC and HOBt in chloroform and coupling of the amine with pyridine as
base. This reaction was successful, but because of the low yield, we changed
the method. The piperazine derivative 12 was prepared by activation of the acid
with N,N’-carbonyldiimidazole (CDI) in anhydrous chloroform and 1-(2-me-
thoxyphenyl)piperazine hydrochloride (24) in high yield (90 %) (cf. Scheme 4).
N NH2
+Cl -
OCH3 CO2H
CH3
N N
OCH3
O
+
CDI
CHCl3
OCH3
24 25 12
Scheme 4: Synthesis of the piperazine derivative 12
The vinylogous dimethylamine 16 was prepared from 5-acetyl-2,3-dihydroben-
zo[b]furan (26) by a modified method described by Tanaka et al. (Tanaka et al.
1998) and Wright et al. (Wright et al. 1992). The aldol condensation was carried
out at high temperature using N,N-dimethylformamide dimethyl acetal as rea-
gent and as solvent (cf. Scheme 5).
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O
O
O
O
N
CH3
H3C
(CH3)2NC(OCH3)2
∆T
26 16
Scheme 5: Aldol condensation of 5-acetyl-2,3-dihydrobenzo[b]furan (26) and
N,N-dimethylformamide dimethyl acetal.
To synthesise the benzimidazol derivative 17 the method described by
Tittelbach et al. (Tittelbach et al. 1988) was tried, that is benzimidazole-2-thione
was treated with acetic anhydride at room temperature. However, it was not
possible to get the desired product according to this method. All attempts to
improve the reaction, e.g. increasing the reaction time or using the more reac-
tive acetyl chloride instead of acetic anhydride were unsuccessful. Finally,
compound 17 was obtained by the acetylation of the benzimidazole-2-thione
(27) with triethylamine as base and N,N-dimethylaminopyridine (DMAP) as
catalyst at room temperature. It was possible to isolate the mono- and the di-
acetylated compounds 17 and 28 (cf. Scheme 6). Compound 28 is a by-product
of this reaction and the product of hydrolytic cleavage of compound 17 at ambi-
ent temperature and moisture.
HN NH
S
N NH
S
N N
S OOO
+
AcCl / CH2Cl2
Et3N / DMAP
27 17 28
Scheme 6: N-Acetylation of benzimidazole-2-thione (27)
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4. Pharmacological investigations
On the basis of our LUDI search, the proposed inhibitors compounds 1-19 were
investigated for activity on the bovine testicular hyaluronidase (BTH) and the S.
agalactiae hyaluronate lyase (hylB4755) using an optimised colorimetric method
(Muckenschnabel et al. 1998; Muckenschnabel et al. 1998) and a turbidimetric
method (Di Ferrante 1956) as described in chapter 3. The inhibitory effects on
BTH and hylB4755 at optimum pH (BTH pH 3.6, hylB4755 pH 5.0) and at physio-
logical pH (7.4) are summarised in Table 2 and Table 3, respectively.
As aforementioned, the proposals of chemical structures resulting from LUDI
calculations are based on a homology model of two hyaluronan lyases (S.
pneumoniae and S. agalactiae) and are intended to be S. agalactiae hylB4755
inhibitors. As expected the compounds 1-19 showed different inhibitory activi-
ties on the bovine testicular hyaluronidase and on the bacterial hyaluronidase.
Surprisingly, within the series of tested compounds, we identified five com-
pounds (1, 4, 16, 17 and 19) with inhibitory activity on the bovine testicular
hyaluronidase. The furan derivative 1 induced 77 % inhibition of BTH at a con-
centration of 10 mM at pH 3.6. At physiological pH (7.4) an IC50 value of 4 mM
was determined. The inhibition of BTH by compound 4 was only 23 % at opti-
mum pH (3.6) and 29 % at physiological pH (7.4), compound 16 produced 38 %
inhibition at a concentration of 2 mM at pH 3.6 and the IC50 value of indole-2-
carboxylic acid (19) on the bovine testicular enzyme (pH 3.6) was 7.1 mM. The
benzimidazole-2-thione derivative 17 was the compound with the highest in-
hibitory activity (IC50 250 µM) on the bovine testicular hyaluronidase (pH 7.4).
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Table 2: Inhibitory activities of compounds 1, 4, 16, 17 and 19 on BTH
No Structure BTH
IC50 [µM] or ( % Inhibition)
pH 3.6 pH 7.4
1
O
O2N
O 78 %a
(10 mM) 4000
4
O
NO2O2N
23 %a
(5 mM)
29 %a
(5 mM)
16
O
O
N
38 %a
(20 mM)
inactive
(≤ 20 mM)
17
N
N
S
O
O
inactive
(≤ 20 mM) 250
19 N
H
CO2H 7100 inactive(≤ 20 mM)
a % inhibition of BTH at indicated inhibitor concentration
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Table 3: Inhibitory activities of compounds 1-19 on hyaluronate lyase
No Structure LUDI
Score
hylB4755
IC50 [µM] or (% Inhibition)
pH 5.0 pH 7.4
1
O
O2N
O
687 310 160
2
CO2H
HO2C
579 3710 900
3
CO2H
CO2H
555 2680
inactive
(≤ 20 mM)
4
O
NO2O2N
505 2900
inactive
(≤ 5 mM)
5
N
OCH3
452
inactive
(≤ 20 mM)
inactive
(≤ 20 mM)
6
N
S
O
OCH3
441
inactive
(≤ 5.25 mM) n.d
7 CO2HHO2C 436 2500
inactive
(≤ 20 mM)
8
N
CH3
O2N
CH3
H3C O
429
inactive
(≤ 2.5 mM) n.d
9
N CO2H
OH
426 4470
inactive
(≤ 10 mM)
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10 N
NN
O
407
inactive
(≤ 0.1 mM)
inactive
(≤ 0.1 mM)
11
N
CO2CH3
405 11000 5000
12 N N
OCH3 O
CH3
392
38 %a
(20 mM)
83 %a
(20 mM)
13
NC
NC O OC4H9
391
inactive
(≤ 5 mM) n.d.
14
S
NO2
Cl
O
384
20 %a
(20 mM)
50 %a
(20 mM)
15
O
CO2H
382
50 %a
(20 mM)
35 %a
(20 mM)
16
O
O
N
364 610
46 %a
(2 mM)
17
N
N
S
O
O
363 160 5
18 N
O
357
inactive
(≤ 20 mM)
inactive
(≤ 20 mM)
19 N
H
CO2H 328 3550
44 %a
(20 mM)
a % inhibition of hylB4755 at indicated inhibitor concentration
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Among the tested substances we identified six compounds 5, 6, 8, 10, 13 and
18 which were inactive on the hyaluronate lyase despite high or moderate LUDI
scores (cf. Table 3).
The compound with the highest LUDI score of 687 corresponding to a predicted
Ki value of about 1 µM, was the furan derivative 1. The determined IC50 value of
this compound was 310 µM at optimum pH (5.0) and 160 µM at physiological
pH (7.4). The concentration-dependent inhibition of compound 1 on hylB4755 is
diagrammed in Fig. 2. Though the LUDI score of compound 1 did not reflect the
obtained IC50 value, the measured and the predicted IC50 value are approxi-
mately in the same order of magnitude.
log c [M]
-5,0 -4,5 -4,0 -3,5 -3,0 -2,5 -2,0
Ac
tiv
ity
[%
]
0
20
40
60
80
100 pH 5.0
pH 7.4
Fig. 2: Enzyme activity of hyaluronate lyase in the presence of 1-furan-2-yl-3-
(4-nitrophenyl)propenone (1) at optimum (5.0) and physiological pH (7.4)
Compounds 2, 3 and 7 with LUDI scores of 579, 555 and 436, respectively, are
three related compounds, which showed a concentration dependent inhibitory
activity on the hyaluronate lyase. The inhibition curves of the compounds 2, 3
and 7 are depicted in Fig. 3. The IC50 values determined on the hyaluronate
lyase at optimum pH (5.0) were 3.71 mM (2), 2.68 mM (3) and 2.5 mM (5) and
were lower than expected from the LUDI score. Presumably, the LUDI scoring
function did not perform well due to inaccurately predicted hydrogen bonding
contribution (Ajay et al. 1995). Possibly, the LUDI scores just tend to overesti-
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mate binding of these compounds at a highly charged (pH-dependent) active
site. Other studies have shown predicted affinities to be accurate to about
1.3-1.5 lg units (Böhm 1998; Grüneberg et al. 2001). Additionally, depending on
the enzyme, the inhibitory activity of the compounds were determined at differ-
ent pH e.g. hylB4755 at pH 5 and pH 7.4 corresponding to optimum and physio-
logical pH. Although the protonation states of the molecules are dependent on
the pH of the experimental measurement (pH 5 and 7.4), the LUDI scoring
function consider only the protonation states of the amino acids residues inside
the active site at neutral pH, a defined parameter of our constructed hylB4755
model.
The IC50 value of 0.9 mM was determined for benzene-1,4-diacetic acid (2) at
physiological pH, whereas isophthalic acid (3) and terephthalic acid (7) showed
no inhibition of the enzyme at this pH. It is conspicuous that the inhibitors
showed different activities at pH 5.0 and 7.4, and it may be speculated about
the factors accounting for these differences. For example, the portion of
charged test-compound depends on the pH value of the incubation mixture just
like the protonation state of amino acids residues inside the active site of the
enzyme.
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Fig. 3: Inhibitory effects of the three related acids 2, 3 and 7 on the bacterial
hyaluronidase at optimum pH (5.0)
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The inhibitory activity of 2,8-dinitrodibenzofuran (4), kynurenic acid (9) and
methylisoquinoline-3-carboxylate (11) on the bacterial hyaluronidase was in the
millimolar range, whereas the calculated LUDI scores of 505, 426 and 405 pre-
dict an inhibitory activity in the submillimolar range. The determined IC50 values
were 2.9 mM for compound 4, 4.47 mM for compound 9 at pH 5.0, 11 mM and
5 mM for compound 11 at pH 5.0 and pH 7.4, respectively (cf. Table 3).
Weak and incomplete inhibition of the bacterial enzyme was produced by com-
pounds 12, 14 and 15. The inhibitory effects of these three substances ranged
from 20 % to 83 % at concentration of 15 mM and 20 mM (cf. Table 3).
One of the most potent inhibitors of  the hyaluronate lyase at optimum pH was
found for the 1-(2,3-dihydrobenzo[b]furan-5-yl)-3-(dimethylamino)propenone
(16) (cf. Table 3). An IC50 value of 0.61 mM was determined on the bacterial
enzyme at pH 5.0, whereas the percentual inhibition at pH 7.4 was only 46 % at
a concentration of 2 mM (cf. Fig. 4). In the case of compound 16 the deter-
mined IC50 value and the predicted LUDI score of 364 are in good agreement.
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Fig. 4: Enzyme activity of hyaluronate lyase from S. agalactiae in the presence
of 1-(2,3-dihydrobenzo[b]furan-5-yl)-3-(dimethylamino)propenone (16) at opti-
mum pH (5.0) and physiological pH (7.4)
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The LUDI score of indole-2-carboxylic acid (19) was calculated to be 328 corre-
sponding to a  predicted Ki value of approximately 1 mM for the bacterial en-
zyme. The measured IC50 values of the indole derivative 19 were 7.1 mM on
the bovine testicular hyaluronidase and 3.55 mM on the bacterial hyaluronidase
at optimum pH (5.0). The concentration-dependent inhibitory effect of indole-2-
carboxylic acid on BTH and on hylB4755 are diagrammed in Fig. 5. The IC50
value of compound 19 determined on the hyaluronate lyase is in agreement
with the predicted value from the LUDI score.
The indole-2-carboxylic acid was a first lead with millimolar enzyme inhibitory
activity which seemed to be sufficiently promising for further investigation and
structural optimisation. The chemical work and the pharmacological investiga-
tions based on the results achieved for this indole derivative are described in
chapter 9.
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Fig. 5: Inhibitory effect of indole-2-carboxylic acid (19) on the bovine testicular
hyaluronidase (pH 3.6) and the hyaluronate lyase (pH 5.0)
Within the series of tested compounds the highest inhibitory activity on the
hyaluronate lyase was found for 1,3-diacetylbenzimidazole-2-thione (17) with
an IC50 value of 160 µM at optimum pH (5.0) and 5 µM at physiological pH (7.4)
(cf. Fig 6). Surprisingly, despite a LUDI score of 363 (predicted Ki value of about
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1 mM), the determined IC50 values were in the micromolar range. In particular
at pH 7.4 the compound was almost one order of magnitude more active than
expected.
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Fig. 6: Enzyme activity of the S. agalactiae hyaluronate lyase in the presence
of 1,3-diacetylbenzimidazole-2-thione (17) at pH 5.0 and pH 7.4
The predicted binding mode of compound 17 inside the active site of the
hylB4755 model is depicted in Fig. 7. Different hydrophobic interactions as well
as hydrogen bonds are probably responsible for the inhibition of the hyaluro-
nate lyase by 1,3-diacetylbenzimidazole-2-thione. The interaction of the sulphur
atom of compound 17 with the indole moiety of the amino acid Trp460 is of hy-
drophobic nature. Further hydrophobic interactions can be postulated with the
amino acids Arg468, Arg630, Val579, and Tyr576, whereby the amino acid
residue Val579 lies perpendicular to the phenyl moiety of the inhibitor. The two
important hydrogen bonds are formed between the oxygen atom of the two
acetyl groups of the inhibitor and the amino acid residues Arg409 and Arg634
(cf. Fig. 7).
To verify the predicted binding mode of compound 17 inside the active site of
the hylB4755 model, co-crystallisation experiments were carried out. Unfortu-
nately, due to solubility problems and degradation of the inhibitor by moisture it
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was not possible to co-crystallise the inhibitor inside the active site of the hyalu-
ronate lyase, so that the binding mode predicted by LUDI calculations could not
be confirmed.
The inhibition curve of the compound 17 determined on hylB4755 at physiologi-
cal pH suggests two different binding modes with different affinity. It is conceiv-
able that the inhibitor binds inside the active site of the enzyme and additionally
at other regions of the enzyme.
Val579
Tyr576
Arg634
Arg630
Trp460
Arg409
Arg468
Fig. 7: Predicted binding mode of compound 17 inside the active site of the
hylB4755 model; O: red; N: blue; S: yellow; H-bonds: dotted lines (Botzki 2004).
In addition to compound 17, both benzimidazole-2-thione derivatives 27 and 28
were tested for inhibition of BTH and hylB4755. The unsubstituted benzimidaz-
ole-2-thione (27) was the starting material for the synthesis of compound 17.
Compound 28 is a synthetic intermediate and the product of hydrolytic cleavage
of compound 17. The activities of the three compounds determined on the bo-
vine testicular hyaluronidase as well as on the bacterial enzyme are summa-
rised in Table 4.
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Table 4: Inhibitory activity of the benzimidazole derivatives 17, 27 and 28 on
the bovine testicular hyaluronidase and the S. agalactiae hyaluronate lyase
N
N
SR1
R2
Compound BTH
IC50 [µM]
hylB4755
IC50 [µM]
R1 R2 pH 3.6 pH 7.4 pH 5.0 pH 7.4
17 Ac Ac inactive(≤ 20 mM) 390 160 5
27 H H 4100 3200 2210 1280
28 Ac H inactive(≤ 2 mM) 110 660 40
The inhibitory activities of the non-substituted benzimidazole derivative 27 were
in the millimolar range for both hyaluronidases (cf. Table 4). The concentration-
dependent effects of compound 27 are illustrated in Fig. 8. In comparison to
compound 17, the absence of both acetyl groups at the nitrogen atoms led to
an 8-fold decrease in inhibitory activity on BTH (pH 7.4) and a 14- and 256-fold
decrease in activity on hylB4755 at optimum and physiological pH, respectively.
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Fig. 8: Effect of benzimidazole-2-thione (27) on the activity of BTH and hylB4755
at different pH values.
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Fig. 9: Inhibitory effects of 1-acetylbenzimidazole-2-thione (28) on the activity
of the bovine testicular hyaluronidase and the bacterial hyaluronidase at opti-
mum and physiological pH.
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The mono-acetylated benzimidazole-2-thione derivative 28 showed concentra-
tion dependent inhibitory effects on BTH and on hylB4755, except for BTH at op-
timum pH (3.6). The enzyme inhibition curves are depicted in Fig. 9. The de-
termined IC50 values were 110 µM on the bovine testicular enzyme at physio-
logical pH, 660 µM and 40 µM on hylB4755 at pH 5.0 and pH 7.4, respectively.
Summarising the results of the three related compounds, 1-acetylbenzimid-
azole-2-thione (28) was the most potent BTH inhibitor, whereas 1,3-diacetyl-
benzimidazole-2-thione (17) was the most potent S. agalactiae hyaluronate ly-
ase inhibitor. The dependence of the potency on the number of acetyl groups
could be interpreted as a hint that the inhibitors bind actually inside the active
site of the enzymes.
5. Summary
In this chapter, a de novo design approach is presented, starting from the X-ray
structure of bacterial hyaluronate lyases and molecular modelling investiga-
tions. The aim was to identify promising leads for the development of hyalu-
ronidase inhibitors. Based on the constructed hylB4755 model, 29717 com-
pounds from the LeadQuest® and the Accelrys database and 196908 com-
pounds from the ChemACX database were virtually screened with LUDI result-
ing in 212 and 1063 hits, respectively. The final selection of compounds for
purchase, synthesis and enzyme testing included the following criteria: (a) a
predominantly high LUDI score above 325, (b) commercial availability, (c) effi-
cient synthetic feasibility. 19 compounds of all 1275 hits were selected for
pharmacological investigations, 13 compounds therefrom revealed inhibitory
activity on the bacterial hyaluronidase. One of the 13 active compounds proved
to have IC50 value in the micromolar range (IC50(17) 5 µM). Additionally, 5 of the
investigated compounds showed inhibitory activities in the millimolar range on
the bovine testicular hyaluronidase.
The results demonstrate that the chosen strategy based on a homology model
of the hyaluronan lyase hylB4755 is useful to identify promising leads despite
partly non-correlating LUDI scores.
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Starting from the results obtained by a de novo design, different projects were
envisaged:
• Inspired by the structures of the compound 5, 15 and 18, diphenylpropionic
acids and diphenylacrylic acids have been investigated (cf. chapter 8).
• Due to the inhibitory activity of indole-2-carboxylic acid (19), a series of in-
dole derivative and phenylindole derivatives was investigated. This led to
the discovery of a new class of indole-type hyaluronidase inhibitors. Design,
synthesis and pharmacological investigations of this class of compounds as
well as a X-ray analysis of an inhibitor-enzyme complex are reported in
chapter 9.
• The most promising lead discovered by virtual screening was 1,3-diacetyl-
benzimidazole-2-thione (17) with an IC50 value in the micromolar range.
Structural modifications of this compound are subject of ongoing work.
6. Experimental section
6.1 General conditions
For a detailed description of the general procedures, equipments and chemi-
cals used in the chemistry part, see section 4.1 of chapter 5.
6.2 Chemistry
1-Furan-2-yl-3-(4-nitrophenyl)propenone (1)
To a solution of 4-nitrobenzaldehyde (5.0 g, 33.10 mmol), 2-acetylfurane
(3.65 g, 33.10 mmol) and ethanol (300 ml) an aqueous solution (60 %) of po-
tassium hydroxide (25 ml) was slowly added. After stirring at room temperature
for 16 h, the reaction mixture was diluted with water and acidified with concen-
trated hydrochloric acid. The precipitated product was collected, washed with
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water and recrystallised from dimethylsulphoxide to give a brown crystalline
solid.
Yield: 4.21 g (17.31 mmol, 52 %, brown crystalline solid)
Mp: 205-210 °C [Lit.: 228-232 °C (Kabli et al. 1991)]
1H-NMR ([D6]DMSO):
δ [ppm] = 6.83 (dd, 1H, 3J = 1.7 Hz, 3J = 3.6 Hz, furyl H-4), 7.82 (d, 1H, 3J =
15.8 Hz, =CH), 7.90 (d, 1H, 3J = 15.8 Hz, =CH), 7.91 (dd, 1H, 4J = 0.7 Hz, 3J =
3.6 Hz, furyl H-3), 8.11 (dd, 1H, 4J = 0.7 Hz, 3J = 1.7 Hz, furyl H-5), 8.12-8.16
(m, 2H, C6H4), 8.27-8.31 (m, 2H, C6H4)
13C-NMR ([D6]DMSO):
δ [ppm] = 112.8 (+, furyl), 120.4 (+, furyl), 123.9 (+, C6H4), 125.9 (+, =CH),
129.7 (+, C6H4), 139.9 (+, =CH), 140.8 (Cquart, C6H4), 148.0 (Cquart, C6H4), 148.9
(+, furyl), 152.6 (Cquart, furyl), 176.1 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 243 ([M•+], 100), 242 ([M-H]+, 28)
IR [cm-1]: 3157 (C-H) michael system, 3115 (C-H) aromatic, 1663 (C=O), 1613
(C=C), 1511 (N-O), 1336 (N-O), 1167 (C-O),  883, 837, 769, 754
Analysis:
calculated C: 64.20 H: 3.73 N: 5.76
found C: 64.12 H: 3.55 N: 5.73
C13H9NO4 (243.22)
2,8-Dinitrodibenzofuran (4)
To a solution of dibenzofuran (5.0 g, 29.73 mmol) and acetic anhydride (30 ml)
concentrated HNO3 (10 ml) was carefully added dropwise. After stirring at room
temperature for 16 h, the reaction mixture was poured into ice water and diluted
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with water. The precipitated product was collected, washed with water and re-
crystallised from dimethylsulphoxide to give a light pink solid.
Yield: 0.90 g (3.49 mmol, 12 %, light pink solid)
Mp: 305-307 °C [Lit. 329-330 °C (Yamashiro 1938)]
1H-NMR ([D6]DMSO):
δ [ppm] = 8.08 (d, 2H, 3J = 9.1 Hz, H-4, H-6), 8.53 (dd, 2H, 4J = 2.5 Hz, 3J = 9.1
Hz, H-3, H-7), 9.51 (d, 2H, 4J = 2.5 Hz, H-1, H-9)
13C-NMR ([D6]DMSO):
δ [ppm] = 113.1 (+, ar), 119.2 (+, ar), 123.7 (Cquart, ar), 124.6 (+, ar), 144.2
(Cquart, CO), 159.7 (Cquart, CNO2)
MS (PI-EIMS (70 eV)): m/z (%) = 258 ([M•+], 100), 228 ([M-NO]+, 16), 212 ([M-
NO2]+, 20), 138 ([M-2NO2-CO]+, 26)
IR [cm-1]: 3101 (C-H) aromatic, 1517 (N-O), 1466 (C-H), 1343 (N-O), 1200 (C-
O), 1018, 783, 748, 664
Analysis:
calculated C: 55.82 H: 2.34 N: 10.85
found C: 55.73 H: 2.31 N: 10.82
C12H6NO5 (258.19)
Diphenylmethanone-O-methyloxime (5)
A solution of benzophenone (5.70 g, 31.30 mmol), methoxylamine hydrochlo-
ride (2.67 g, 32.40 mmol), pyridine (100 ml) and ethanol (100 ml) was stirred
under reflux for 24 h. After evaporation of the solvent, the residue was diluted
with water (100 ml) and extracted three times with ethyl acetate (50 ml). The
organic solution was washed with water (3 x 50 ml), dried over sodium sulphate
and the solvent was removed under reduced pressure. The product was puri-
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fied by column chromatography on silica gel eluting with a 15:1 (v/v) mixture
containing ethyl acetate and petroleum ether 60 - 80 °C to give a white solid.
Yield: 4.68 g (27.6 mmol, 88 %, white solid)
Mp: 43-45 °C [Lit. 49-51 °C (Kerr et al. 1970)]
1H-NMR (CDCl3):
δ [ppm] = 3.86 (s, 3H, OCH3), 7.21-7.31 (m, 2H, C6H5), 7.33-7.41 (m, 5H,
C6H5), 7.41-7.50 (m, 3H, C6H5)
13C-NMR (CDCl3):
δ [ppm] = 61.9 (+, OCH3), 127.2 (+, C6H5), 128.3 (+, C6H5), 128.4 (+, C6H5),
128.6 (+, C6H5), 128.8 (+, C6H5), 129.5 (+, C6H5), 132.9 (Cquart, C6H5), 135.7
(Cquart, C6H5), 156.1 (Cquart, C=N)
MS (PI-EIMS (70eV)): m/z (%) = 211 ([M•+], 61), 180 ([M - OCH3]+, 100)
IR [cm-1]: 2939 (C-H) aromatic, 2900 (C-H) aliphatic, 1579 (C=N), 1442 (C-H),
1048, 983, 878, 771, 692, 649
Analysis:
calculated C: 79.60 H: 6.20 N: 6.63
found C: 79.53 H: 6.45 N: 6.65
C14H13NO (211.26)
1-(2-Methoxyphenyl)-4-(3-methylbenzoyl)piperazine (12)
A solution of 1-(2-methoxyphenyl)piperazine hydrochloride (1.0 g, 4.37 mmol),
1,1’-carbonyldiimidazole (0.71 g, 4.37 mmol) and anhydrous chloroform (20 ml)
was stirred at room temperature for 30 min. Afterwards, m-toluene sulphonic
acid (0.60 g, 4.37 mmol) was added and the reaction mixture was stirred at
ambient temperature for 16 h. After evaporation of the chloroform the residue
was diluted with water (100 ml) and extracted three times with ethyl acetate
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(50 ml). The combined organic layer was washed with water (2 x 50 ml), dried
over sodium sulphate and the solvent was removed under reduced pressure.
The product was purified by column chromatography on silica gel eluting with a
2:1 (v/v) mixture of ethyl acetate and petroleum ether 60 - 80 °C to give a white
solid.
Yield: 1.22 g (3.93 mmol, 90 %, white solid)
Mp: 82-84 °C
1H-NMR (CDCl3):
δ [ppm] = 2.38 (s, 3H, CH3), 2.86-3.35 (m, 4H, CH2), 3.48-3.83 (m, 2H, CH2),
3.87 (s, 3H, OCH3), 3.91-4.15 (m, 2H, CH2), 6.85-7.42 (m, 8H, C6H4)
13C-NMR (CDCl3):
δ [ppm] = 21.4 (+, CH3), 42.3 (-, NCH2CH2NCO), 47.9 (-, NCH2CH2NCO), 50.9
(-, NCH2CH2NCO), 51.2 (-, NCH2CH2NCO), 55.5 (+, OCH3), 111.5 (+, C6H4),
118.7 (Cquart, C6H4), 121.1 (+, C6H4), 123.8 (+, C6H4), 124.0 (+, C6H4), 127.2 (+,
C6H4), 127.7 (+, C6H4), 128.3 (+, C6H4), 130.4 (+, C6H4), 135.8 (Cquart, C6H4),
138.5 (Cquart, C6H4), 152.3 (Cquart, C6H4), 170.6 (Cquart, C=O)
MS (PI-DCIMS (NH3)): m/z (%) = 311 ([MH+], 100)
IR [cm-1]: 3057 (C-H) aromatic, 2860 (C-H) aliphatic, 2815 (C-H) aliphatic,
1632 (C=O), 1499 (C-H), 1431 (C-H), 1242 (C-O), 1023, 795, 745
Analysis:
calculated C: 73.53 H: 7.14 N: 9.03
found C: 73.44 H: 7.65 N: 8.56
C19H22N2O2 (310.38)
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1-(2,3-Dihydrobenzo[b]furan-5-yl)-3-dimethylaminopropenone (16)
A solution of 5-acetyl-2,3-dihydrobenzo[b]furan (0.45 g, 2.77 mmol) and N,N-di-
methylformamide dimethyl acetale (10 ml) was stirred and heated under reflux
for 14 h. The solvent was removed under reduced pressure and the residue
was recrystallised from diethyl ether to give the pure product as a yellow solid.
Yield: 0.19 g (0.87 mmol, 31 %, yellow solid)
Mp: 102-104 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 2.88 (br, 3H, NCH3), 3.11 (br, 3H, NCH3), 3.20 (t, 2H, 3J = 8.8 Hz, H-
3), 4.58 (t, 2H, 3J = 8.8 Hz, H-2), 5.79 (d, 1H, 3J = 12.4 Hz, =CHCO), 6.77 (d,
1H, 3J = 8.5 Hz, H-7), 7.65 (d, 1H, 3J = 12.4 Hz, =CHCN), 7.72 (dd, 1H, 4J = 1.9
Hz, J = 8.5 Hz, H-6), 7.82 (d, 1H, 4J = 1.9 Hz, H-4)
13C-NMR ([D6]DMSO) / HMQC-NMR:
δ [ppm] = 28.5 (-, C-3), 36.9 (+, NCH3), 44.3 (+, NCH3), 71.5 (-, C-2), 90.6 (+,
=CHCO), 108.1 (+, C-7), 124.4 (+, C-4), 127.2 (Cquart, C-9), 128.1 (+, C-6),
132.9 (Cquart, C-5), 153.5 (+, =CHN), 162.0 (Cquart, C-8), 184.7 (Cquart, C=O)
MS (PI-CIMS (NH3)): m/z (%) = 218 ([MH+], 100)
IR [cm-1]: 3000 (C-H) aromatic, 2888 (C-H) aliphatic, 1637 (C=O), 1601 (C=C),
1546 (C=C), 1428 (C-H), 1352 (C-H), 1239 (C-O),  1102, 925, 740
Analysis:
calculated C: 71.78 H: 6.96 N: 6.45
found C: 71.42 H: 7.37 N: 6.19
C13H15NO2 (217.27)
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1,3-Diacetylbenzimidazole-2-thione (17)
A solution of benzimidazole-2-thione (1.50 g, 10.0 mmol), triethylamine (2.88 g,
28.50 mmol), catalytic amount (100 mg) of DMAP and anhydrous dichlo-
romethane was stirred at room temperature for 10 min. A solution of acetyl
chloride (2.83 g, 36.0 mmol) and anhydrous dichloromethane was added drop-
wise to the mixture and stirring was continued for 16 h. After diluting with water
(100 ml) and dichloromethane (50 ml), the organic phase was separated,
washed three times with an aqueous solution of potassium hydrogen sulphate
(1 M, 50 ml) and water (50 ml), dried over sodium sulphate and the solvent was
removed under reduced pressure. The product was purified by column chro-
matography on silica gel eluting with a 1:8 (v/v) mixture containing ethyl acetate
and petroleum ether 60 - 80 °C to give a white solid. The product decompose at
ambient temperature and moisture to 1-acetylbenzimidazole-2-thione (28).
Yield: 1.30 g (5.55 mmol, 56 %, white solid)
Mp: 100-102 °C [Lit. 102-103°C (Tittelbach et al. 1988)]
1H-NMR (CDCl3):
δ [ppm] = 3.05 (s, 6H, OCH3), 7.31 (dd, 2H, 4J = 3.4 Hz, 3J = 6,3 Hz, H-5 and H-
6), 7.97 (dd, 2H, 4J = 3.4 Hz, 3J = 6,3 Hz, H-4 and H-7)
MS (PI-EIMS (70eV)): m/z (%) = 234 ([M•+], 11), 192 ([M-CH2=C=O]+, 18), 150
([M-2CH2=C=O]+, 100)
IR [cm-1]: 3018 (C-H) aromatic, 2900 (C-H) aliphatic, 1719 (C=O), 1467 δ(C-H),
1366 (C-H), 1153 (C=S), 987, 743, 67
C11H10N2O2S (234.20)
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1-Acetylbenzimidazole-2-thione (28)
The product was isolated as by-product of the aforementioned reaction.
Yield: 0.51g (2.60 mmol, 26 %, white solid)
Mp: 177-180 °C [Lit.: 191-192 °C (Gosselin et al. 1978)]
1H-NMR (CDCl3):
δ [ppm] = 3.01 (s, 3H, COCH3), 7.16-7.35 (m, 3H, H-4, H-5, H-6), 8.00 (d, 1H,
3J = 7.4 Hz, H-7), 13.34 (s, 1H, NH)
13C-NMR (CDCl3):
δ [ppm] = 27.9 (+, COCH3), 109.4 (+, C6H4), 115.3 (+, C6H4), 123.3 (+, C6H4),
125.3 (+, C6H4), 130.8 (Cquart, C6H4), 130.9 (Cquart, C6H4), 169.5 (Cquart, C=O),
172.0 (Cquart, C=S)
IR [cm-1]: 3110 (N-H), 3060 (C-H)  aromatic, 2931 (C-H) aliphatic, 1714 (C=O),
1512 (C=C), 1454 (C-H), 1362 (C-H), 1204 (C-O), 1152 (C=S), 985, 742, 687,
632
C9H8N2O1S (192.24)
6.3 Theoretical methods
The construction of the hylB4755 model and the LUDI calculations have been
carried out by Alexander Botzki (Institute of Pharmacy, University of Regens-
burg, 93040 Regensburg, Germany) and are subject of his PhD project. More
detailed information about the used enzyme model, the calculation methods,
databases and LUDI will be given in the thesis of A. Botzki (Botzki 2004).
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6.3.1 Database preparation
The LeadQuest® databases Vol. 1&2 (Tripos 1998), the ChemACX database
(CambrigeSoft, Cambrige, UK) and the Accelrys database (Accelrys Inc., San
Diego, CA, USA) were converted into 3D using the CONVERTER module from
Insight 2000 (Accelrys Inc., San Diego, CA, USA). To allow for energy minimum
conformations of the resulting 3D structures, all-trans conformations for the
chain portions of the molecules and chair conformations for 6-membered rings
consisting of all sp3 atoms were applied. For each molecule of the original 2D
databases two stereoisomeres (if possible) were generated. The resulting da-
tabase was prepared for use with the LUDI programme (Accelrys Inc.) by
means of the LUDI module genfra 5 (Böhm 1992; Böhm 1992) constructing a
structure and a target database with types of each target site (e.g. acceptor or
donor atom) in the fragments.
6.3.2 LUDI calculations with the hylB4755 model
A LUDI approach was set up with a sphere of 5 Å radius in the space of the
active site of hylB4755. The centre of this sphere was determined as the geomet-
ric mean of six amino acid residues inside the active site of the model (Arg409,
Trp460, Tyr576, Val579 and Arg634). The values of the most important LUDI
parameters for design of hylB4755 ligands were as follows: the maximal RMSD
of the fit between the fragment and the interaction sites was 0.45 Å, the density
of lipophilic and  polar interaction sites per protein atom was set to 35 and the
minimal contact surface between ligand and protein was set to 30 %. The re-
trieved candidate molecules were ranked with respect to their expected binding
affinity using the empirical scoring function developed by Böhm (Böhm 1994)
with a minimal scoring value of 300 (predicted Ki value of 1mM). All other pa-
rameters were set to default values. Conducting a LUDI run with the con-
structed LeadQuest® Database resulted in 122 hits. To enable a larger sphere
(r = 8 Å) and to consider rotatable bonds in reasonable CPU time, these hits
were combined with 1020 compounds from the Accelrys database as supplied
within the LUDI module. Recalculation with this combined hit database pro-
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posed 212 new hits. Sixteen of the proposed 212 hits were selected for testing
hyaluronan lyase inhibition according to high LUDI scores, availability and effi-
cient synthetic feasibility (cf. Table 1).
The LUDI run with the ChemACX database resulted in 1063 hits from which 3
of them were selected for testing hyaluronan lyase inhibition also according to
high LUDI score, availability and efficient synthetic feasibility (cf. compounds 1,
4 and 10 of Table 1).
6.4 Pharmacological methods
The inhibitory effect of the compounds on the activity hyaluronidases were de-
termined by the method of Reissig (Reissig et al. 1955) based on the Morgan-
Elson reaction and by a turbidimetric assay according to the description of Di
Ferrante (Di Ferrante 1956), as described in chapter 3.
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Chapter 8
Diphenylacrylic acids and diphenylpropionic
acids as potential inhibitors of hyaluronidases:
synthesis and pharmacological investigations
1. Introduction
For a de novo design of enzyme inhibitors we followed a structure-based stra-
tegy. Initially, a model of hylB4755 hyaluronidase was constructed by partially
superimposing corresponding domains of the crystal structures of S. agalactiae
(hylB3502) (Li et al. 2001) and S. pneumoniae hyaluronate lyases (Li et al. 2000)
using Sybyl 6.8 (Tripos Inc., St. Louis). Subsequent LUDI calculations based on
this model resulted in different proposals. Nineteen compounds were selected
for biological investigations. The results are described in chapter 7.
The compounds 1-3 (cf. Fig. 1) were among the structure suggested by LUDI.
The structures of theses compounds, the arrangement of the phenyl rings and
the predicted binding modes at the active site of hylB4755 are similar. According
to the LUDI scores (LS) of 452 (1), 382 (2) and 357 (3), the compounds should
have inhibitory activities in the low millimolar range.
N
OCH3 O
CO2H
N
O
1 (LS 452) 2 (LS 382) 3 (LS 357)
Fig. 1: Three of the “LUDI proposals” and their respective LUDI score (LUDI
scores give a rough estimate of the inhibition constant Ki value, i.e. LS of 600
and 300 correspond to Ki value of 1 µM and 1 mM, respectively.)
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However, the results of the pharmacological investigations of these three com-
pounds were disappointing because only compound 2 showed an inhibitory
effect on hyaluronidases. The inhibition by compound 2 at a concentration of
20 mM was only 50 % on BTH and 35 % on hylB4755 (cf. chapter 7).
As the carboxylic acid 2 was the only active substance among the compounds
1-3 structural modifications were made: We decided to keep the two phenyl
rings and to introduce an acid functionality by incorporating acrylic acid or pro-
pionic acid. Comparing the flexibility of the two compounds, the acrylic acid de-
rivatives are more rigid whereas the propionic acid derivatives are more flexible
(cf. Fig. 2). Furthermore, by introducing different substituents at the phenyl
rings a variety of compounds can be synthesised and pharmacological investi-
gated.
CO2H
R1 R2
CO2H
R1 R2
∗
Fig. 2: New proposals for hyaluronidases inhibitors
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2. Chemistry
The acrylic acids 5a-f were prepared by the Horner-Wadsworth-Emmons re-
action described in Scheme 1. The commercially available benzophenones 4a-f
were dissolved in tert-butanol and treated with triethyl phosphonoacetate and
tBuOK under reflux. The prepared esters were cleaved under basic conditions
with sodium hydroxide in methanol to get the corresponding acrylic acids 5a-f.
All unsymmetrical substituted compounds were obtained as mixtures of E/Z-
isomers.
O
R1 R
2
i, ii
R1 R2
CO2H
4a-f 5a-f
Scheme 1: Synthesis of the diphenylacrylic acids 5a-f; used reagents:
i) tBuOK, tBUOH, (EtO)2P(O)CH2CO2Et, ∆T; ii) NaOH, MeOH, ∆T;
The subsequent hydrogenation was carried out according to standard proce-
dures using either palladium on charcoal (Pd/C), 5 bar hydrogen pressure,
room temperature or Lindlar catalyst (Pd/CaCO3) and 1 bar hydrogen pressure
(Scheme 2). All unsymmetrical substituted compounds were obtained as race-
mates.
∗
CO2H
R2R1
i or ii
R1 R2
CO2H
5a-d 6a-d
Scheme 2: Synthesis of the diphenylpropionic acid derivatives 6a-d; used rea-
gents: i) Pd/C, MeOH, H2 5 bar, RT; ii) Pd/CaCO3, H2, RT;
No R1 R2
a F H
b F F
c CH3 H
d CF3 H
e Cl H
f Br Br
No R1 R2
a F H
b F F
c CH3 H
d CF3 H
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3. Pharmacological investigations
First, a series of diphenylpropionic acids 7-11 with hydroxy-, bromo and chloro
substituents at the phenyl rings and (4,4’-dichlorodiphenyl)acetic acid (12) were
examined. Their inhibitory effects on the bovine testicular hyaluronidase and on
the hyaluronate lyase at optimum pH (BTH 3.6, hylB4755 5.0) and physiological
pH (7.4) are summarised in Table 1.
Table 1: Inhibitory activities of the diphenylalkanoic acids 7-121 determined on
BTH and hylB4755 at different pH
X
R1 R2
7-12
No Substituents BTH hylB4755
IC50 [µM] or ( % Inhibition)
X R1 R2 pH 3.6 pH 7.4 pH 5.0 pH 7.4
7 CH2COOH H H 3200 inactivea 2200 8900
8 CH2COOH OH H inactivea inactivea inactivea inactivea
9 CH2COOH OH OH inactivea inactivea inactivea inactivea
10 CH2COOH Br H 200 5100 330 740
11 CH2COOH Cl Cl inactiveb inactivea 560 (79 %)c
12 COOH Cl Cl 400 8300 400 1600
a at concentrations ≤ 15 mM; b at concentrations ≤ 1.8 mM
c % inhibition of the enzyme at an inhibitor concentration of 2 mM
1 The compounds 7-12 were kindly provided from Dr. Ch. Hutzler, Institute of Pharmacy, Univer-
sity of Regenbsurg, Germany
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The IC50 values of the unsubstituted diphenylpropionic acid 7 were 3.2 mM for
the bovine testicular and 2.2 mM for the bacterial enzyme at optimum pH (BTH
pH 3.6, hylB4755 pH 5.0) and 8.9 mM for the hyaluronate lyases at physiological
pH. The introduction of one or two hydroxy groups at the phenyl rings (com-
pounds 8 and 9) led to a complete loss of the inhibitory activity. This observa-
tion was surprising, because earlier investigations of diverse compounds sug-
gested hat hydroxy groups may substantially contribute to an increase in in-
hibitory activity.
In contrast to hydroxylation (8, 9), the introduction of one bromo substituent at
the phenyl ring (compound 10) led to a more potent inhibitor for both hyaluro-
nidases. The IC50 values determined for compound 10 were 200 µM (BTH at
pH 3.6), 5.1 mM (BTH at pH 7.4), 330 µM (hylB4755 at pH 5.0) and 740 µM
(hylB4755 at pH 7.4) (cf. Table 1, Fig. 3). In comparison to the unsubstituted di-
phenylpropionic acid 7, the brominated derivative 10 showed a 7- to 16-fold
higher inhibition of the bacterial and the bovine testicular enzyme.
log c [M]
-4,5 -4,0 -3,5 -3,0 -2,5 -2,0 -1,5
Ac
tiv
ity
[%
]
0
20
40
60
80
100 BTH (pH 3.6)BTH ( pH 7.4)
hylB4755 (pH 5.0)
hylB4755 (pH 7.4)
Fig. 3: Inhibitory effect of 3-(4-bromophenyl)-3-phenylpropionic acid (10) on the
activity of BTH and hylB4755 at optimum and physiological pH
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The 4,4’-dichloro substitution of the phenyl rings (compound 11), led to a com-
plete loss of activity on the bovine testicular enzyme, whereas the IC50 value for
inhibition of the hyaluronate lyase at optimum pH (5.0) was 4-fold lower than for
compound 7. The inhibition of the bacterial enzyme at physiological pH was
79 % at a concentration of 0.89 mM, unfortunately, the IC50 value could not be
determined due to poor solubility at higher concentration.
The inhibitory effects of 4,4’-dichlorodiphenylacetic acid (12) are comparable
with the effects of the brominated diphenylpropionic acid (10). Compound 12 in-
hibited the hyaluronidases with IC50 values of 400 µM (BTH at pH 3.6), 8.3 mM
(BTH at pH 7.4), 400 µM (hylB4755 at pH 5.0) and 1.6 mM (hylB4755 at pH 7.4).
This results suggested that this class of substances was promising and worth-
while to be investigated in more detail. Apart from the importance of the con-
formational flexibility between C-2 and C-3, the influence of fluoro, trifluo-
romethyl and methyl substituents at the phenyl rings should be examined. The
conformational flexibility can be constrained for example, by double bond
between C-2 and C-3. Therefore, we synthesised diphenylacrylic acids and di-
phenylpropionic acids, with different substitution pattern.
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The synthesised diphenylacrylic acids 5a-f and propionic acids 6a-d were
tested for inhibition of the bovine testicular hyaluronidase and the bacterial
hyaluronidase using an optimised turbidimetric assay. The inhibitory activities of
the enzymes at optimum pH (BTH 3.6, hylB4755 5.0) and at physiological pH
(7.4) are summarised in Table 2.
Table 2: IC50 values of the diphenylacrylic acids 5a-f and the diphenylpropionic
acids 6a-d for the inhibition of BTH and hylB4755
R1 R2
CO2H
∗
R1 R2
CO2H
5a-f 6a-d
No Substituents BTH hylB4755
IC50 [µM] or ( % Inhibition)
R1 R2 pH 3.6 pH 7.4 pH 5.0 pH 7.4
5a F H inactivea inactivea 1600 inactivea
5b F F 1580 inactiveb 1410 3550
5c CH3 H 3160 (50 %)c 1120 7080
5d CF3 H (55 %)c (80 %)c (80 %)c 2000
5e Cl H 11200 14000 890 2200
5f Br Br 150 2660 260 330
6a F H 2820 inactiveb 1780 4470
6b F F 1600 inactivea 1200 (32 %)d
6c CH3 H inactivea inactivea 1260 (20 %)d
6d CF3 H 600 inactivea 380 780
a at concentrations ≤ 2 mM; b at concentrations ≤ 20 mM; c % inhibition of the enzyme
at an inhibitor concentration of 20 mM; d % inhibition of the enzyme at an inhibitor con-
centration of 2 mM
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The diphenylacrylic acids 5a-e were more active inhibitors of the bacterial en-
zyme than of the bovine testicular hyaluronidase. Whereas the monofluorinated
acrylic acid 5a inhibited only the bacterial enzyme (IC50 = 1.6 mM), the difluori-
nated compound 5b showed inhibition of both hyaluronidases with IC50 values
of 1.58 mM (BTH at pH 3.6), 1.41 mM (hylB4755 at pH 5.0) and 3.55 mM
(hylB4755 at pH 7.4). Compared to 5b, the trifluoromethylsubstituted diphenyl-
propionic acid 5d showed a weaker inhibition of the BTH (at pH 3.6 and 7.4)
and of the hylB4755 at pH 5.0 but a stronger inhibitory activity of hylB4755 at
physiological pH (IC50 value 2 mM). The inhibitory activities of 5c on the bovine
testicular and the bacterial hyaluronidase were similar to those of 5b. For the
chloro substituted compound 5e, IC50 values of 11.2 mM (BTH at pH 3.6),
14 mM (BTH at pH 7.4), 0.89 mM (hylB4755 at pH 5.0) and 2.2 mM (hylB4755 at
pH 7.4) were determined (cf. Table 2).
Within the series of the substituted diphenylacrylic acids, the highest inhibitory
activity on both the bovine testicular and the bacterial enzyme was found for the
dibrominated compound 5f. The IC50 values were 150 µM (BTH at pH 3.6),
2.66 mM (BTH at pH 7.4), 260 µM (hylB4755 at pH 5.0) and 330 µM (hylB4755 at
pH 7.4) (cf. Table. 2, Fig. 4). The acrylic acid 5f was a 1.3 - 2.25-fold more ac-
tive than the monobrominated compound acid 10. The introduction of the C=C
double bond and the introduction of a second bromo substituent on the phenyl
ring seem to enhance potency.
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Fig. 4: Effect of 4,4’-dibromodiphenylacrylic acid (5f) on the activities of the bo-
vine testicular and the bacterial hyaluronidase at their optimum pH and at the
physiological pH (7.4).
The inhibitory activities of the synthesised propionic acids 6a-c (cf. Table 2)
were in the same range for the bacterial hyaluronidase but different for the bo-
vine testicular enzyme. Whereas compound 6c was inactive on the BTH, the
compounds 6a and 6b showed inhibition in the millimolar range at optimum pH
(3.6). The determined IC50 values were 2.82 mM (6a) and 1.6 mM (6b). The
IC50 values for the inhibition of the bacterial hyaluronidase at optimum pH (5.0)
were 1.78 mM (14 a), 1.2 mM (6b) and 1.26 mM (6c). The inhibitory activity
seems to be independent of monofluor, difluor or methy substitution of the par-
ent compound.
Within the series of ring-substituted diphenylpropionic acids, compound 6d
(3-(4-trifluoromethylphenyl)-3-phenyl-propionic acid) was the most potent in-
hibitor of the bacterial enzyme at optimum (5.0) and physiological pH and of
BTH at optimum pH (3.6) (cf. Table 2). The IC50 values were 600 µM (BTH at
pH 3.6), 380 µM (hylB4755 at pH 5.0) and 780 µM (hylB4755 at pH 7.4). Interest-
ingly, the hydrogenation of the C=C double bond (5d vs. 6d) led to a consid-
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erably more potent compound on both the bovine testicular and the bacterial
enzyme. The inhibition curves of compound 6d are depicted in Fig. 5.
log c [M]
-4,5 -4,0 -3,5 -3,0 -2,5
Ac
tiv
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[%
]
0
20
40
60
80
100
BTH 3.6
BTH 7.4
hylB 5.0
hylB 7.4
Fig. 5: Inhibitory effect of 14 d on the activity of BTH and hylB4755 at different
pH values
In addition to the aforementioned diphenylalkanoic acids and diphenylalkenoic
acids, 3-(4-fluorophenyl)-3-pyridin-2-yl-propionic acid (15) and two symmetric
dibenzylacetic acids 14 and 15 were tested (cf. Table 3). The propionic acid 13
is a heterocyclic analogue of the synthesised derivative 6a. The replacement of
phenyl with pyridyl (compound 13) led to complete loss of activity on BTH at pH
3.6 and pH 7.4 (cf. Table 3) and to a decrease in inhibitory activity on hylB4755
at pH 5.0 and a complete loss of activity at the physiological pH (7.4).
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Table 3: Inhibition of 13-15 on the bovine testicular hyaluronidase and the hy-
aluronate lyase at optimum and physiological pH.
∗
CO2H
N
F
CO2H
∗
CO2H FF
∗
13 14 15
No BTH hylB4755
IC50 [µM] or ( % Inhibition)
pH 3.6 pH 7.4 pH 5.0 pH 7.4
13 inactivea inactivea (66 %)a inactivea
14 (79 %)b inactivec (82 %)b inactivec
15 1000 inactivec 1600 inactivec
a at concentrations ≤ 20 mM
b % inhibition of the enzyme at an inhibitor concentration of 2 mM
c at concentrations ≤ 2 mM
2-Benzyl-3-phenylpropionic acid (14) and 2-fluorobenzyl-3-fluorophenylpropi-
onic acid (15), structurally similar compounds to 3,3-diphenylpropionic acid (7)
and 3,3-bis(4-fluorophenyl)propionic acid (5b), showed weak or no inhibition of
the enzyme activity (cf. Table 3). Compound 14 at a concentration of 2 mM in-
hibited the bovine testicular hyaluronidase (pH 3.6) and the bacterial enzyme
(pH 5.0) by about 80 %. This compound was inactive on both enzymes at
physiological pH (7.4).
The obtained IC50 values of compound 15 were 1 mM for the bovine testicular
hyaluronidase at pH 3.6 and 1.6 mM for the bacterial enzyme at pH 5.0. The
inhibitory effect of compound 15 on BTH and hylB4755 was comparable to those
of the fluorinated diphenyl propionic acid 5b.
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4. Summary
A de novo design approach starting from the x-ray structures of bacterial hyalu-
ronate lyase and molecular modelling investigation, led to the discovery of first
lead structures with enzyme inhibitory activities in the millimolar range. The
structural modification of these compounds resulted in new hyaluronidase in-
hibitors: the diphenylacrylic and diphenylpropionic acids. Within the series of
the examined diphenylacrylic and diphenylpropionic acids, 3,3-bis-(4-bromo-
phenyl)-acrylic acid (5f), 3-(4-bromophenyl)-3-phenylpropionic acid (10) and
3-(4-trifluoromethyl-phenyl)-3-phenylpropionic acid (6d) were the most potent
inhibitors on the bovine testicular hyaluronidase and the bacterial enzyme (IC50
values (BTH/hylB4755): 150 µM / 260 µM, 200 µM / 330 µM and 660 µM /
380 µM, respectively).
Since the inhibitory activities of the new compounds were only in the low milli-
molar range additional structural modifications are necessary. Such modifi-
cation might be an introduction of e.g. alkyl chains, which increase the lipo-
philicity of the compounds, or inserting carbon chains between C-1 and C-3.
Earlier examinations indicated that carboxylic acids and hydroxy groups are
important for the solubility but also for better inhibitory activities, so that the in-
troduction of a second carboxylic group or/and a hydroxy group might increase
the potency. Nevertheless, additional molecular modelling studies with respect
to the binding mode could be helpful for further investigations.
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5. Experimental section
5.1 General conditions
For a detailed description of the general procedures, equipments and chemi-
cals used in the chemistry part, see section 4.1 of chapter 5.
5.2 Chemistry
5.2.1 Synthesis of the diphenylacrylic acids 5a-f
General procedure for the preparation of the acrylic acids
A solution of potassium tert-butylate (2 eq), triethyl phosphonoacetate (1 eq)
and the corresponding benzophenone (1 eq) in tert-butanol (100 ml) was stirred
and heated under reflux for 24 h. After evaporation of the solvent the residue
was treated with methanol (100 ml), water (50 ml) and sodium hydroxide (5 eq),
stirred and heated under reflux for 24 h again. The solvent was removed under
reduced pressure and the solid was diluted with water. After several extractions
with chloroform the aqueous solution was acidified with concentrated hydro-
chloric acid and extracted again with chloroform (4 x 70 ml). The last organic
layers were combined, dried over magnesium sulphate and the solvent was
removed under reduced pressure.
(EZ)-3-(4-Fluorophenyl)-3-phenylacrylic acid (5a)
Reaction of 4-fluorobenzophenone (1.00 g, 5.00 mmol) with triethyl phosphono-
acetate (1.12 g, 5.00 mmol); purification of the product by column chromatog-
raphy on silica gel eluting with a 1:4 (v/v) mixture of ethyl acetate and petroleum
ether 60-80 °C;
Yield: 1.99 g (8.22 mmol, 82 %, white solid)
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190
Mp: 127-129 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 6.36 / 6.37 (s, 1H, =CHCO2H), 7.13-7.23 (m, 4H, ph), 7.25-7.33 (m,
2H, ph), 7.35-7.41 (m, 3H, ph), 12.21 (s, 1H, COOH)
13C-NMR ([D6]DMSO):
δ [ppm] = 114.6 / 114.9 (+, ph), 115.2 / 115.5 (+, ph), 118.8 / 119.0 (+,
=CHCO2H), 127.8 / 127.9 (+, ph), 128.5 / 128.8 (+, ph), 129.3 (+, ph), 129.9 /
130.1 (+, ph), 131.0 / 131.1 (+, ph), 134.9 / 135.0 (Cquart, ph), 136.8 /136.9
(Cquart, ph), 152.4 / 152.8 (Cquart, C=CHCO2H), 161.8 (Cquart, 1JC,F = 244.7 Hz,
=CF), 162.5 (Cquart, 1JC,F = 247.9 Hz, =CF), 166.6 / 166.6 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 242 ([M•+], 100), 241 ([M-H]+, 77), 225 ([M-
OH]+, 17), 197 ([M-CO2H]+, 35), 196 ([M-CO2H-H]+, 67)
IR [cm-1]: 3100 (O-H) carboxylic acid, 2930 (C-H) aromatic, 1690 (C=O), 1599
(C=C), 1415 δ(C-H), 1212 (C-O), 1157 (C-F), 837, 775, 697, 617
Analysis:
calculated C: 73.29 H: 4.58
found C: 73.28 H: 4.23
C15H11FO2 • 0.2 H2O (245.83)
3,3-Bis(4-fluorophenyl)acrylic acid (5b)
Reaction of 4,4’-difluorobenzophenone (2.18 g, 10.00 mmol) and triethyl phos-
phonoacetate (2.24 g, 10.00 mmol); recrystallisation of the product from a 2:1
(v/v) mixture of petroleum ether 60-80 °C and dichloromethane;
Yield: 1.48 g (5.69 mmol, 57 %, white crystalline solid)
Mp: 124-127 °C [Li.: 146 °C (Bergmann et al. 1948)]
Diphenylacrylic acids and diphenylpropionic acids
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1H-NMR ([D6]DMSO):
δ [ppm] = 6.26 (s, 1H, =CHCO2H), 6.98-7.10 (m, 4H, ph), 7.13-7.20 (m, 2H, ph),
7.21-7.29 (m, 2H, ph), 7.33-8.36 (br, 1H, COOH)
13C-NMR ([D6]DMSO):
δ [ppm] = 115.0 (+, =CHCO2H), 115.3 (+, ph), 115.5 (+, ph), 115.7 (+, ph),
116.3 (+, ph), 130.4 (+, ph), 130.5 (+, ph), 131.2 (+, ph), 131.3 (+, ph), 134.0
(Cquart, 4JC,F = 3.7 Hz, C-1), 137.0 (Cquart, 4JC,F = 3.0 Hz, C-1´), 157.1 (Cquart,
C=CHCO2H), 163.0 (Cquart, 1JC,F = 248.3 Hz, C-F), 163.8 (Cquart, 1JC,F = 251.2
Hz, C-F), 170.7 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 260 ([M•+], 100), 259 ([M-H]+, 36), 215 ([M-
CO2H]+, 28), 214 ([M-CO2H-H]+, 47)
IR [cm-1]: 3100 (O-H) carboxylic acid, 2934 (C-H) aromatic, 1691 (C=O), 1598
(C=C), 1418 (C-H), 1209 (C-O), 1156 (C-F), 900, 837, 804, 683
Analysis:
calculated C:  69.23 H:  3.87
found C:  69.28 H:  4.17
C15H10F2O2 (260.23)
(EZ)-3-(4-Methylphenyl)-3-phenylacrylic acid (5c)
Reaction of 4-methylbenzophenone (1.96 g, 10.00 mmol) and triethyl phospho-
noacetate (2.24 g, 10.00 mmol); recrystallisation of the product from a 2:1 (v/v)
mixture of petroleum ether 60-80 °C and dichloromethane;
Yield: 2.16 g (9.06 mmol, 91 %, white solid)
Mp: 120-123 °C
Diphenylacrylic acids and diphenylpropionic acids
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1H-NMR ([D6]DMSO):
δ [ppm] = 2.30 / 2.34 (s, 3H, CH3), 6.30 / 6.33 (s, 1H, =CHCO2H), 7.00-7.07 (m,
1H, ph), 7.09-7.21 (m, 4H, ph), 7.22-7.30 (m, 1H, ph), 7.32-7.43 (m, 3H, ph),
12.12 (s, 1H, COOH)
13C-NMR ([D6]DMSO):
δ [ppm] = 20.7 / 20.8 (+, CH3), 117.7 / 118.5 (+, =CHCO2H), 127.7 (+, ph),
127.8 (+, ph), 127.9 (+, ph), 128.8 (+, ph), 128.8 (+, ph), 128.9 (+, ph), 128.9 (+,
ph), 129.0 (+, ph), 129.1 (+, ph), 135.8 (Cquart, ph), 137.2 / 137.6 (Cquart, ph),
138.9 / 140.8 (Cquart, ph), 153.7 / 153.8 (Cquart, C=CHCO2H), 166.7 / 166.8
(Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 238 ([M•+], 100), 237 ([M-H]+, 50), 221 ([M-
OH]+, 15), 193 ([M-CO2H]+, 20), 178 ([M-CO2H-CH3]+, 34)
IR [cm-1]: 3100 (O-H) carboxylic acid, 2916 (C-H) aromatic, 1692 (C=O), 1594
(C=C), 1493 (C-H), 1351 (C-H), 1205 (C-O), 877, 822, 775, 731, 698,685
Analysis:
calculated C:  80.65 H:  5.92
found C:  80.15 H:  5.84
C16H14O2 (238.29)
(EZ)-3-(4-Trifluoromethylphenyl)-3-phenylacrylic acid (5d)
Reaction of 4-trifluoromethylbenzophenone (2.50 g, 10.00 mmol) and triethyl
phosphonoacetate (2.24 g, 10.00 mmol); recrystallisation of the product from a
2:1 (v/v) mixture of petroleum ether 60-80 °C and dichloromethane;
Yield: 2.75 g (9.41 mmol, 94 %, white solid)
Mp: 153-155 °C
Diphenylacrylic acids and diphenylpropionic acids
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1H-NMR ([D6]DMSO):
δ [ppm] = 6.48 (s, 1H, =CHCO2H), 7.24-7.32 (m, 2H, ph), 7.34-7.43 (m, 5H, ph),
7.72-7.79 (m, 2H, ph), 12.32 (s, 1H, COOH)
13C-NMR ([D6]DMSO):
δ [ppm] = 119.6 (+, C=CHCO2H), 121.1 (+, ph), 124.2 (Cquart, 1JC,F = 272.1 Hz,
CF3), 124.7 (+, 3JC,F = 3.8 Hz, CCH(CF3), 125.3 (+, ph), 127.7 (+, ph), 128.1
(Cquart, 2JC,F = 31.8 Hz, C(CF3)), 128.6 (+, ph), 128.9 (+, ph), 129.5 (+, ph),
129.7 (+, ph), 139.4 (Cquart, ph), 143.3 (Cquart, ph), 152.5 (Cquart, C=CHCO2H),
166.3 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 292 ([M•+], 100), 291 ([M-H]+, 81), 275 ([M-
OH]+, 15), 247 ([M-CO2H]+, 23), 178 ([M-CO2H-CF3]+, 27)
IR [cm-1]: 3100 (O-H)  carboxylic acid, 2981 (C-H) aromatic, 1681 (C=O), 1624
(C=C), 1408 (C-H), 1330 (C-F), 1206 (C-O), 1117, 1067, 835, 774, 694, 641
Analysis:
calculated C:  65.76 H:  3.79
found C:  65.96 H:  4.10
C16H11F3O2 (292.26)
(EZ)-3-(4-Chlorophenyl)-3-phenylacrylic acid (5e)
Reaction of 4-chlorobenzophenone (3.40 g, 10.00 mmol) and triethyl phospho-
noacetate (2.24 g, 10.00 mmol); recrystallisation of the product from a 2:1 (v/v)
mixture of petroleum ether 60-80 °C and dichloromethane;
Yield: 2.25 g (8.70 mmol, 87 %, white solid)
Mp: 139-140 °C
Diphenylacrylic acids and diphenylpropionic acids
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1H-NMR ([D6]DMSO):
δ [ppm] = 6.39 (s, 1H, =CHCO2H), 7.12-7.20 (m, 2H, ph), 7.24-7.31 (m, 2H,
ph), 7.33-7.42 (m, 3H, ph), 7.42-7.48 (m, 2H, ph), 12.27 (s, 1H, COOH)
13C-NMR ([D6]DMSO):
δ [ppm] = 119.2 / 119.4 (+, =CHCO2H), 127.8 (+, ph), 127.9 (+, ph), 127.9 (+,
ph), 128.5 (+, ph), 128.5 (+, ph), 128.8 (+, ph), 129.3 (+, ph), 129.6 (+, ph),
130.8 (+, ph), 132.5 / 133.9 (Cquart, ph), 137.6 / 138.3 (Cquart, ph), 139.3 / 139.9
(Cquart, ph), 152.0 / 152.6 (Cquart, C=CHCO2H), 166.4 / 166.5 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 258 ([M•+], 100), 257 ([M-H]+, 56), 241 ([M-
OH]+, 15)
IR [cm-1]: 3100 (O-H)  carboxylic acid, 3006 (C-H) aromatic, 1690 (C=O), 1610
(C=C), 1408 (C-H), 1212 (C-O), 1085 (C-Cl), 833, 768, 723, 696, 612
Analysis:
calculated C:  69.64 H:  4.29
found C:  69.38 H:  4.14
C21H16O4 (332.35)
3,3-Bis(4-bromophenyl)acrylic acid (5f)
Reaction of 4,4’-dibromobenzophenone (3.40 g, 10.00 mmol) and triethyl phos-
phonoacetate (2.24 g, 10.00 mmol); recrystallisation of the product from a 2:1
(v/v) mixture of petroleum ether 60-80 °C and dichloromethane;
Yield: 3.00 g (7.85 mmol, 79 %, white solid)
Mp: 170-171 °C [Lit.: 190 - 191 °C (Bergmann et al. 1948)]
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1H-NMR ([D6]DMSO):
δ [ppm] = 6.43 (s, 1H, =CHCO2H), 7.09-7.13 (m, 2H, phenyl), 7.19-7.24 (m, 2H,
ph), 7.55-7.61 (m, 4H, ph), 12.34 (s, 1H, COOH)
13C-NMR ([D6]DMSO):
δ [ppm] = 119.7 (+, =CHCO2H), 121.4 (Cquart, ph), 122.8 (Cquart, ph), 129.8 (+,
ph), 130.9 (+, ph), 131.0 (+, ph), 131.5 (+, ph), 137.5 (Cquart, ph), 139.0 (Cquart,
ph), 151.3 (Cquart, C=CHCO2H), 166.3 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 381 ([M•+], 100), 364 ([M-OH]+, 8), 303 ([M-
Br]+, 3), 256 ([M-Br-CO2H]+, 20)
IR [cm-1]: 3100 (O-H)  carboxylic acid, 2921 (C-H) aromatic, 1692 (C=O), 1610
(C=C), 1581 (C=C), 1413 (C-H), 1210 (C-O), 1073 (C-Br), 1010, 827, 765, 714
Analysis:
calculated C:  47.15 H:  2.64
found C:  46.94 H:  2.60
C15H10Br2O2 (382,07)
6.2.2 Synthesis of the diphenylpropionic acids 6a-d
(RS)-3-(4-Fluorophenyl)-3-phenylpropionic acid (6a)
3-(4-Fluorophenyl)-3-phenylacrylic acid (1.0 g, 4.13 mmol) was dissolved in
methanol (40 ml), treated with a catalytic amount (75 mg) of palladium on char-
coal (10 % Pd/C) and stirred at room temperature under a hydrogen atmos-
phere (5 bar) for 24 h. Afterwards, the reaction mixture was filtrated and the
solvent was removed under reduced pressure. The product was recrystallised
from a 2:1 (v/v) mixture of petroleum ether 60-80 °C and dichloromethane.
Yield: 0.9 g (3.68 mmol, 89 %, white crystalline solid)
Mp: 92-94 °C
Diphenylacrylic acids and diphenylpropionic acids
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1H-NMR (CDCl3):
δ [ppm] = 3.02 (dd, 1H, 3J = 8.1 Hz, 2J = 16.0 Hz, -CHCH2-), 3.08 (dd, 1H, 3J =
7.7 Hz, 2J = 16.0 Hz, -CH2-), 4.50 (dd, 1H, 3J = 7.7 Hz, 3J = 8.1 Hz, -CHCH2),
6.91-7.00 (m, 2H, ph), 7.14-7.30 (m, 7H, ph), 7.52 (br, 1H, COOH)
13C-NMR (CDCl3):
δ [ppm] = 40.5 (-, -CHCH2-), 45.9 (+, -CHCH2-), 115.3 (+, ph), 115.6 (+, ph),
126.8 (+, ph), 127.5 (+, ph), 128.7 (+, ph), 129.1 (+, ph), 129.2 (+, ph), 138.9
(Cquart, 4JC,F = 3.7 Hz, C-1), 143.0 (Cquart, ph), 161.6 (Cquart, 1JC,F= 245.1 Hz, C-
4), 177.4 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 244 ([M•+], 29), 185 ([M-CH2CO2H]+, 100)
IR [cm-1]: 3100 (O-H) carboxylic acid, 3033 (C-H) aromatic, 2910 (C-H) ali-
phatic, 1702 (C=O), 1413 (C-H), 1307 (C-H), 1210 (C-O), 1162 (C-F), 914, 837,
799, 745, 715, 698
Analysis:
calculated C:  73.76 H:  5,36
found C:  73.68 H:  5.35
C15H13FO2 (244.27)
3,3-Bis(4-fluorophenyl)propionic acid (6b)
3,3-Bis(4-fluorophenyl)acrylic acid (1.59 g, 6.11 mmol) was dissolved in ethanol
(40 ml), treated with a catalytic amount (100 mg) of Lindlar catalyst (5 %
Pd/CaCO3) and stirred at room temperature under a hydrogen atmosphere for
24 h. After filtration, the solvent was removed under reduced pressure and the
product was purified first by column chromatography on silica gel eluting with a
4:1 (v/v) mixture containing petroleum ether 60-80 °C and chloroform and then
by recrystallisation from a 2:1 (v/v) mixture of petroleum ether 60-80 °C and
dichloromethane.
Diphenylacrylic acids and diphenylpropionic acids
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Yield: 1.46 g ( 5.57 mmol, 92 %, white crystalline solid)
Mp: 103-105°C [Lit.: 107 - 108 °C (Bergmann et al. 1948)]
1H-NMR ([D6]DMSO):
δ [ppm] = 3.02 (d, 2H, 3J = 8.0 Hz, CHCH2CO2H), 4.46 Hz (t, 1H, 3J = 8.0 Hz,
CHCH2CO2H), 7.05-7.15 (m, 4H, ph), 7.32-7.41 (m, 4H, ph), 12.17 (s, 1H,
CO2H)
13C-NMR ([D6]DMSO):
δ [ppm] = 39.7 (-,CHCH2CO2H), 45.0 (+, CHCH2CO2H), 114.9 (+, ph), 115.1 (+,
ph), 129.2 (+, ph), 129.3 (+, ph), 140.2 (Cquart, ph), 140.2 (Cquart, ph), 160.6
(Cquart, 1JC,F = 242.5 Hz, C-F), 172.5 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 262 ([M•+], 20), 203 ([M-CO2H]+, 100), 201
([M-2H]+, 125), 183 ([M-H-F]+, 33)
IR [cm-1]: 3100 (O-H)  carboxylic acid, 3064 (C-H) aromatic, 2907 (C-H) ali-
phatic, 1700 (C=O), 1410 (C-H), 1266-1214 (C-O), 1159, 1104, 828, 791, 756,
717, 671
Analysis:
calculated C: 66.41 H: 4.64
found C: 66.54 H: 4.65
C15H12F2O2 (262.25)
(RS)-3-(4-Methylphenyl)-3-phenylpropionic acid (6c)
3-(4-Methylphenyl)-3-phenylacrylic acid (0.50 g, 2.08 mmol) in ethanol (40 ml)
was treated with a catalytic amount (50 mg) of Lindlar catalyst (5 % Pd/CaCO3)
and stirred at room temperature under a hydrogen atmosphere for 24 h. After-
wards, the reaction mixture was filtrated, the solvent was removed under re-
duced pressure and the pure product was dried in vacuo.
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Yield: 0.48 g (2.00 mmol, 96 %, white solid)
Mp: 123-125 °C
1H-NMR ([D6]DMSO):
[ppm] = 2.22 (s, 3H, CH3), 2.98 (d, 2H, J = 7.96 Hz, -CHCH2-), 4.37 (t, 1H, J =
7.96 Hz, -CHCH2-), 7.03-7.10 (m, 2H, ph), 7.11-7.32 (m, 7H, ph), 12.12 (br, 1H,
COOH)
13C-NMR ([D6]DMSO):
[ppm] = 20.4 (+, CH3), 40.2 (-, -CHCH2-), 46.2 (+, -CHCH2-), 126.0 (+, ph),
127.3 (+, ph), 127.3 (+, ph), 128.2 (+, ph), 128.8 (+, ph), 135.1 (Cquart, ph),
141.1 (Cquart, ph), 144.3 (Cquart, ph), 172.6 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 240 ([M•+], 34), 181 ([M-CH2CO2H]+, 100),
166 ([M-CH2CO2H-CH3]+, 16), 165 ([M-CH2CO2H-CH3-H]+, 20)
IR [cm-1]: 3100 (O-H)  carboxylic acid, 3026 (C-H) aromatic, 2913 (C-H) ali-
phatic, 2622 (C-H) aliphatic, 1695 (C=O), 1417 δ(C-H), 1223 (C-O), 944, 821,
741, 698, 612
Analysis:
calculated C: 79.97 H: 6.71
found C: 79.95 H: 6.91
C16H16O2 (240.31)
(RS)-(-3-(4-Trifluoromethylphenyl)-3-phenyl-propionic acid (6d)
3-(4-Trifluoromethylphenyl)-3-phenylacrylic acid (0.25 g, 0.86 mmol) in ethanol
(20 ml) was treated with a catalytic amount (50 mg) of Lindlar catalyst (5 %
Pd/CaCO3) and stirred at room temperature under a hydrogen atmosphere for
24 h. Afterwards, the reaction mixture was filtrated, the solvent was removed
under reduced pressure and the pure product was dried in vacuo.
Diphenylacrylic acids and diphenylpropionic acids
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Yield: 0.24 g (0.82 mmol, 95 %, white solid)
Mp: 79-81 °C
1H-NMR ([D6]DMSO):
δ [ppm] = 3.06 (m, 1H, CHCH2), 3.13 (m, 1H, CHCH2), 4.54 (m, 1H, CHCH2),
7.14-7.24 (m, 1H, ph), 7.24-7.39 (m, 4H, ph), 7.53-7.68 (m, 4H, ph), 12.23 (br,
1H, COOH)
13C-NMR ([D6]DMSO):
δ [ppm] = 40.2 (-, CHCH2), 46.3 (+, CHCH2), 124.2 (Cquart, 1JC,F = 272.0 Hz,
CF3), 125.2 (+, 4JC,F = 3.7 Hz, C=C(CF3), 126.4 (+, ph), 126.9 (Cquart, 3JC,F =
31.7 Hz, C(CF3)), 127.5 (+, ph), 128.3 (+, ph), 128.5 (+, ph), 143.2 (Cquart, ph),
148.9 (Cquart, ph), 172.4 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 294 ([M•+], 33), 275 ([M-F]+, 5), 235 ([M-
CH2CO2H]+, 100)
IR [cm-1]: 3100 (O-H)  carboxylic acid, 3028 (C-H) aromatic, 2873 (C-H) ali-
phatic, 2595 (C-H) aliphatic, 1707 (C=O), 1421 (C-H), 1326 (C-F), 1208 (C-O),
1017, 959, 865, 741, 699, 615
Analysis:
calculated C: 65.30 H: 4.45
found C: 65.59 H: 4.78
C16H13F3O2 (294.28)
2-Benzyl-3-phenylpropionic acid (14)
Crude 2-benzyl-3-phenylpropionic acid was kindly provided by Dr. Fabien Leur-
quin. The compound was purified by recrystallisation from a 2:1 (v/v) mixture of
petroleum ether 60-80 °C and dichloromethane.
Mp: 68-70 °C
Diphenylacrylic acids and diphenylpropionic acids
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1H-NMR ([D6]DMSO):
δ [ppm] = 2.73-2.90 (m, 5H, CH2CHCH2), 7.16-7.21 (m, 6H, ph), 7.25-7.31 (m,
4H, ph), 12.12 (s, 1H, COOH)
13C-NMR ([D6]DMSO):
δ [ppm] = 37.6 (-, CH2CHCH2), 48.6 (+, CH2CHCH2), 126.1 (+, ph), 128.1 (+,
ph), 128.7 (+, ph), 139.2 (Cquart, ph), 175.4 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 240 ([M•+], 50), 149 ([M-C7H7]+, 79), 131 ([M-
C7H7-H2O]+, 44), 91 ([C7H7]+, 100)
IR [cm-1]: 3100 (O-H) carboxylic acid, 3020 (C-H) aromatic, 2962 (C-H) ali-
phatic, 1700 (C=O), 1420 (C-H), 1259 (C-O), 1017, 797, 745, 694
Analysis:
calculated C: 79.97 H: 6.71
found C: 79.88 H: 7.09
C16H16O2 (240.30)
2-(4-Fluorobenzyl)-3-(4-fluorophenyl)propionic acid (15)
Crude 2-(4-fluorobenzyl)-3-(4-fluorophenyl)propionic acid was kindly provided
by Dr. Fabien Leurquin. The compound was purified by recrystallisation from a
2:1 (v/v) mixture of petroleum ether 60-80 °C and dichloromethane.
Mp: 92-94 °C
1H-NMR (CDCl3):
δ [ppm] = 2.67-2.84 (m, 2H, CHCH2), 2.85-2.92 (m, 2H, CHCH2), 2.93-3.03 (m,
1H, CHCH2), 6.91-7.07 (m, 4H, ph), 7.06-7.12 (m, 4H, ph), 7.36 (br, 1H, COOH)
Diphenylacrylic acids and diphenylpropionic acids
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13C-NMR (CDCl3):
δ [ppm] = 36.9 (-, CHCH2), 50.00 (+, CHCH2), 115.2 (+, ph), 115.5 (+, ph),
130.3 (+, ph), 130.4 (+, ph), 134.1 (Cquart, ph), 134.2 (Cquart, ph), 161.7 (Cquart,
1JC,F = 244.7 Hz, C-F), 180.3 (Cquart, C=O)
MS (PI-EIMS (70 eV)): m/z (%) = 276 ([M•+], 27), 109 ([FC6H4CH]+, 100)
IR [cm-1]: 3100 (O-H)  carboxylic acid, 3015 (C-H) aromatic, 2900 (C-H) ali-
phatic, 1713 (C=O), 1506 (C=C), 1454 (C-H), 1210 (C-O), 1175 (C-F), 834, 734
Analysis:
calculated C: 69.56 H: 5.11
found C: 69.52 H: 5.28
C16H14F2O2 (276.28)
5.3 Pharmacological methods
The inhibitory effect of the diphenyl derivatives on the activities of hyaluroni-
dases were determined by a turbidimetric assay according to the method of Di
Ferrante (Di Ferrante 1956) described in chapter 3.
Diphenylacrylic acids and diphenylpropionic acids
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Chapter 9
Indole derivatives as hyaluronidase inhibitors
synthesis, pharmacology and binding mode elu-
cidation by X-ray analysis of an enzyme-inhibitor
complex
1. Introduction
Starting from crystal structures of two homologous bacterial lyases (Streptococ-
cus pneumoniae (Ponnuraj et al. 2000) and S. agalactiae 3502 hylB3502 (Li et al.
2001); sequence identity: 70 %), a structure-based strategy for designing in-
hibitors of bacterial hyaluronan lyases (S. agalactiae, hylB4755) was followed.
From the results of LUDI calculations (Accelrys Inc. (Böhm 1992)), using the
LeadQuest® databases Vol. 1&2 (Tripos 2000), promising compounds were
selected and pharmacological investigations were carried out (cf. chapter 7).
One of the compounds suggested by LUDI was indole-2-carboxylic acid (1) (cf.
Fig. 1). A LUDI score of 328 was calculated for compound 1 corresponding to a
Ki value of about 1 mM.
N
H
CO2H
1
Fig. 1: Structure of indole-2-carboxylic acid
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The measured IC50 values of the indole derivative 1 were 7.1 mM on the bovine
testicular enzyme at optimum pH (3.6) and 3.55 mM on the bacterial hyaluroni-
dase at optimum pH (5.0). The concentration-dependent effect of indole-2-
carboxylic acid on BTH and on hylB4755 are depicted in Fig. 2. The IC50 value of
compound 1 determined on the hyaluronate lyase is in agreement with the pre-
dicted value (LUDI score).
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Fig. 2: Inhibitory effect of indole-2-carboxylic acid (1) on the bovine testicular
hyaluronidase and on the hyaluronate lyase from S. agalactiae at optimum pH
Indole-2-carboxylic acid was a first lead with millimolar enzyme inhibitory activ-
ity predicted by a de novo design approach and molecular modelling investiga-
tions. Starting from these results structurally related indole derivatives were in-
vestigated.
2. Chemistry
All 2-phenylindole derivatives were synthesised according to the method of
Bischler and Brown (Bischler 1892; Brown 1972). Hydroxy substituted com-
pounds were expected to have higher inhibitory potential. Because of their high
reactivity, these compounds were liberated by cleavage of corresponding
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methyl ethers at the end of the synthetic route. Starting materials for the indole
synthesis were 4’-methoxypropiophenone (2a) or 4’-methoxyacetophenone
(2b). Both compounds were converted into the corresponding bromo com-
pounds 3a and 3b by direct bromination. Acid catalysis prevented a multiple
bromination at the aliphatic carbon atom and bromination at the phenyl ring
(Rival et al. 1992). The final ring closure was achieved at high temperature
(175 °C) with the corresponding ring-substituted aniline in presence of N,N-di-
methylaniline (cf. Scheme 1). The use of a two-fold excess of aniline increased
the yields up to 34 % - 66 %. The mechanism was described by Bischler and
Borsche (Bischler 1893; Borsche et al. 1908) as a multi-step reaction. In the
first step, the brominated phenone reacts with one aniline molecule via a nu-
cleophilic substitution to an α-aminoketone. This α-aminoketone is converted to
a Schiff's base after nucleophilic addition of a second aniline molecule to the
carbonyl group and subsequent condensation reaction. The final cyclisation of
the endiamine takes place under displacement of the “first” aniline molecule
after 1,3-H-shift to give the corresponding 2-phenylindole.
O
R1
H3CO H3CO
O
R1
Br
Br2, dioxane, CH2Cl2, RT
Br2, CH3CO2H, HBr; Rt
or
2a,b 3a,b
NH2
R2
N,N-dimethylaniline
xylene, 175 °C
N
H
OCH3R
2
R1
4a-c
Scheme 1: Synthesis of the phenylindole derivatives 4a-c
No R1 R2
a H 5-OCH3
b CH3 5-OCH3
c CH3 6-OCH3
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The N-substitution of the indoles were carried out according to standard proce-
dures. The 2-phenylindoles 5a-d were prepared by treating the 2-phenylindole
4b with sodium hydride in dimethylformamide and the corresponding alkyl halo-
gen via a nucleophilic substitution (cf. Scheme 2).
N
H
OCH3 N
OCH3
CH3
R
NaH / DMF
RI
H3CO H3CO
CH3
65-99 %
4b 5a-d
Scheme 2: Alkylation of the 2-phenylindole derivative 4b
The cleavage of the methyl ether was carried out with BBr3 in anhydrous dichlo-
romethane. Boron tribromide as a Lewis acid forms a complex with the ether
oxygen, which is hydrolysed to the desired hydroxy compound, boronic acid
and two molecules of hydrogen bromide (McOmie et al. 1968) (Scheme 3).
N
OH
R2
R1
R3
BBr3 / CH2Cl2
N
OCH3
R2
R1
R3
65-99 %
4a-c, 5a-d 6a-g
Scheme 3: Cleavage of the methyl ether with boron tribromide
No 5a 5b 5c 5d
R CH3 C3H7 C5H11 C7H15
No R1 R2 R3
6a H 5-OH H
6b CH3 6-OH H
6c CH3 5-OH H
6d CH3 5-OH CH3
6e CH3 5-OH C3H7
6f CH3 5-OH C5H11
6g CH3 5-OH C7H15
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3. Pharmacological investigations
The widely used method for the determination of an inhibitory activity on hyalu-
ronidases is the Morgan-Elson assay. This colorimetric assay is based on the
reaction of N-acetyl-D-glucosamine at the reducing ends with N,N-dimethyl-
aminobenzaldehyde (Ehrlich reagent) to give a red coloured product (Hynes et
al. 1994; Muckenschnabel et al. 1998). This method could not be used for the
examination of the indole derivatives because the Ehrlich’s reagent is well
known to react with indole rings (cf. for example Van-Urk reaction (Dibbern et
al. 1963)). N,N-Dimethylaminobenzaldehyde reacts with the indole moiety ei-
ther in position 2 or in position 3 to the corresponding alcohol as intermediate.
After elimination of water under acidic conditions a coloured product (cyanine)
is formed. This product is also detectable at 590 nm like the coloured product of
the Morgan-Elson reaction. As the colorimetric assay could not be applied, all
indole derivatives were investigated for hyaluronidase inhibition with a turbidi-
metric assay according to the method of Di Ferrante described in chapter 3.
Starting from the results of compound 1, the structurally related compounds 1,
7-15 were investigated. The inhibitory effect of these compounds are summa-
rised in Table 1.
The inhibitory effect of unsubstituted indole (7) on the bovine testicular and on
the bacterial hyaluronidase was lower than the inhibition by indole-2-carboxylic
(1) acid. The IC50 values of compound 7 determined on BTH and hylB4755 were
in the millimolar range (cf. Table 1). The shift of the carboxylic acid from posi-
tion 2 to position 3 (cf. compound 8) led to a complete loss of activity for the
bovine testicular enzyme. The IC50 value of compound 8 determined on the
bacterial hyaluronidase at optimum pH (5.0) was comparable to that of com-
pound 1, namely 3 mM (cf. Table 1). Obviously, the presence and the position
of the carboxylic group is not crucial for the inhibition of the hyaluronate lyase,
since the inhibitory effects of all three compounds were similar. By contrast,
concerning inhibition of the bovine testicular hyaluronidase, the shift of the car-
boxylic acid from position 2 to 3 led to a complete loss of activity, whereas the
lack of the carboxylic group resulted only in about two-fold decrease in activity.
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Table 1: Inhibitory activities of the indole derivatives 1 and 7-15 determined on
the bovine testicular hyaluronidase (BTH) and the bacterial enzyme (hylB4755)
No Structure BTH hylB4755
IC50 [µM] or (% Inhibition)
pH 3.6 pH 7.4 pH 5.0 pH 7.4
1 N
H
CO2H 7000 inactive a 4000 inactive a
7 N
H
14100 22400 7100 5600
8
N
H
CO2H
inactive a inactive a 3000 inactive a
9
N
H
CO2H
inactive a inactive a 4000 inactive a
10
N
H
CO2H
H3CO
CH3 inactiveb inactiveb inactiveb inactiveb
11
N
H
CO2H
inactive a inactive a 3500 (76 %)c
12
N
H
CO2H
inactive a inactive a 2200 (28 %) c
13
N
H
CH3
O
inactive a inactive a 24000 15800
14
N
H
NH2
O
inactive a inactive a (45 %) c (30 %) c
15 N
CO2H
CH3
H3CO
O
Cl
540 5490 350 1140
a at concentrations ≤ 20 mM; b at concentrations ≤ 2 mM; c % inhibition of the enzyme at an
inhibitor concentration of 2 mM;
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The introduction of an additional methylene group between the carboxylic acid
as in compound 9 did not lead to significant differences in inhibitory activity
compared to the lower homologue 8. Additional methyl and methoxy substitu-
tion in the positions 2 and 5 (cf. compound 10) led to a complete loss of activity.
The compounds 11 and 12 were inactive on the bovine testicular enzyme at
optimum and physiological pH, whereas the IC50 values on the bacterial hyalu-
ronidase at optimum pH (5.0) were similar to that of compound 1: 3.5 mM (11)
and 2.2 mM (12) (cf. Table 1), i.e. homologisation of the side chain to 3 or 4
carbon atoms (cf. compounds 11 and 12) did not lead to increase of the inhibi-
tory activity.
3-Acetylindole (13) induced a concentration-dependent inhibition of the hyalu-
ronate lyase. The calculated IC50 values were 24 mM at pH 5.0 and 15.8 mM at
pH 7.4 (cf. Table 1). Whereas 3-acetylindole showed a complete inhibition of
the bacterial hyaluronidase, indole-3-carboxamide (14) induced only a weak
inhibition of hylB4755 by 45 % at pH 5.0 and 30 % at pH 7.4 at a concentration of
2 mM. Both indole derivatives were inactive on the bovine testicular hyaluroni-
dase at both pH values.
The N-benzoyl derivative of compound 10, indomethacin (15) proved to be the
most potent inhibitor of this series. The IC50 values of compound 15 on the bo-
vine testicular enzyme were 540 µM at optimum pH (3.6) and 5.49 mM at
physiological pH. The IC50 values for the inhibition of the bacterial hyaluroni-
dase were 350 µM at optimum pH (5.0) and 1.14 mM at physiological pH (7.4)
(cf. Table 1). The inhibition curves of indomethacin are depicted in Fig. 3.
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Fig. 3: Inhibitory effects of indomethacin (15) on BTH and hylB4755 at optimum
pH (3.6 and 5.0, respectively) and physiological pH (7.4).
Compared to the structure suggested by LUDI calculations, compound 1, the
analagues with lipophilic substituents like phenyl and methyl were 13- and
11-fold more potent inhibitors of the bovine testicular hyaluronidase and the
hyaluronate lyase, respectively.
In parallel to the compounds 1 and 7-15, the inhibitory effects of the 2-phen-
ylindole derivatives 16-271 and 4b on the bovine testicular and the bacterial
hyaluronidases were investigated. The tested 2-phenylindole derivatives 16-27
and 4b possess various functional groups like hydroxy, methoxy, methyl and
sulphamoyloxy groups in positions 3, 4’, 5 and 6 and diverse N-substituents.
The structures of the examined phenylindole derivatives and their inhibitory ef-
fects on BTH and hylB4755 are summarised in Table 2 and Table 3.
1 The compounds 16-25 were kindly provided from Prof. Dr. E. von Angerer, Institute of Phar-
macy, University of Regensburg, Germany
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Table 2: Inhibitory effects of 2-phenylindole derivatives 16-22 on BTH and
hylB4755 at optimum and physiological pH.
No Structure BTH hylB4755
% Inhibition at Concentration [mM]a
pH 3.6 pH 7.4 pH 5.0 pH 7.4
16 NH2NO2SO
OSO2NH2
(CH3)4
N
CH3
inactive
(≤ 1)
inactive
(≤ 1)
inactive
(≤ 1)
inactive
(≤ 1)
17 NH2NO2SO
OSO2NH2
(CH2)4
ON
H3C
(CH2)6(CF2)3CF3
CH3
inactive
(≤ 1)
inactive
(≤ 1)
inactive
(≤ 1)
inactive
(≤ 1)
18 NH2NO2SO
OSO2NH2
(CH3)4
N
(CH2)6(CF2)3CF3H3C
CH3
inactive
(≤ 2)
12 %
(2)
inactive
(≤ 2)
19 %
(2)
19
N
H
OCH3
CH3
H3CO2C inactive
(≤ 2)
inactive
(≤ 2)
inactive
(≤ 2)
inactive
(≤ 2)
20
N
H
OCH3
CHO
H3CO inactive
(≤ 0.2)
inactive
(≤ 0.2)
inactive
(≤ 0.2)
30 %
(0.2)
21
N
H
OCH3
CH3O
CH3O
inactive
(≤ 0.2)
inactive
(≤ 0.2)
inactive
(≤ 0.2)
inactive
(≤ 0.2)
22
N
CH3
CH2CH3
H3CO inactive
(≤ 0.1)
inactive
(≤ 0.1)
inactive
(≤ 0.1)
inactive
(≤ 0.1)
a concentration [mM] given in paranthese
Indole derivatives as hyaluronidase inhibitors
212
Table 3: Effects of the 2-phenylindole derivatives 4b and 23-27 on the bovine
testicular hyaluronidase and S. agalactiae hyaluronate lyase
No Structure BTH
IC50 [µM]
hylB4755
IC50 [µM]
pH 3.6 pH 7.4 pH 5.0 pH 7.4
4b
N
H
CH3
H3CO
OCH3 1590 2840 880 93
23 N OHHO
(CH2)9CH3
inactivea inactivea 13 17
24 N OHH2NO2SO
(CH2)9CH3
inactiveb inactiveb 8 13
25
N
OSO2NH2
H2NO2SO
(CH2)9CH3
inactivea inactivea 11 16
26 NH2NO2SO
OSO2NH2
(CH2)5
ON
1000 inactivec (77 %)d 12600
27
N
CH3
CH2CH3
H2NO2SO
OSO2NH2
(45 %)d 18000 (47 %)d 4000
a at concentrations ≤ 3.6 m;b at concentrations ≤ 1.8 mM; c at concentrations ≤ 2 mM;
d % inhibition of the enzyme at an inhibitor concentration of 2 mM
Within this series the phenylindoles 16, 17, 19, 21 and 22 were inactive on the
bovine testicular hyaluronidase and the hyaluronate lyase at optimum pH and
at physiological pH. The phenylindole 18 with a methyl group in position 3, a
sulphamoyloxy group in position 4’ and 6 and a 15-member side chain at the
nitrogen atom induced a weak inhibition of BTH and hylB4755 by about 10-20 %
at a concentration of 1.8 mM at pH 7.4. This compound was inactive on both
hyaluronidases at pH 3.6 or 5.0, respectively. Compound 20, the 4’,5-pheny-
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lindole-3-carbaldehyde, induced only an inhibition of hylB4755 at physiological
pH by 30 % at a concentration of 200 µM. Due to poor solubility the tested
compounds could not be investigated at higher concentration than denoted.
Among the investigated 2-phenylindole derivatives, the compounds 4b and
23-25 proved to be the most interesting compounds. The inhibitory effects on
BTH and hylB4755 are summarised in Table 3.
The dimethoxy indole derivative 4b was active on both hyaluronidases at milli-
molar concentration (IC50 values: at BTH 1.59 mM (pH 3.6) / 2.84 mM (pH 7.4),
at hylB4755 0.88 mM (pH 5.0) / 93 µM (pH 7.4)) (Table 3).
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Fig. 4: Inhibitory effects of 5-methoxy-2-(4’-methoxyphenyl)-3-methylindole (4b)
on the bovine testicular hyaluronidase and the bacterial hyaluronidase from S.
agalactiae at optimum and physiological pH.
Whereas compound 4b inhibited both hyaluronidases, the compounds 23-25
were selective for hyaluronate lyase (Table 3). The calculated IC50 values on
hylB4755 at optimum pH (5.0) were 13 µM (23), 8µM (24) and 11 µM (25). The
inhibitory effects were concentration dependent for all three compounds, al-
though a residual enzyme activity of 18-27 % could not be blocked by increas-
ing the inhibition concentration as shown in Fig. 5.
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Fig. 5: Inhibitory effects of the phenylindole derivatives 23-25 determined on
the hyaluronate lyase from S. agalactiae at pH 5.0
The inhibitory effects of the 2-phenylindole derivatives 23-25 determined on the
hyaluronate lyase at pH 7.4 were in the micromolar range, too. The calculated
IC50 values were 17 µM (23), 13.3 µM (24) and 16 µM (25) (cf. Table 3). For all
three compounds a flattening of the curves at lower concentration range could
be observed as shown in Fig. 6, suggesting two different binding modes with
different affinities.
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Fig. 6: Inhibitory effects of the compound 23-25 on hylB4755
Indole derivatives as hyaluronidase inhibitors
215
Compared to the N-unsubstituted compound 4b, the analogues with 10-mem-
bered alkyl chain at the indole-N were about 6-fold and 70-fold more potent in-
hibitors of the bacterial hyaluronidase at physiological pH and at optimum pH,
respectively. Moreover, different H-bonding patterns of 4b vs. 23-25 are con-
ceivable, as the substituents in position 4’ and 5 in compounds 23-25 may act
as donors at the active site of hylB4755. Nevertheless, the increase in affinity
and selectivity appears to be mainly dependent on the presence of a large lipo-
philic substituent at the nitrogen atom.
To determine the binding mode of hyaluronate lyase inhibitors and thereby to
verify the hylB4755 model an X-ray analysis of the enzyme-inhibitor complex was
performed in co-operation with M. Jedrzejas (Children's Hospital Oakland Re-
search Institute, Oakland, USA). It was possible to crystallise the inhibitor 25
inside the active site of S. pneumoniae hyaluronate lyase (cf. section 4 of this
chapter).
The phenylindole derivatives 26 and 27 which have two sulphamoyloxy sub-
stituents in position 4’ and 5 or 6 were only weakly active at both the bovine
testicular hyaluronidase and the S. agalactiae hyaluronate lyase (Table 3). The
phenylindole derivative 26 with a 6-oxo-6-pyrrolidin-1-yl-hexyl side chain was
active on the bovine testicular enzyme at the optimum pH (IC50 = 1 mM) but
inactive at physiological pH. Compound 26 induced inhibition of the bacterial
hyaluronidase at millimolar concentration, too. The lower inhibitory potency of
compound 26 on hylB4755 compared to the co-crystallised inhibitor 25 may re-
sult from the larger space required for the binding of the hydrophobic tail of the
compound 26 than for the decyl substituent of compound 25. Even if the oxy-
gen atom of the carbonyl function could interact with the arginine residue
Arg366, the pyrrolidine moiety is too bulky for the small crevice between the
amino acid residues His399 and Phe343.
The phenylindole 27 excited our interest because of the structural similarity to
the potent indole derivative 25 possessing both sulphamoyloxy groups in posi-
tion 4’ and 5 and an ethyl group at the nitrogen instead of a decyl group. The
inhibitory activities of compound 27 on BTH and hylB4755 at optimum pH were in
the millimolar range. At pH 7.4, compound 27 induced an inhibition in the milli-
molar range (IC50 =  1.8 mM (BTH) and 4 mM (hylB4755). On the bovine testicu-
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lar enzyme an increase in inhibitory potency was achieved by shortening the
alkyl chain from 10 to 2 carbon atoms (compound 25 vs. compound 27),
whereas the potency on the hyaluronate lyase was 250-times lower. Concider-
ing the results obtained for the alkyl substituted hydroxylated phenylindole de-
rivatives 6c-g, IC50 values in the range of 200 µM should be expected. One ex-
planation for the discrepancy between the expected and the found results could
be a negative influence on the binding mode by the methyl group in position 3
together with the bulky sulphamoyloxy group in position 5 of the indole ring.
To explore the structure-activity relationships concerning the role of a methyl
substituent in position 3, the importance of the methoxy group in position 5 vs.
6 and the optimal N-alkyl chain length the phenylindole derivatives 4a-b, 5a-d,
and 6a-g were synthesised and tested for inhibition of bovine testicular hyalu-
ronidase and bacterial hyaluronidase in an optimised turbidimetric assay (cf.
chapter 3). The inhibitory effects on both hyaluronidases are summarised in
Table 4.
Whereas the phenylindole derivatives 4b induced an inhibition of the bovine
testicular and the bacterial hyaluronidase in the millimolar range its structural
isomer 4c was inactive at concentrations ≤ 100 µM. Nevertheless, this differ-
ence should not be over-interpreted as the solubility of compound 4c is ex-
tremely poor, so that partial precipitation in the course of the pharmacological
assay cannot be precluded. The inhibition of BTH and hylB4755 by compound 4a
which is lacking the 3-methyl group ranged between 13 % and 27 % at a con-
centration of 500 µM.
The N-substituted indoles 5a-d were inactive at the concentration tested (50µM
- 250 µM) due to poor solubility.
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Table 4: IC50 values of the synthesised 2-phenylindole derivatives (4a-c, 5a-d,
6a-g) determined on the bovine testicular hyaluronidase and the hyaluronate
lyase
N
R4R2
R1
R3
No Subtitution BTH hylB4755
IC50 [µM] or (% Inhibition)a
R1 R2 R3 R4 pH 3.6 pH 7.4 pH 5.0 pH 7.4
4a H 5-OCH3 H OCH3 inactiveb (13 %)b (27 %)b (21 %)b
4b CH3 5-OCH3 H OCH3 1590 2840 880 93
4c CH3 6-OCH3 H OCH3 inactive inactive inactive inactive
5a CH3 5-OCH3 CH3 OCH3 inactive inactive inactive inactive
5b CH3 5-OCH3 C3H7 OCH3 inactivec inactivec inactivec inactivec
5c CH3 5-OCH3 C5H11 OCH3 inactive inactive inactive inactive
5d CH3 5-OCH3 C7H15 OCH3 inactived inactived inactived inactived
6a H 5-OH H OH (15 %)e (31 %)e (75 %)e 160
6b CH3 6-OH H OH (50 %)e (46 %)e 330 120
6c CH3 5-OH H OH inactivef (45 %)f 740 280
6d CH3 5-OH CH3 OH inactivee inactivee 480 220
6e CH3 5-OH C3H7 OH inactiveb inactiveb 220 160
6f CH3 5-OH C5H11 OH inactive inactive 23 36
6g CH3 5-OH C7H15 OH inactive inactive 26 12
a at concentrations ≤ 100 µM unless otherwise indicated
b 500 µM; c 200 µM; d 50 µM; e 1000 µM; f 2000 µM
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To increase the solubility of the indoles the introduction of polar groups such as
hydroxy groups should be useful. Moreover, this polar substituent could interact
with functional groups in the active site of the enzyme thereby increasing the
affinity of the inhibitor. Therefore, the hydroxylated phenylindole derivatives
6a-g were synthesised. The inhibition of the bovine testicular hyaluronidase
induced by the compounds 6a-c ranged from 15 % to 50 % (cf. Table 4). Com-
paring the inhibitory effect of the phenylindole derivative 6a with 6b on BTH,
the compound with an additional methyl group in position 3 (compound 6b) was
the more potent one.
Generally, the phenylindole derivatives 6a-g were more active on the hyaluro-
nate lyase than on the bovine testicular hyaluronidase. For instance, the IC50
values determined on hylB4755 at physiological pH were between 100 µM and
300 µM for 6a-e, and the inhibitory potency could be further increased to IC50
values of 36 µM (6f) and 12 µM (6g) by extending the chain length of the N-
substituent (cf. Table 4). Exemplarily, the concentration inhibition curves of the
compounds 6a-c on the hyaluronate lyase at optimum pH (5.0) are depicted in
Fig. 7.
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Fig. 7: Effects of the hydroxylated phenylindole derivatives 6a-c on hylB4755 at
optimum pH (5.0)
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Obviously, the methyl group in position 3 is not essential for inhibitory activity
although it appeares to contribute to the increase in potency observed in the
series of compounds listed in Table 4. By the introduction of a methyl group in
position 3 the binding modes described in section 4 are no longer possible. As-
suming the same binding mode for a 3-methylindole derivative as for 25 in the
crystal structure, the additional methyl group would lead to sterical clashes with
the amino acid residue Asn290 (cf. Fig. 13 at section 4 of this chapter). The
distance between the nitrogen atom of the asparagin residue and the carbon
atom C-3 of the indole ring is just about 3 Å, so that the required space for a
methyl group would be too small. Nevertheless, the methylated indole deriva-
tive appear to bind to the active site of the enzyme. One possible explanation
is, that the asparagin residue Asn290 possesses the ability to rotate so that the
sterical hindrance could be repealed. In addition, by the introduction of the
methyl group a coplanar orientation of the phenyl and the indole ring as formed
for 25 in the crystal structure could be prevented. Thereby, the spatial require-
ment of the 2-phenylindole moiety is higher, so that the inhibitor should be di-
rected to the more open part of the binding cleft.
The indole derivative 6b with the hydroxy group in position 6 is about 2-fold
more potent than the 5-hydroxy isomer 6c. In consideration of the crystal struc-
ture of the enzyme-inhibitor complex (cf. section 4 of this chapter) one explana-
tion for the higher inhibition of hylB4755 by compound 6b may be the stronger
possible hydrogen bonds to the amino acids Arg466/Ser463 and Trp292/-
Asp352/Asn349 of the protein. Comparing the inhibitory effect of the indole de-
rivatives 6a-c, the optimal structure seems to be a phenylindole derivative with
a methyl group in position 3 and two hydroxy groups in the positions 4’ and 6.
The increase in activity and selectivity for the bacterial enzyme achieved by
N-substitution (6d-g) is in accordance with the results obtained with the com-
pounds 23-25. For these investigations the indole substitution pattern (6c-g)
different from that of the compounds 23-25 was used (5-OH instead of 6-OH)
due to low yield and difficult purification of 6-hydroxy-2-(4’-hydroxyphenyl)-
indole.
The concentration inhibition curves obtained with 6c-g on bacterial hyaluroni-
dase are depicted in Fig. 8 and Fig. 9. At pH 5.0, the phenylindole 6c without
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any alkyl substituent at the nitrogen atom induced the weakest inhibition of
hylB4755 (IC50 = 740 µM), whereas the compounds with the chain length of 5 (cf.
compound 6f) and 7 carbon atoms (cf. compound 6g) were the most active
hyaluronate lyase inhibitors (IC50 = 23 µM and 26 µM, respectively).
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Fig. 8: Inhibitory effects of the hydroxy phenylindole derivatives 6c-g on the
activity of the bacterial hyaluronidase at optimum pH (5.0)
At pH 7.4, the enhancement of the potency by enlarging the alkyl chain length
could be observed, too. The phenylindole 6g with the heptyl group was the
strongest inhibitor of the hyaluronate lyase and achieved about 3-fold higher
potency  than compound 6f with a pentyl substituent (IC50 = 12 µM and 36 µM,
respectively). For the phenylindoles 6c-e a flattening of the inhibition curves at
lower concentrations could be observed. This might result from different binding
modes of the indole derivatives with different affinities.
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Fig. 9: Effects of the phenylindole derivatives 6c-g determined on the activity of
S. agalactiae hyaluronate lyase at physiological pH (7.4)
The dependency of the potency on the length of the N-alkyl chain is an addi-
tional hint that the 2-phenylindole derivatives with a methyl group in position 3
bind to the catalytic site of the enzyme in a similar way as found for compound
25 (cf. crystal structure of the enzyme-inhibitor complex section 4 of this chap-
ter). Even if the position of the phenylindole moiety is slightly changed by intro-
ducing a methyl group in comparison to the inhibitor 25 (Fig. 10–12, section 4
of this chapter), the hydrophobic alkyl chain may bind in the same cleft of the
active site as the hydrophobic tail of compound 25.
4. X-ray analysis of the enzyme-inhibitor complex of
compound 25 inside the active site of S. pneumoniae
hyaluronate lyase
To determine the binding mode of the 2-phenylindole derivatives inside the ac-
tive site of the bacterial hyaluronidase an X-ray analysis of the enzyme-inhibitor
complex would be helpful. Therefore, we started co-crystallisation experiments
for the indole derivatives 24 and 25 in co-operation with Mark J. Jedrzejas
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(Children's Hospital Oakland Research Institute, Oakland, California 94609,
USA) and Daniel J. Rigden (National Centre of Genetic Resources and Bio-
technology, Cenargen/Embrapa, Brasília, D.F. 70770-900, Brazil). The co-
crystallisation experiments were successful for the phenylindole derivative 25
inside the active site of S. pneumoniae hyaluronate lyase. The crystals of the
enzyme-inhibitor complex were analysed by X-ray diffraction and the structure
was solved by rigid bond refinement (cf. section 6.3 of this chapter)
Binding mode of 6-sulphamoyloxy-2-(4-sulphamoyloxyphenyl)-
1-decyl-indole (25) inside the active site of Streptococcus pneu-
moniae hyaluronate lyase
X-ray crystallography was used for the determination of the binding mode of the
phenylindole derivative 25 inside the active site of the bacterial hyaluronidase
from S. pneumoniae. The density at the catalytic site allowed for a satisfactory
modelling of compound 25 as shown in Fig. 10.
Fig. 10: Schematic representation of the electron density map |2Fo-Fc| (con-
toured at 0.65 σ) of the phenylindole 25 inside the active site of S. pneumoniae
hyaluronate lyase [adapted from D. J. Rigden (personal communication)].
Trp292
Arg466
B A
Arg462
Met579
Phe349
Trp291
Indole derivatives as hyaluronidase inhibitors
223
In general, the inhibitor was reasonably well converted by electron density in
the final map, but the clear exception was the sulphonamide group carried by
the phenyl moiety of the inhibitor, for which the density was completely lacking
(cf. Fig. 10). Presumably, findings reflect solvent exposure and suggest free
rotation about the sulphonamide-phenyl bond. The sulphonamide group linked
by the phenyl moiety was included in the final model only for the sake of com-
pleteness. During structure solution and refinement it became clear that the
second sulphonamide group carried by the indole moiety can adopt two differ-
ent conformations A and B (cf. Fig 10 and Fig. 11). As shown in both figures the
existence of these alternative binding modes leads to small shifts in position of
the indole ring. Whereas the position of the sulphonamide group in mode A is
well-defined by the electron density, the position of the sulphonamide group in
mode B is less well-defined. But, if this second mode were omitted a clear posi-
tive difference electron density would remain. Thus, the inclusion of the second
mode in the model is justifiable. Presumably, mode A is favoured and is more
highly occupied than mode B, but a specification is not justifiable by the avail-
able resolution. In the final model, an additional difference density was evident
at the catalytic site, which suggested an availability of alternative modes of in-
hibitor binding. However, only the conformations shown before were well sup-
ported by electron density. The likely existence of other binding modes and/or
the incomplete occupancy of the binding modes in the final model are also ap-
parent in the elevated B-factors for the inhibitor in the final structure (cf. Table
5, section 6.4 of this chapter).
As shown in Fig. 10-12, the binding of the indole derivative 25 involves hydro-
phobic interaction of the rings and the aliphatic tail and hydrogen bonds be-
tween the indole linked sulphonamide group and the protein. The aliphatic tail
of the substituted phenylindole 25 lies in a surface crevice. The alkyl chain is
lined mainly by hydrophobic residues (Met579, Trp291 and Phe343), but also
by the amino acids Arg336, Glu388 and His399 (cf. Fig. 12). The phenyl moiety
of the inhibitor is sandwiched between the amino acids Trp291 and Asn580,
whereby the interaction with Trp292 involves an approximately perpendicular
ring arrangement (cf. Fig. 10, 12). The indole ring of the inhibitor is bound on
one side by Trp292 in an energetically favourable manner, thereby the two ring
systems lie parallel. The other side of the indole ring is in contact with the
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guanidinium part of the amino acid Arg462 (cf. Fig 10-12). Such cation-π inter-
action can be highly energetically favourable (Gallivan et al. 1999).
Val411
Asp352
Asn349
Trp292Arg462
Arg466
Ser463
A B
Fig. 11: Comparison of the modelled alternative binding modes for phenylin-
dole derivative 25 in the vicinity of the indole sulphonamide group. The cyan
spheres represent water molecules, possible hydrogen bonds are shown as
light green dotted lines. Alternative modes A and B are drawn and labelled in
purple and green, respectively [adapted from D. J. Rigden (personal communi-
cation)].
Each alternative binding mode of the sulphonamide group carried by the indole
ring forms a network of hydrogen bonding interaction with protein and solvent
(cf. Fig. 12). The interactions of the sulphonamide group in binding mode A
seem particularly favourable, with a twin interaction between the amino acid
Arg466 and two sulphonamide oxygen atoms. Both oxygen atoms together with
the amide nitrogen form additional interaction with the protein (Ser463) involv-
ing water molecules (cf. Fig. 12). The interaction in the binding mode B are dif-
ferent from those of mode A. There is a single direct hydrogen bond between
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one sulphonamide oxygen and the amino acid Trp292. In addition, the sul-
phonamide oxygen can interact via water hydrogen bonds with the amino acids
Asp352 and Asn349 of the protein.
Successive structural determinations (Li et al. 2000; Ponnuraj et al. 2000; Li et
al. 2001; Jedrzejas 2002; Jedrzejas et al. 2002; Mello et al. 2002; Nukui et al.
2003) and mutagenesis studies (Li et al. 2000; Kelly et al. 2001; Nukui et al.
2003) have enabled the proposal of a firmly supported catalytic mechanism
(Jedrzejas 2001; Jedrzejas 2002; Jedrzejas et al. 2002; Jedrzejas 2003). The
catalysis occurs at the most constricted part of the catalytic cleft. The basic
amino acids involved in catalysis are Asn349, His399 and Tyr408. In addition, a
hydrophobic patch composed by the amino acids Trp291, Trp292 and Phe343
are implicated in the precise positioning of the substrate.
Fig. 12: Schematic representation of the alternative binding mode A of the
phenylindole 25 inside the catalytic site of S. pneumoniae hyaluronate lyase
(Botzki 2004)
Arg466
Tyr408
Arg462
His499 Phe343
Arg366
Trp291
Trp292
Asn290
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The ring system of the phenylindole compound 25 binds within the catalytic site
of the enzyme (cf. Fig. 10-12) which explains the inhibition of the hyaluronidase
activity. Atoms of the inhibitor lie within 3.0 Å and 3.1 Å of the catalytic key resi-
dues Tyr408 and His399, respectively. In addition, the inhibitor is also linked to
the protein by water mediated hydrogen bonds between the nitrogen atom of
Asn349 and the sulphonamide group of the indole moiety in binding mode B.
Furthermore, all amino acids of the hydrophobic patch are involved in binding of
the inhibitor. The tryptophan residues Trp291 and Trp292 are important, be-
cause they contribute to the strong hydrophobic interactions with the phenyl
and the indole rings of the inhibitor.
Previously, the binding mode of palmitoyl vitamin C was determined (Rigden et
al., unpublished results). The results obtained for the vitamin C derivative agree
with those of compound 25. The binding of the two different inhibitors causes
no significant changes in the protein structure. The vitamin C structure binds in
exactly the same portion of the catalytic site as the indole ring of the compound
25. Even the binding of the aliphatic tails are generally similar.
5. Summary and future perspectives
5.1 Summary
A de novo design approach starting from X-ray structure of bacterial hyaluro-
nate lyases and molecular modelling investigations led to the discovery of in-
dole-2-carboxylic acid (1) as a first lead with millimolar enzyme inhibitory activity
(IC50 of 7.1 mM (BTH) and 3.55 mM (hylB4755)).
The investigation of further indole compounds with different substituents like
acetic acid, acetyl, carboxamide, butyric acid, methyl etc. at the indole moiety
(cf. compounds 7-15) did not lead to more potent inhibitors. The first improve-
ment was obtained with indomethacin (15), which was 11-times more potent
than compound 1 on the S. agalactiae hyaluronate lyase (IC50 = 350 µM) and
13-times more potent on the bovine testicular hyaluronidase (IC50 = 540 µM) at
optimum pH. Furthermore, in contrast to 1 indomethacin also showed inhibitory
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activities on both enzymes at physiological pH (IC50 = 5.49 mM (BTH) and
1.14 mM (hylB4755.
In addition to the compounds 7-15, we investigated a series of phenylindole
derivatives 4a and 16-27 with hydroxy, methoxy, methyl and/or sulphamoyloxy
substituents at the phenyl and indole rings and different substituents at the ni-
trogen atom. Generally, the phenylindoles were more active on the bacterial
than on the bovine testicular hyaluronidase. Highest hyaluronan lyase inhibitory
potency resides in the phenylindole derivatives 23-25 with hydroxy and/or sul-
phamoyl groups in the positions 4’ and 6 and with a 10-membered alkyl chain
at the nitrogen atom (IC50 values ranging from 8 µM to 17 µM). These phenylin-
dole derivatives are 27-fold and 67-fold more potent on hylB4755 at optimum pH
(5.0) and physiological pH (7.4), respectively, than indomethacin and around
300-times more active than our first lead 1.
Structure-activity relationship studies revealed that a hydroxy group in position
6 is more favourable than in position 5. Furthermore, the introduction a methyl
group in position 3 and an alkyl chain in position1 leads to an increase in activ-
ity and selectivity for the bacterial vs. the bovine enzyme. Of all synthesised
indole derivatives (4a-c, 5a-d, 6a-g) only the compounds without N-substituents
were active on the bovine testicular hyaluronidase.
In conclusion, compared to the first lead, indole-2-carboxylic acid (1), the in-
crease of lipophilicity by introducing phenyl and alkyl substituents and the intro-
duction of hydroxy and/or sulphamoyloxy groups resulted in about 500-fold
more potent inhibitor with remarkable selectivity for the bacterial vs. the bovine
testicular hyaluronidase.
On the basis of the X-ray analysis2 of the enzyme-inhibitor complex, S. pneu-
moniae hyaluronate lyase-6-sulphamoyloxy-2-(4-sulphamoyloxyphenyl)-1-dec-
yl-1-indole (25) we were able to determine the binding mode of the phenylin-
dole compound. The inhibitor 25 binds within the catalytic site of the enzyme
whereby hydrophobic interactions with the amino acids Trp292, Trp291, His399
and Met579 and hydrogen bonds with Asn466, Ser463, Asp352, Asn349 and
Trp292 are involved.
2 in co-operation with Mark J. Jedrzejas (Children's Hospital Oakland Research Institute, Oak-
land, California 94609, USA) and Daniel J. Rigden (National Centre of Genetic Resources and
Biotechnology, Cenargen/Embrapa, Brasília, D.F. 70770-900, Brazil).
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5.2 Future perspectives
Based on the previously described pharmacological results and the X-ray
analysis of an enzyme-inhibitor complex, phenylindole derivative 25 bound at
the active site of S. pneumoniae hyaluronidase, further new phenylindole-type
hyaluronidase inhibitors can be suggested.
Fig. 13: General structure of phenylindole-type hyaluronidase inhibitors
Based on the structure-activity relationships compounds having the substitution
patter R1, R3 = OH, R2 = CH3 and X = C5H11 or C7H15 are expected to be more
potent inhibitors of the hyaluronate lyase that the compounds discussed above.
Based on the X-ray structure of the enzyme-inhibitor complex 25 the following
structural modifications outlined below are reasonable concerning the residues
R1 and R2 as well as the substituents X at the nitrogen atom. In addition to the
potency the solubility of the compounds could be taken into account.
• By introducing acidic groups in the positions 4’ (R3) and 6 (R1) the solubility
of the compounds would probably increase. At position 4’, different solvent
exposed substituents which do not interact with the protein might be intro-
duced. The ideal substituents at position 6 should be  carboxylic acid
(-CO2H), acetic acid (-CH2CO2H) and acetyl (-C(O)CH3) moieties because
the oxygen atoms of these substituents could form hydrogen bonds with the
amino acid residues Arg466 and Ser463 at the active site of the enzyme.
This analysis should be carried out without changing the substituent X for
better comparison with the phenylindole derivative 25.
N
R3
R2
R1
X
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• Based on the results obtained with compound 26, 5- to 7-membered alkyl
chain with a terminal amide, amino or alcohol  function would be interesting;
the alkyl chain would act as a spacer and the new functionality as a possible
donnor/acceptor of hydrogen bonds with the amino acids His399 or Arg366.
• The introduction of a phenyl ring or a 2-pyridyl ring linked to indole-N via a
4-membered carbon chain should be investigated as hydrophobic interac-
tions of the phenyl/2-pyridyl ring with the amino acids His399 and Phe343
appear possible. In addition, the nitrogen atom of the 2-pyridyl ring could
form hydrogen bond with Arg366.
• The superposition of crystal structures of a substrate-like hexasaccharide
and the co-crystallised phenylindole 25 both with S. pneumoniae hyaluroni-
dase may lead to suggestions of new inhibitor structures combining the
phenylindole moiety and a carbohydrate portion. As scaffold the phenyl-
indole with an hydroxy group in the position 4’, the 10-membered N-alkyl
substituent (X = C10H21) appears promissing, whereas glucuronic acid
(GlAc) could be used as a carbohydrate building block linked via a spacer
with the indole moiety in position 6 (Fig. 14).
N
OH
C10H21
O
GlAc
Fig. 14: Proposal of a new hyaluronate lyase inhibitor
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6. Experimental section
6.1 General conditions
For a detailed description of the general procedures, equipments and chemi-
cals used in the chemistry part, see section 4.1 of chapter 5.
6.2 Chemistry
6.2.1 Synthesis of the brominated compounds 3a-b
2-Bromo-4’-methoxyacetophenone (3a)
To a solution of 4-methoxyacetophenone (8.41 g, 56.00 mmol), dioxane (200
ml) and dichloromethane (100 ml), bromine (8.95 g, 56.00 mmol) was slowly
added so that the brown colour always disappeared. Afterwards the reaction
mixture was stirred at room temperature for 1 h. After washing with water (2 x
200 ml) the aqueous solution was extracted several times with ethyl acetate. All
combined organic layer were dried over sodium sulphate and the solvent was
removed under reduced pressure. The product was purified by recrystallisation
from ethanol to give a white crystalline solid. (von Angerer et al. 1984)
Yield: 10.84 g (47.32 mmol, 85  %, white crystalline solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 3.89 (s, 3H, OCH3), 4.40 (s, 2H, -CH2Br), 6.94-6.99 (m, 2H, ph), 7.95-
8.00 (m, 2H, ph)
C9H9BrO2 (229.07)
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2-Bromo-4’-methoxypropiophenone (3b)
To a solution of 4’-methoxypropiophenone (31.86 g, 194.0 mmol), a few drops
of aqueous hydrobromic acid (48 %) and glacial acetic acid (150 ml), bromine
(31.00 g, 194.00 mmol) was slowly added so that the temperature did not ex-
ceed 20 °C. The reaction mixture was stirred at room temperature for 30 min.
After cooling, the mixture was poured into ice water, then the precipitated prod-
uct was collected and washed with water. The product was purified by re-
crystallisation from ethanol to give a white solid. (von Angerer et al. 1984)
Yield: 36.73 g (151.10 mmol, 79 %, white solid)
1H-NMR (CDCl3):
δ [ppm] = 1.89 (d, 3H, 3J = 6.7 Hz, CHBrCH3), 3.89 (s, 3H, OCH3), 5.27 (q, 1H,
3J = 6.7 Hz, CHBrCH3), 6.93-6.99 (m, 2H, ph), 7.95-8.04 (m, 2H, ph)
C10H11BrO2 (243.10)
6.2.2 Synthesis of the phenylindole derivatives 4a-c
All three methoxylated phenylindoles 4a-c were synthesised by the following
general procedure:
A solution of m- or p-anisidine (2.11 eq) and N,N-dimethylaniline was stirred at
175 °C. To this solution, a solution of the pertinent α-bromophenone (1 eq) dis-
solved in xylene was added dropwise and stirring was continued for 3 h. After
cooling to room temperature, the reaction mixture was diluted with ethyl acetate
(200 ml) and aqueous hydrochloric acid (2 N, 200 ml) and the layers were
separated. The water phase was extracted three times with ethyl acetate
(100 ml). Afterwards the combined organic layers were washed with water
(100 ml) and dried over magnesium sulphate, and the solvent was removed
under reduced pressure. The product was purified by column chromatography
on silica gel eluting with dichloromethane and recrystallised from ethanol to give
a white solid.
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5-Methoxy-2-(4-methoxyphenyl)indole (4a)
Reaction of p-anisidine (4.56 g, 37.0 mmol), N,N-dimethylaniline (15 ml) and
2-bromo-4’-methoxyacetophenone (4,01 g, 17.50 mmol);
Yield: 1.56 g (6.16 mmol, 34 %, white solid)
Mp: 196-198° [Lit. 206-208 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 3.75 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 6.66 (d, 1H, 4J = 1.4 Hz, H-
3), 6.71 (dd, 1H, 4J = 2.5 Hz, 3J = 8.8 Hz, H-6), 6.99 (d, 1H, 4J = 2.5 Hz, H-4),
7.00-7.04 (m, 2H, ph), 7.25 (d, 1H, 3J = 8.8 Hz, H-7), 7.73-7.77 (m, 2H, ph),
11.21 (s, 1H, NH)
13C-NMR ([D6]DMSO):
δ [ppm] = 55.1 (+, OCH3), 55.2 (+, OCH3), 97.2 (+, indole), 101.4 (+, indole),
110.9 (+, indole), 111.6 (+, indole), 114.2 (+, ph), 124.9 (Cquart, indole), 126.1
(+, ph), 129.2 (Cquart, ph), 132.0 (Cquart, indole), 138.2 (Cquart, indole), 153.5
(Cquart, indole), 158.6 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 253 ([M•+], 100), 237 ([M-CH3]+, 24), 209 ([M-
CH3-CO]+, 22)
IR [cm-1]: 3441 (N-H), 2999 (C-H) aromatic, 2900 (C-H) aliphatic, 1606 (C=C),
1543 (N-H), 1478 (C-H), 1394 (C-H), 1215 (C-O), 1154 (C-N), 1118, 1022, 831,
779, 752
Analysis:
calculated C: 75.57 H:  5.97 N: 5.53
found C: 75.07 H:  5.86 N: 5.41
C16H15NO2 (253.30)
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5-Methoxy-2-(4-methoxyphenyl)-3-methylindole (4b)
Reaction of p-anisidine (4.56 g, 37.0 mmol), N,N-dimethylaniline (15 ml) and
2-bromo-4’-methoxypropiophenone (4.25 g, 17.50 mmol)
Yield: 3.10 g (11.60 mmol, 66 %, white crystalline solid)
Mp: 128-130 °C [Lit. 135-137 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 2.35 (s, 3H, 3-CH3), 3.78 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 6.72 (dd,
1H, 4J = 2.4 Hz, 3J = 8.6 Hz, H-6), 6.97 (d, 1H, 4J = 2.4 Hz, H-4), 7.05-7.08 (m,
2H, ph), 7.22 (d, 1H, 3J = 8.80 Hz, H-7), 7.56-7.59 (m, 2H, ph), 10.84 (s, 1H,
NH)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.8 (+, CH3), 55.1 (+, OCH3), 55.3 (+, OCH3), 100.0 (+, indole), 105.4
(Cquart, indole), 111.0 (+, indole), 111.4 (+, indole), 114.1 (+, ph), 125.7 (Cquart,
indole), 128.6 (+, ph), 129.8 (Cquart, ph), 130.8 (Cquart, indole), 134.4 (Cquart, in-
dole), 153.1 (Cquart, indole), 158.2 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 267 ([M•+], 100)
IR [cm-1]: 3382 (N-H), 2990 (C-H) aromatic, 2900 (C-H) aliphatic, 1608 (C=C),
1550 (N-H), 1449 (C-H), 1217 (C-O), 1178 (C-N), 1062, 1027, 839, 802, 622
Analysis:
calculated C: 76.38 H: 6.41 N: 5.24
found C: 76.20 H: 6.27 N: 5.20
C17H17NO2 (267.33)
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6-Methoxy-2-(4-methoxyphenyl)-3-methylindole (4c)
Reaction of m-anisidine (4.56 g, 37.0 mmol), N,N-dimethylaniline (15 ml) and
2-bromo-4’-methoxypropiophenone (4,25 g, 17.50 mmol).
Yield: 1.63 g (6.10 mmol, 35 %, white solid)
Mp: 125-127 °C [Lit. 133-135 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 2.34 (s, 3H, 3-CH3), 3.77 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 6.66 (dd,
1H, 4J = 2.3 Hz, 3J = 8.6 Hz, H-5), 6.83 (d, 1H, 4J = 2.3 Hz, H-7), 7.36 (d, 1H, 3J
= 8.6 Hz,  H-4), 7.04-7.09 (m, 2H, ph), 7.53-7.57 (m, 2H, ph)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.8 (+, CH3), 55.1 (+, OCH3), 55.1 (+, OCH3), 94.1 (+, indole), 105.5
(Cquart, indole), 108.4 (+, indole), 114.1 (+, ph), 118.7 (+, indole), 123.9 (Cquart,
indole), 125.8 (Cquart, ph), 128.3 (+, ph), 132.4 (Cquart, indole), 136.4 (Cquart, in-
dole), 155.6 (Cquart, indole), 158.0 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 267 ([M•+], 79), 252 ([M-CH3]+, 100)
IR [cm-1]: 3441 (N-H), 3000 (C-H) aromatic, 2900 (C-H) aliphatic, 1573 (C=C),
1513 (N-H), 1454 (C-H), 1327 (C-H), 1257 (C-O), 1185 (C-N), 1125, 1018, 823,
806
Analysis:
calculated C: 74.62 H: 6.39 N: 5.12
found C: 74.47 H: 6.17 N: 5.07
C17H17NO2 (267.33)
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6.2.3 Synthesis of the N-alkylated phenylindole derivatives 5a-d
The N-alkylated 2-phenylindoles 5a-d were synthesised from the 2-phenyl-
indole 4b by alkylation reaction at the nitrogen atom.
To an ice-cold solution of sodium hydride (1.60 eq) in DMF (10 - 15 ml) stirred
under a nitrogen atmosphere, a solution of the 2-phenylindole 4b (1 eq) in DMF
(10 - 15 ml) was slowly added and stirring was continued, until the gas genera-
tion ceased. Afterwards, a solution of the pertinent iodoalkane (1 eq) in DMF
(10- 15 ml) was added dropwise. The reaction mixture was allowed to warm up
to room temperature and stirring was continued for 2 h. The products were pu-
rified by colomn chromatography.
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-methylindole (5a)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methylindole (4b) (0.50 g,
1.87 mmol), sodium hydride (0.12 g, 3.0 mmol) and methyl iodide (0.27 g,
1.87 mmol). After dilution with water (100 ml) the precipitate was collected and
washed with large amount of water. The product was purified by column chro-
matography on silica gel eluting with a 5:1 (v/v) mixture of petroleum ether
60-80 °C and ethyl acetate.
Yield: 0.50 g (1.78 mmol, 95 %, white solid)
Mp: 129-131 °C [Lit. 139-141 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 2.15 (s, 3H, CH3), 3.34 (s, 3H, NCH3), 3.78 (s, 3H, OCH3), 3.82 (s,3H,
OCH3), 6.79 (dd, 1H, 4J = 2.4 Hz, 3J = 8.7 Hz, H-6), 6.99 (d, 1H,4J = 2.4 Hz,  H-
4), 7.30 (d, 1H, 3J = 8.7 Hz, H-7), 7.04-7.11 (m, 2H, ph), 7.33-7.39 (m, 2H, ph)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.4 (+, CH3), 30.8 (+, NCH3), 55.2 (+, OCH3), 55.4 (+, OCH3), 100.2
(+, indole), 106.6 (Cquart, indole), 110.3 (+, indole), 111.1 (+, indole), 113.9 (+,
ph), 123.7 (Cquart, indole), 128.2 (Cquart, ph), 131.5 (+, ph), 132.0 (Cquart, indole),
137.7 (Cquart, indole), 153.4 (Cquart, indole), 158.8 (Cquart, indole)
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MS (PI-EIMS (70 eV)): m/z (%) = 281 ([M•+], 100), 266 ([M-CH3]+, 30)
IR [cm-1]: 2921 (C-H) aromatic, 2846 (C-H) aliphatic, 1600 (C=C), 1486 (C-H),
1239 (C-O), 1176 (C-N), 1066, 1031, 906, 840, 795, 609
Analysis:
calculated C: 76.84 H: 6.81 N: 4.98
found C: 76.59 H: 6.98 N: 4.77
C18H19NO2 (281.35)
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-propylindole (5b)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methylindole (4b) (1.0 g,
3.74 mmol), sodium hydride (0.24 g, 6.0 mmol) and propyl iodide (0.46 g,
3.74 mmol). After diluting with water (100 ml) the reaction mixture was ex-
tracted three times with ethyl acetate (100 ml). The combined organic layers
were dried over magnesium sulphate and the solvent was removed under re-
duced pressure. The product was purified by column chromatography on silica
gel eluting with a 10:1 (v/v) mixture of petroleum ether 60-80 °C and ethyl ace-
tate.
Yield: 1.03 g (3.33 mmol, 89 %, white solid)
Mp: 113-115 °C [Lit. 119-121 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 0.61 (t, 3H, 3J = 7.4 Hz, NCH2CH2CH3), 1.46 (m, 2H, NCH2CH2CH3),
2.12 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.95 (t, 2H, 3J = 7.3
Hz, NCH2CH2CH3), 6.78 (dd, 1H, 4J = 2.5 Hz, 3J = 8.8 Hz, H-6), 6.99 (d, 1H, 4J
= 2.5 Hz, H-4), 7.06-7.10 (m, 2H, ph), 7.30-7.35 (m, 3H, H-7 and ph)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.2 (+, CH3), 10.9 (+, NCH2CH2CH3), 22.8 (-, NCH2CH2CH3), 44.7 (-,
NCH2CH2CH3), 55.1 (+, OCH3), 55.4 (+, OCH3), 100.4 (+, indole), 106.9 (Cquart,
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indole), 110.6 (+, indole), 110.9 (+, indole), 113.9 (+, ph), 123.9 (Cquart, indole),
128.3 (Cquart, ph), 131.2 (Cquart, indole), 131.3 (+, ph), 137.5 (Cquart, indole),
153.3 (Cquart, indole), 158.8 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 309 ([M•+], 91), 280 ([M-C2H5]+, 100)
IR [cm-1]: 2922 (C-H) aromatic, 2849 (C-H) aliphatic, 1609 (C=C), 1450 (C-H),
1223 (C-O), 1176 (C-N), 1039, 908, 842, 800, 621
Analysis:
calculated C: 77.64 H: 7.49 N: 4.53
found C: 77.80 H: 7.61 N: 4.27
C20H23NO2 (309.40)
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-pentylindole (5c)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methylindole (4b) 1.0 g,
3.74 mmol), sodium hydride (0.24 g, 6.0 mmol) and pentyl iodide (0.57 g,
3.74 mmol). After diluting with water (100 ml) the mixture was extracted three
times with ethyl acetate (100 ml). The combined organic layer were dried over
magnesium sulphate and the solvent was removed under reduced pressure.
The product was purified by column chromatography on silica gel eluting with a
10:1 (v/v) mixture of petroleum ether 60-80 °C and ethyl acetate.
Yield: 1.21 g (3.59 mmol, 96 %, white solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 0.70 (t, 3H, 3J = 7.2 Hz, CH2CH3), 0.97-1.11 (m, 4H, CH2CH2), 1.43
(q, 2H, 3J = 7.2 Hz, NCH2CH2), 2.12 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 3.83 (s,
3H, OCH3), 3.98 (t, 2H, 3J = 7.3 Hz, NCH2CH2), 6.78 (dd, 1H, 4J = 2.5 Hz, 3J =
8.8 Hz, H-6), 6.99 (d, 1H, 4J = 2.5 Hz, H-4), 7.06-7.10 (m, 2H, ph), 7.30-7.33
(m, 3H, indole and ph)
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13C-NMR ([D6]DMSO):
δ [ppm] = 9.2 (+, CH3), 13.6 (+, CH2CH3), 21.5 (-, -CH2CH3), 28.1 (-, -CH2-),
29.1 (-, -CH2-), 43.0 (-, NCH2-), 55.1 (+, OCH3), 55.4 (+, OCH3), 100.4 (+, in-
dole), 106.9 (Cquart, indole), 110.5 (+, indole), 110.9 (+, indole), 113.9 (+, ph),
124.0 (Cquart, indole), 128.4 (Cquart, ph), 131.2 (Cquart, indole), 131.4 (+, ph),
137.5 (Cquart, indole), 153.3 (Cquart, indole), 158.8 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 337 ([M•+], 89), 280 ([M-C4H9]+, 100), 265 ([M-
C4H9-CH3]+, 19), 249 ([M-C4H9-CH3-CO]+, 19)
IR [cm-1]: 2956 (C-H) aromatic, 2864 (C-H) aliphatic, 1611 (C=C), 1480 (C-H),
1457 (C-H), 1242 (C-O), 1168 (C-N), 1035, 905, 834, 797
Analysis:
calculated C: 78.30 H: 8.06 N: 4.15
found C: 78.11 H: 7.98 N: 4.01
C22H27NO2 (337.46)
5-Methoxy-2-(4-methoxyphenyl)-3-methyl-1-heptylindole (5d)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methylindole (4b) (0.50 g,
1.87 mmol), sodium hydride (0.12 g, 3.0 mmol) and heptyl iodide (0.37 g,
1.87 mmol). After diluting with water (100 ml) the mixture was extracted with
ethyl acetate (3 x 100 ml). The combined organic layers were dried over mag-
nesium sulphate and the solvent was removed under reduced pressure. The
product was purified by column chromatography on silica gel eluting with a 5:1
(v/v) mixture of petroleum ether 60-80 °C and ethyl acetate.
Yield: 0.65 g (1.78 mmol, 95 %, white solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 0.78 (t, 3H, 3J = 6.9 Hz, -CH2CH3), 1.00-1.16 (m, 6H, -CH2-), 1-18-
1.26 (m, 2H, -CH2-), 1.35-1.46 (m, 2H, -CH2-), 2.11 (s, 3H, CH3), 3.79 (s, 3H,
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OCH3), 3.83 (s, 3H, OCH3), 3.98 (t, 2H, 3J = 7.1 Hz, NCH2CH2-), 6.78 (dd, 1H,
4J = 2.5 Hz, 3J = 7.9 Hz, H-6), 6.99 (d, 1H, 4J = 2.5 Hz, H-4), 7.07-7.08 (m, 2H,
ph), 7.30-7.33 (m, 3H, indole and ph)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.3 (+, CH3), 13.8 (+, -CH2CH3), 21.9 (-, -CH2CH3),  25.9 (-, -CH2-),
27.9 (-, -CH2-), 30.9 (-, -CH2-), 42.9 (-, NCH2-), 55.1 (+, OCH3), 55.4 (+, OCH3),
100.4 (+, indole), 106.9 (Cquart, indole), 110.9 (+, indole), 110.9 (+, indole),
113.9 (+, ph), 124.0 (Cquart, indole), 128.4 (Cquart, ph), 131.2 (Cquart, indole),
131.4 (+, ph), 137.5 (Cquart, indole), 153.3 (Cquart, indole), 158.8 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 365 ([M•+], 98), 280 ([M-C6H13]+, 100), 265
([M-C4H9-CH3]+, 17), 249 ([M-C4H9-CH3-CO]+, 17)
IR [cm-1]: 2925 (C-H) aromatic, 2849 (C-H) aliphatic, 1611 (C=C), 1483 (C-H),
1457 (C-H), 1241 (C-O), 1172 (C-N), 1034, 907, 834, 795, 611
Analysis:
calculated C: 78.86 H: 8.55 N: 3.83
found C: 78.40 H: 8.68 N: 3.67
C24H31NO2 (365.51)
6.2.4 Cleavage of the methyl ether
To a solution of BBr3 (10 eq) in anhydrous dichloromethane (10 ml), a solution
of the corresponding methoxy-substituted phenylindole (1 eq) in anhydrous di-
chloromethane (100 ml) was added under a nitrogen atmosphere at –10 °C.
The reaction mixture was stirred for 1 h at -10 °C and 3 days at room tempera-
ture, then it was diluted with a saturated solution of sodium hydrogen carbonate
(100 - 150 ml) and ethyl acetate (150 - 200 ml) and stirred for additional 30 min.
After separation, the aqueous phase was extracted three times with ethyl ace-
tate (50 ml). The combined organic layers were dried over magnesium sulphate
and the solvent was removed under reduced pressure.
Indole derivatives as hyaluronidase inhibitors
240
5-Hydroxy-2-(4-hydroxyphenyl)indole (6a)
Reaction of 5-methoxy-2-(4-methoxyphenyl)indole (4a) (1.0 g, 3.95 mmol)  and
BBr3 (39.50 mmol). The product was purified by column chromatography on si-
lica gel eluting with a 1:2 (v/v) mixture of petroleum ether 60-80 °C and ethyl
acetate to give a green solid.
Yield: 0.23 g (0.96 mmol, 24 %, green solid)
Mp: 265-267 °C [Lit. 265-268 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 6.50 (d, 1H, 4J = 1.7 Hz, H-3), 6.56 (dd, 1H, 4J = 2.2 Hz, 3J = 8.5 Hz,
H-6), 6.79 (d, 1H, 4J = 2.2 Hz, H-4), 6.82 (d, 2H, 3J = 8.8 Hz, H-2’, H-6’), 7.13
(d, 1H, 3J = 8.5 Hz, H-7), 7.61 (d, 2H, 3J = 8.8 Hz, H-3’, H-5’), 8.59 (s, 1H, OH),
9.56 (s, 1H, OH), 10.98 (s, 1H, NH)
13C-NMR ([D6]DMSO):
δ [ppm] = 96.1 (+, indole), 103.4 (+, indole), 110.9 (+, indole), 111.1 (+, indole),
115.5 (+, ph), 123.6 (Cquart, indole), 126.1 (+, ph), 129.6 (Cquart, ph), 131.3
(Cquart, indole), 138.5 (Cquart, indole), 150.7 (Cquart, indole), 156.8 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 225 ([M•+], 100)
IR [cm-1]: 3427 (N-H), 3309 (O-H), 1596 (C=C), 1441 (C-H), 1376 (C-H), 1260
(C-O), 1138 (C-N), 952, 831, 778
Analysis:
calculated C: 74.06 H: 4.92 N: 6.16
found C: 73.86 H: 5.28 N: 5.55
C14H11NO2 (225.24)
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6-Hydroxy-2-(4-hydroxyphenyl)-3-methylindole (6b)
Reaction of 6-methoxy-2-(4-methoxyphenyl)indole (4c) (0.54 g, 2.0 mmol) and
BBr3 (20 mmol). The product was purified by column chromatography on silica
gel eluting with a 3:2 (v/v)  mixture of petroleum ether 60-80 °C and ethyl ace-
tate to give a light green solid.
Yield: 0.31 g (1.30 mmol, 65 %, light green solid)
Mp: 234-238 °C [Lit. 250-253 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 2.29 (s, 3H, CH3), 6.51 (dd, 1H, 4J = 2.0 Hz, 3J = 8.4 Hz, H-5), 6.69
(d, 1H, 4J = 2.0 Hz, H-7), 6.85-6.89 (m, 2H, ph), 7.23 (d, 1H, 3J = 8.4 Hz, H-4),
7.40-7.42 (m, 2H, ph), 8.85 (br, 1H, OH), 9.52 (br, 1H, OH), 10.56 (s, 1H, NH)
13C-NMR ([D6]DMSO):
δ [ppm] = 10.1 (+, CH3), 96.6 (+, indole), 105.4 (Cquart, indole), 109.3 (+, indole),
115.9 (+, ph), 118.9 (+, indole), 123.7 (Cquart, indole), 124.8 (Cquart, ph), 128.8
(+, ph), 132.2 (Cquart, indole), 137.2 (Cquart, indole), 153.5 (Cquart, indole), 156.6
(Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 239 ([M•+], 100), 238 ([M-H]+, 80)
IR [cm-1]: 3397 (N-H), 3254 (O-H), 1514 (C=C), 1435 (C-H), 1378 (C-H), 1223
(C-O), 1150 (C-N), 956, 841, 829, 801, 652, 627
Analysis:
calculated C: 73.36 H: 5.45 N: 5.70
found C: 73.59 H: 5.36 N: 5.44
C15H13NO2 • 0.35 H2O (245.59)
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5-Hydroxy-2-(4-hydroxyphenyl)-3-methylindole (6c)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methylindole (4b) (0.54 g,
2.0 mmol) and BBr3 (20 mmol). The product was purified by column chromato-
graphy on silica gel eluting with a 3:2 (v/v) mixture of petroleum ether 60-80 °C
and ethyl acetate to give a green solid.
Yield: 0.34 g (1.42 mmol, 71 %, green solid)
Mp: 188-190 °C [Lit. 201-204 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 2.27 (s, 3H, CH3), 6.60 (dd, 1H, 4J = 2.2 Hz, 3J = 8.5 Hz, H-6), 6.77
(d, 1H, 4J = 2.2 Hz, H-4), 6.88 (d, 2H, 3J = 8.8 Hz, H-2’, H-6’), 7.10 (d, 1H, 3J =
8.5 Hz, H-7), 7.44 (d, 2H, 3J = 8.8 Hz, H-3’, H-5’), 8.60 (s, 1H, OH), 9.58 (s, 1H,
OH), 10.62 (s, 1H, NH)
13C-NMR ([D6]DMSO):
δ [ppm] = 10.4 (+, CH3), 102.5 (+, indole), 104.7 (Cquart, indole), 111.5 (+, in-
dole), 111.6 (+, indole), 115.9 (+, ph), 124.8 (Cquart, indole), 129.1 (+, ph), 130.6
(Cquart, ph), 130.7 (Cquart, indole), 135.3 (Cquart, indole), 150.8 (Cquart, indole),
156.9 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 239 ([M•+], 100), 238 ([M-H]+, 85)
IR [cm-1]: 3441 (N-H), 3355 (O-H), 1592 (C=C), 1449 (C-H), 1354 (C-H), 1230
(C-O), 1194 (C-N), 939, 830, 791
Analysis:
calculated C: 73.63 H: 5.48 N: 5.75
found C: 73.87 H: 5.47 N: 5.55
C15H13NO2 • 0.3 H2O (244.68)
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5-Hydroxy-2-(4-hydroxyphenyl)-1-methyl-3-methylindole (6d)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methyl-1-methylindole (5a)
(0.53 g, 1.89 mmol) and BBr3 (18.90 mmol). The product was purified by col-
umn chromatography on silica gel eluting with a 1:1 (v/v) mixture of dichlo-
romethane and ethyl acetate to give a light brown solid.
Yield: 0.41 g (1.62 mmol, 86 %, light brown solid)
Mp: 192-195 °C [Lit. 199-200 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 2.09 (s, 3H, CH3), 3.49 (s, 3H, NCH3), 6.66 (dd, 1H, 4J = 2.3 Hz, 3J =
8.6 Hz, H-6), 6.8 (d, 1H, 4J = 2.3 Hz,  H-4), 6.90 (d, 2H, 3J = 8.5 Hz, H-2’, H-6’),
7.18 (d, 1H, 3J = 8.6 Hz, H-7), 7.22 (d, 2H, 3J = 8.5 Hz, H-3’, H-5’), 8.68 (s, 1H,
OH), 9.67 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.9 (+, CH3), 14.6 (+, NCH3), 102.7 (+, indole), 105.9 (Cquart, indole),
110.4 (+, indole), 111.6 (+, indole), 115.7 (+, ph), 122.6 (Cquart, indole), 129.1
(Cquart, ph), 131.9 (Cquart, indole), 131.9 (+, ph), 138.4 (Cquart, indole), 151.1
(Cquart, indole), 157.5 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 253 ([M•+], 100), 238 ([M-H]+, 76)
IR [cm-1]: 3276 (O-H), 2926 (C-H) aliphatic, 1600 (C=C), 1468 (C-H), 1378 (C-
H), 1226 (C-O), 1186 (C-N), 1064, 917, 842, 786
Analysis:
calculated C: 74.81 H: 5.96 N: 5.43
found C: 74.49 H: 6.14 N: 5.07
C16H15NO2 • 0.2 H2O (256.90)
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5-Hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-propylindole (6e)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methyl-1-propylindole (5b)
(0.50 g, 1.62 mmol) and BBr3 (16.20 mmol); The product was purified by col-
umn chromatography on silica gel eluting with a 1:1 (v/v) mixture of dichlo-
romethane and ethyl acetate to give a brown solid.
Yield: 0.45 g (1.60 mmol, 99 %, brown solid)
Mp: 147-149 °C [Lit. 153-154 °C (von Angerer et al. 1984)]
1H-NMR ([D6]DMSO):
δ [ppm] = 0.62 (t, 3H, 3J = 7.5 Hz, NCH2CH2CH3), 1.45 (m, 2H, NCH2CH2CH3),
2.05 (s, 3H, CH3), 3.89 (t, 2H, 3J = 7.3 Hz, NCH2CH2CH3), 6.64 (dd, 1H, 4J =
2.3 Hz, 3J = 8.6 Hz, H-6), 6.78 (d, 1H, 4J = 2.3 Hz, H-4), 6.89 (m, 2H, ph), 7.16-
7.22 (m, 3H, ph and H-7), 8.66 (s, 1H, OH), 9.66 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.8 (+, CH3), 11.6 (+, NCH2CH2CH3), 23.3 (-, NCH2CH2CH3), 45.2 (-,
NCH2CH2CH3), 102.8 (+, indole), 106.4 (Cquart, indole), 110.7 (+, indole), 111.5
(+, indole), 115.8 (+, ph), 122.9 (Cquart, indole), 129.3 (Cquart, ph), 131.1 (Cquart,
indole), 131.8 (+, ph), 138.3 (Cquart, indole), 151.0 (Cquart, indole), 157.5 (Cquart,
ph)
MS (PI-EIMS (70 eV)): m/z (%) = 281 ([M•+], 69), 252 ([M-C2H5]+, 100)
IR [cm-1]: 3400 (O-H), 2921 (C-H) aliphatic, 1600 (C=C), 1464 (C-H), 1345 (C-
H), 1232 (C-O), 1176 (C-N), 914, 839, 795, 613
Analysis:
calculated C: 75.87 H: 6.79 N: 4.91
found C: 75.88 H: 7.15 N: 4.57
C18H19NO2 • 0.2 H2O (284.95)
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5-Hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-pentylindole (6f)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methyl-1-pentylindole (5c)
(0.68 g, 2.0 mmol) and BBr3 (20 mmol). The product was purified by column
chromatography on silica gel eluting with a 1:2 (v/v) mixture of petroleum ether
60-80 °C and ethyl acetate.
Yield: 0.60 g (1.94 mmol, 97 %, dark green crystalline solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 0.79 (t, 3H, 3J = 7.0 Hz, -CH2CH3), 1.01-1.10 (m, 4H, -CH2-), 1.40-
1.47 (m, 2H, -CH2-), 2.05 (s, 3H, CH3), 3.92 (t, 2H, 3J = 7.3 Hz, NCH2CH2-),
6.64 (dd, 1H, 4J = 2.2 Hz, 3J = 8.6 Hz, H-6), 6.78 (d, 1H, 4J = 2.2 Hz, H-4), 6.87-
6.91 (m, 2H, ph), 7.15-7.20 (m, 3H, ph and H-7), 8.61 (s, 1H, OH), 9.60 (s, 1H,
OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.2 (+, CH3), 13.7 (+, -CH2CH3), 21.8 (-, -CH2-), ), 27.9 (-, -CH2-), 29.2
(-, -CH2-), 42.9 (-, NCH2-), 102.3 (+, indole), 105.8 (Cquart, indole), 110.0 (+, in-
dole), 110.9 (+, indole), 115.2 (+, ph), 122.4 (Cquart, indole), 128.7 (Cquart, ph),
130.4 (Cquart, indole), 131.2 (+, ph), 137.7 (Cquart, indole), 150.4 (Cquart, indole),
156.9 (Cquart, ph)
IR [cm-1]: 3349 (O-H), 2925 (C-H) aliphatic, 1613 (C=C), 1461 (C-H), 1357 (C-
H), 1230 (C-O), 1169 (C-N), 918, 836, 791, 716
C20H23NO2 (309.2)
5-Hydroxy-2-(4-hydroxyphenyl)-1-heptyl-3-methylindole (6g)
Reaction of 5-methoxy-2-(4-methoxyphenyl)-3-methyl-1-heptylindole (5d)
(0.73 g, 2.0 mmol) and BBr3 (20 mmol). The product was purified by column
chromatography on silica gel eluting with a 1:1 (v/v) mixture of dichloromethane
and ethyl acetate to give a green solid.
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Yield: 0.65 g ( 1.94 mmol, 97 %, green solid)
1H-NMR ([D6]DMSO):
δ [ppm] = 0.79 (t, 3H, 3J = 7.2 Hz, -CH2CH3), 1.01-1.10 (m, 4H, -CH2-), 1.11-
1.23 (m, 2H, -CH2-), 1.39-1.47 (m, 2H, -CH2-), 2.05 (s, 3H, CH3), 3.92 (t, 2H, 3J
= 7.2 Hz, NCH2CH2-), 6.64 (dd, 1H, 4J = 2.2 Hz, 3J = 8.4 Hz, H-6), 6.79 (d, 1H,
4J = 2.2 Hz, H-4), 6.88-6.98 (m, 2H, ph), 7.15-7.21 (m, 3H, ph and H-7), 8.62 (s,
1H, OH), 9.62 (s, 1H, OH)
13C-NMR ([D6]DMSO):
δ [ppm] = 9.2 (+, =CCH3), 13.7 (+, -CH2CH3), 21.8 (-, -CH2-), 25.8 (-, -CH2-),
27.9 (-, -CH2-), 29.2 (-, -CH2-), 30.9 (-, -CH2-), 42.9 (-, NCH2-), 102.3 (+, indole),
105.8 (Cquart, indole), 110.0 (+, indole), 110.9 (+, indole), 115.2 (+, ph), 122.4
(Cquart, indole), 128.7 (Cquart, ph), 130.4 (Cquart, indole), 131.2 (+, ph), 137.7
(Cquart, indole), 150.4 (Cquart, indole), 156.9 (Cquart, ph)
MS (PI-EIMS (70 eV)): m/z (%) = 337 ([M•+], 100), 294 ([M-C3H7]+, 3), 252 ([M-
C6H13]+, 84)
IR [cm-1]: 3381 (O-H), 2928 (C-H) aliphatic, 1603 (C=C), 1433 (C-H), 1373 (C-
H), 1260 (C-O), 1169 (C-N), 1042, 944, 836
Analysis:
calculated C: 74.72 H: 7.75 N: 3.96
found C: 74.54 H: 7.92 N: 3.54
C22H27NO2 (337.46)
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6.3 X-ray crystallography
The co-crystallisation experiments have been carried out by Mark J. Jedrzejas
(Children's Hospital Oakland Research Institute, Oakland, California 94609,
USA) and Daniel J. Rigden (National Centre of Genetic Resources and Bio-
technology, Cenargen/Embrapa, Brasília, D.F. 70770-900, Brazil).
6.3.1 Enzyme production
The hyaluronate lyase from S. pneumoniae (Jedrzejas et al. 1998; Jedrzejas et
al. 2000; Li et al. 2000; Jedrzejas 2001) was produced as described previously
by Jedrzejas et al. (Jedrzejas et al. 1998). The enzyme was concentrated to
5 mg/ml in 10 mm Tris-HCl buffer (pH 7.4), 150 mM NaCl, 1 mM dithiothreitol
(DTT) using centrifugal spin devices with 50 kDa molecular weight cutoff (milli-
pore). The hyaluronate lyase was used for the production of crystals with the
inhibitor; the enzyme concentration was determined by UV absorption at
280 nm as described elsewhere (Pace et al. 1995; Jedrzejas et al. 1998).
6.3.2 Crystallisation of the complex
To grow the crystals of the enzyme-inhibitor complex the hanging drop vapour
diffusion (McPherson 1999) using Linbro culture plates (HamptonResearch
2003) at room temperature was used. Equal volumes of protein, reservoir solu-
tion (1 µl each) and various amounts of inhibitor solutions (0.1, 0.5 and 1.0 µl)
were mixed and equilibrated against 1 ml of the reservoir solution. The reservoir
solution was prepared as described by Jedrzejas et al. (Jedrzejas et al. 1998)
and contained 0.2 M NaCl, 2 % dioxane, 60 % - 65 % saturated ammonium
sulphate and 0.1 M sodium citrate buffer (pH 6.0).
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6.3.3 X-ray diffraction
The crystals of the enzyme-inhibitor complex were cryoprotected using 30 %
xylitol (w/v), 3.5 M ammonium sulphate and 0.1 M sodium citrate buffer (pH 6.0)
as reported for the native crystals (Li et al. 2000) and frozen in liquid nitrogen.
To pick up and mount the frozen crystals under a nitrogen flow at -180 °C stan-
dard fiber loops (HamptonResearch 2003) of a suitable size were used. The
X-ray diffraction for the inhibitor complex data was collected using rotation (os-
cillation) photography and Quantum 4u CCD detector. The crystallographic set-
up of beamline 5.0.1 of the Berkeley Centre for Structural Biology, Advanced
Light Source, Lawrence Berkeley National Laboratory was used. By using the
HKL2000 software package (Otwinowski et al. 1997) the collected data were
analysed, indexed, integrated, and scaled. The crystals were isomorphous to
the native S. pneumoniae hyaluronate lyase crystals (Jedrzejas et al. 1998).
The statistics of the native diffraction data were analysed.
6.3.4 Structure solution and refinement
The structure was solved by rigid body refinement with the programm CNS
(Brunger et al. 1998) using the crystal structure of S. pneumoniae hyaluronate
lyase in complex with palmitoyl vitamine C (Rigden et al., unpublished results)
as a search model. Refinement proceeded with alternating rounds of computa-
tional refinement with CNS (Brunger et al. 1998) and manual rebuilding using
the programm “O” (Jones et al. 1991). No intensity or sigma-based cut-offs
were applied to the data. Sigma-A-weighted map coefficients (Read 1986) were
used all the time. To monitor the progress of refinement the Rfree value (Brunger
1992), calculated for a test set of 5 % of reflection, was used. Difference den-
sity at the active site was apparent even in initial maps. Whereas the aliphatic
portion of the inhibitor was relatively easily placed, different orientations of the
residual of the inhibitor had to be tested. The possibilities were evaluated by
using the quality of electron density maps, B-factors and the Rfree value as crite-
ria. Sulphate and xylitol molecules, deriving from the crystallisation and cryo-
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cooling solutions respectively, were modelled into suitably shaped regions of
electron density. Final statistics for the model are shown in Table 5.
Programs of the CCP4 package (Collaborative Computational Project 1994)
were used for manipulations and structural superpositions were made with
LSQMAN (Kleywegt 1999).
Table 5: Crystallographic and refinement statistics
Space group P212121
a (Å) 84.20
b (Å) 103.27Unit cell
c (Å) 103.26
Low resolution diffraction limit (Å) 44.0
High resolution diffraction limit (Å) 2/0
Non-hydrogen protein atoms 5824
Sulphate atoms 25
Non-hydrogen xylitol atoms 30
Non-hydrogen w249b atoms 70
Non-hydrogen solvent atoms 560
Number of reflections 27035 (621)
R (%) 17.8 (30.2)
Rfree (%) 20.2 (23.9)
All atoms 27.9
Protein 26.3
Protein main chain 25.8
Protein side chain 27.4
Sulphate 59.9
Xylitol 52.3
Inhibitor 81.6
Mean temperature
factor B (Å)
Solvent 33.5
Bond lengths (Å) 0.006r.m.s. deviation
from ideal values Bond angles (º) 1.3
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6.4 Pharmacological methods
The inhibitory effect of the indole derivatives on the activity of hyaluronidases
were determined by a turbidimetric assay according to the description of Di Fer-
rante (Di Ferrante 1956), as described in chapter 3.
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Chapter 10
Summary
Hyaluronan and hyaluronidases have been used in several medical fields for
many years. For example, sodium hyaluronate is frequently used in the treat-
ment of osteoarthritis; preparations of bovine testicular hyaluronidase have
been applied therapeutically in the fields of internal medicine, ophthalmology
and orthopaedia. Furthermore, it has been reported that some hyaluronidases
play a role in of a variety of diseases, e.g. meningitis, septicaemia, arthroses or
cancer. To prove the role and the importance of hyaluronic acid and hyaluroni-
dases in physiological and pathophysiological processes, selective and potent
hyaluronidase inhibitors are required. As such compounds are not known so
far, the goal of this thesis was to identify and to synthesise lead-like compounds
as inhibitors of bovine testicular hyaluronidase and S. agalactiae hyaluronate
lyase, to optimise the structures and to study the structure-activity relationships.
Additionally, a crystal structure of an enzyme-inhibitor complex  was envisaged
to determine the binding mode of hyaluronate lyase inhibitors.
Starting from the report that heparin and heparan, structurally similar to hyalu-
ronic acid, are hyaluronidase inhibitors, a set of sulphated and non-sulphated
oligosaccharides with three to eight sugar monomers as well as two sugar units
and a phenyl ring were investigated. The results obtained in the present study
suggest that sulphated sugar derivatives are useful as inhibitors of hyaluroni-
dase, whereas the basic structures lacking sulphate groups are inactive. Fur-
thermore, the inhibitory potency strongly depends on the degree of sulphation:
the higher the degree of sulphation the higher the inhibitory activity. As inhibi-
tors of the bovine testicular and the bee venom hyaluronidase sulphated tri-,
tetra-, pentasaccharides and/or sulphated disaccharides with a phenyl moiety
were the most active compounds. By contrast, in case of the hyaluronate lyase,
the highest activity was found for the sulphated octasaccharide.
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Based on mechanistical studies of hyaluronan degradation by hyaluronate ly-
ases, we designed a substrate analogue as potential inhibitor consisting of
three carbohydrate units including a fluorinated glucuronic acid as central
building block. The synthesis of the pertinent protected N-acetylglucosamine
was successful, whereas the attempts to synthesise the fluorinated glucuronic
acid failed. As the problems with the fluorination of hex-4-enopyranoside and
hex-5-enopyranoside derivatives were not conquerable an alternative strategy
should be envisaged, for instance, the synthesis of non-carbohydrate hyalu-
ronidase inhibitors.
Due to inconsistent results published by different authors, we investigated se-
veral assumed inhibitors like disodium cromoglycate, apigenin, kaempferol and
silybinin on the bovine testicular hyaluronidase to obtain comparable data de-
termined under the same conditions. To further elaborate the structure-activity
relationships some flavones (natural compounds) and sulphated flavones were
measured. Subsequently, a variety of new chalcone and flavone derivatives
with different substituents and substitution patterns was synthesised and phar-
macologically investigated. Three chalcone and one flavone derivative induced
inhibition of the bovine testicular hyaluronidase at millimolar concentrations.
Sodium flavone-7-sulphate and sodium 5-hydroxyflavone-7-sulphate were the
most potent bovine testicular hyaluronidase inhibitors with micromolar inhibitory
activity. As hyaluronate lyase inhibitors five chalcone and four flavone deriva-
tives were identified, whereby 4’-chloro-4,6-dimethoxychalcone was the most
potent hyaluronate lyase inhibitor achieving micromolar inhibitory activity.
As part of the hyaluronate lyase project, the main focus of this thesis was the
identification and evaluation of promising lead-like compounds based on a de
novo design approach. The virtual screening of three different databases with
the computer program LUDI resulted in 1275 hit. Of all 19 selected compounds,
13 molecules revealed inhibitory activity on the bacterial hyaluronidase and 5
compounds on the bovine testicular hyaluronidase. 1,3-Diacetylbenzimidazole-
2-thione has an IC50 value in the micromolar range and is therefore the most
potent hyaluronate lyase inhibitor. The results demonstrate that the chosen
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strategy based on a homology model of the hyaluronan lyase hylB4755 is useful
to identify promising leads.
Structural modifications of de novo design lead-like structures resulted in new
hyaluronidase inhibitors: the diphenylacrylic and diphenylpropionic acids. Within
the series of the examined compounds the brominated diphenylacrylic and di-
phenylpropionic acid as well as 3-(4-trifluoromethyl-phenyl)-3-phenylpropionic
acid were the most potent inhibitors on the bovine testicular hyaluronidase and
the bacterial enzyme.
As indole-2-carboxylic acid was identified as a compound with millimolar en-
zyme inhibitory activity a set of indoles with different substituents like acetic
acid, acetyl, carboxamide, butyric acid, methyl etc. as well as a series of
2-phenylindole derivatives with hydroxy, methoxy, methyl and/or sulphamoyloxy
substituents at the phenyl and indole rings and different substituents at the ni-
trogen atom was investigated. Generally, the phenylindoles were more active
on the bacterial enzyme than on the bovine testicular hyaluronidase. Only the
compounds lacking the N-substituent exhibited weak activity on the bovine tes-
ticular enzyme. Structure-activity relationship studies revealed that a hydroxy
group in position 6 is more favourable than in position 5. Furthermore, the in-
troduction of a methyl group in position 3 and a 5 to 10-membered alkyl chain in
position 1 leads to an increase in activity and selectivity for the bacterial vs. the
bovine enzyme. Compared to the first lead-like compound, indole-2-carboxylic
acid, the increase in lipophilicity by introducing phenyl and alkyl substituents
and the introduction of hydroxy and/or sulphamoyloxy groups at the phenyl and
indole ring resulted in about 500-fold more potent inhibitors with remarkable
selectivity for hyaluronan lyases.
On the basis of the X-ray analysis1 of S. pneumoniae hyaluronate lyase in
complex with 6-sulphamoyloxy-2-(4-sulphamoyloxyphenyl)-1-decylindole we
were able to determine the binding mode of the inhibitor. The phenylindole
binds within the catalytic site of the enzyme whereby hydrophobic interactions
1 in co-operation with Mark J. Jedrzejas (Children's Hospital Oakland Research Institute, Oak-
land, California 94609, USA) and Daniel J. Rigden (National Centre of Genetic Resources and
Biotechnology, Cenargen/Embrapa, Brasília, D.F. 70770-900, Brazil).
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with the amino acids Trp292, Trp291, His399 and Met579 and hydrogen bonds
with Asn466, Ser463, Asp352, Asn349 and Trp292 are involved.
In summary, ligand-based and structure-based approaches led to the identifi-
cation of hyaluronidase inhibitors with micromolar inhibitory activity. Especially,
by de novo design we achieved potent hyaluronate lyase inhibitors which can
be used as pharmacological tools to study the role of hyaluronic acid and hyalu-
ronidases in physiological and pathophysiological processes.
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List of abbreviations
Ac acetyl
Bn benzyl
BSA bovine serum albumin
BTH bovine testicular hyaluronidase
BVH bee venom hyaluronidase
CDI N,N’-carbonyldiimidazole
CTAB cetyltrimethylammonium bromide
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene
DMAP p-dimethylaminobenzaldehyd
DMF N,N-dimethylformamide
DMSO dimethyl sulphoxide
GluNAc N-acetyl-D-glucosamine
h hour
HA hyaluronic acid
HMPT hexamethylphosphoric triamide
hylB3502 S. agalactiae hyaluronate lyases strain 3502
hylB4755 S. agalactiae hyaluronate lyases strain 4755
hylSpn S. pneumoniae hyaluronate lyases
IC50 concentration of inhibitor giving a 50% decrease of the
enzyme activity
IU international units
min minutes
Mp melting point
MS mass spectrometry
MW molecular weight
n.d. not determined
NMR nuclear magnetic resonance
PG protecting group
pH negative logarithm of the hydrogen ion concentration
Ph phenyl
ppm parts per million
RT room temperature
THF tetrahydrofuran
TMS (nuclear magnetic resonance) tetramethyl silane
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Ts tosyl (4-methylphenylsulfonyl)
UV ultra violet
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